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Abstract 
 
Cardiovascular disease (CVD) remains the single leading cause of mortality and is 
strongly associated with obesity and cardiometabolic disease (inclusive of metabolic 
syndrome [MetS], impaired glucose tolerance and type 2 diabetes [T2D]). Impairments 
in vascular reactivity, stemming from such endothelial dysfunction, as well as possible 
disruptions to endothelium-independent activity and maladaptation to the vascular 
smooth muscle, increase susceptibility to endothelial injury and, thus, promote 
atherosclerotic change. Several large cross-sectional studies provide evidence that 
chronic impairments in vascular reactivity may present early in the decline of 
cardiometabolic health, such as in those considered overweight. However, whether 
there is a pathophysiological continuum in in the impairment of vascular reactivity 
between early stages and diabetic complications has never been addressed. Excess 
sugar consumption is one of the main dietary factors driving the increased prevalence 
of obesity, insulin resistance and CVD, but the overall effect of acute hyperglycemia 
on vascular reactivity is currently unclear due to discrepant findings. Considering this, 
the primary aim of this research program was to examine the extent and nature of 
vascular impairment across the spectrum of cardiometabolic health; with a focus on the 
mediating effects of excess sugar consumption and the validity and accuracy of current 
methods used to quantify vascular reactivity in affected individuals. 
 
Study one evaluated the effect of acute hyperglycemia on vascular reactivity through a 
systematic review and meta-analysis; presenting evidence that excess sugar 
consumption may transiently impair endothelium-dependent vascular reactivity in the 
macrocirculation of those considered healthy or obese and of those with 
cardiometabolic disease (30 studies; n = 884; standardized mean difference [SMD], -
1.40; 95% CI, -1.68 to -1.12; P<0.01); while microvascular endothelium-dependent (9 
studies; n = 181; SMD, -0.63; 95% CI, -1.36 to 0.11; P=0.09) and endothelium-
independent vascular reactivity (6 studies; n = 144; SMD, -0.07; 95% CI, -0.30 to 0.16; 
P=0.55) remain unaffected. However, these findings were ultimately inconclusive due 
to inadequate reporting of macrovascular data in nearly all studies included in the 
analyses and considerable heterogeneity in microvascular endothelial data; and due to 
a limited availability of endothelium-independent data. 
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Considering this, study two aimed to clarify the effect of acute hyperglycemia on 
vascular function, by assessing the impact of sugar-sweetened beverage (SSB) 
consumption, one of the most prominent sources of added sugar in the human diet. 
Compared to water consumption, a single 600 mL SSB impaired microvascular and 
macrovascular endothelial function in a healthy population, as indicated by a decrease 
in the vascular response to acetylcholine iontophoresis (208.3 ± 24.3 vs. 144.2 ± 15.7 
%, P<0.01) and by reduced flow-mediated dilation (0.019 ± 0.002 vs. 0.014 ± 0.002 
%/s-1, P<0.01), respectively. Similar to findings in study one, endothelium-independent 
vascular reactivity remained unaffected. Experimental models suggested that this SSB-
mediated endothelial dysfunction is partly due to an acute hyperglycemic-mediated 
increase in oxidative stress that reduces the bioavailability of nitric oxide, a key 
vasodilating agent. 
 
Combined, study one and two demonstrated that excess sugar consumption transiently 
impairs endothelial function in those considered healthy or obese and in those with 
cardiometabolic diseases; and, subsequently, that it may have a significant role in the 
initial and ongoing development of chronic vascular dysfunction, obesity, MetS, T2D 
and CVD. Despite this, whether there is a pathophysiological continuum in vascular 
dysfunction between early stages and diabetic complications was still unclear. 
Therefore, study three assessed, in a systematic review and network meta-analysis, the 
extent and nature of impairment in vascular reactivity across the spectrum of 
cardiometabolic health (i.e. overweight, obesity, impaired glucose tolerance, MetS, 
T2D and T2D with complications). One hundred and ninety three articles (7226 healthy 
subjects and 19,344 overweight or obese patients, or those with cardiometabolic 
diseases) were analysed, revealing a pathophysiological continuum where there is 
progressive impairment in endothelium-dependent and endothelium-independent 
vascular reactivity throughout the pathogenesis of T2D and its complications. 
Interestingly, meta-regressions revealed that for every 1 mmol/l increase in fasting 
blood glucose concentration, flow-mediated dilation decreased by 0.52 %. 
 
One of the most commonly used techniques to assess microvascular reactivity is 
iontophoresis of a vasoactive agent; a methodology that, within itself, presents a range 
of varying protocols for researchers to choose from, with no standardization of the 
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protocols or data expression. In addition to a lack of standardization amongst the variety 
of techniques used to assess microvascular reactivity, the considerable heterogeneity, 
observed in the microvascular data from studies one and three, may have also been 
influenced by non-specific vasodilatory effects that can be induced by the iontophoresis 
technique. Indeed, there is no consensus as to which protocols of iontophoresis are free 
of confounding, non-specific vasodilatory effects. Considering this, study four 
evaluated commonly used protocols of iontophoresis finding that seven out of the ten 
published methods assessed in this present study induce non-specific vasodilatory 
effects that may confound vascular data. Providing updated methodological 
recommendations, this study found that iontophoresis of acetylcholine or sodium 
nitroprusside in sodium chloride (0.02 mA for 200 and 400 s, respectively) and 
acetylcholine in deionized water (0.1 mA for 30 s) mediate the least non-specific 
vasodilatory effects when iontophoresis is coupled with laser speckle contrast imaging; 
while the cutaneous microvascular responses to each tested insulin protocol were 
mediated mainly by non-specific effects.  
 
In conclusion, this program of research demonstrates that there is a pathophysiological 
continuum in vascular dysfunction; where endothelium-dependent and endothelium-
independent vascular reactivity are progressively impaired throughout the pathogenesis 
of T2D and its complications. Additionally, this research confirmed that excess sugar 
consumption induces transient impairments in endothelial function, which may 
contribute to the development of chronic vascular dysfunction, obesity, MetS, T2D and 
CVD. Further research is needed to assess if transient impairments in vascular function, 
mediated by several dietary and lifestyles factors, develop into chronic impairments, 
when the individual is still considered clinically healthy, or after the clinical onset of 
an overweight state. However, several issues within the current methodology for 
assessing vascular reactivity should be addressed first. Regardless, this research 
continues to inform public health policy that transient and chronic impairments of 
vascular function, which are representative of critical events in the pathogenesis of 
CVD and are associated with CVD mortality, occur early, long before the clinical onset 
of obesity, MetS and T2D. Furthermore, from a clinical perspective, the findings of this 
research program importantly provide further understanding of the development of 
vascular dysfunction, which may enhance the timing and, subsequent, effectiveness of 
treatment strategies that aim to improve vascular health and CVD outcomes. 
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Abstract (Français) 
 
Les maladies cardiovasculaires est la première cause de mortalité dans le monde et 
fortement associées à l’obésité et aux pathologies métaboliques (incluant l’intolérance 
au glucose, le syndrome métaboliques [SMET] et le diabète de type 2 [DT2]). La 
dysfonction vasculaire, au-delà de son caractère essentiel dans l’homéostasie 
vasculaire, est également largement reconnue comme un précurseur et un marqueur 
précoce de l’athérosclérose et des pathologies cardiovasculaires. Cette dysfonction 
vasculaire est fortement influencée par différents facteurs de risque tels que 
l’hyperglycémie, l’obésité, l’insulino-résistance ou encore l’inflammation, mais peut 
aussi initier le développement de l’obésité et surtout de l’insulino-résistance. 
Cependant, il n’est pas clairement démontré comment la dysfonction vasculaire évolue 
le long du continuum de la maladie cardiométabolique depuis un excès de poids, 
initiateur de l’obésité, jusqu’à la pathologie DT2 présentant des complications. Le 
développement de la dysfonction vasculaire chronique pourrait débuter notamment par 
des altérations transitoires de la réactivité endothéliale. La consommation importante 
de sucre, le facteur nutritionnel le plus largement associé avec l’obésité, les pathologies 
cardiométaboliques ou cardiovasculaires, pourrait être un médiateur majeur de la 
dysfonction vasculaire transitoire. Néanmoins, les effets de l’hyperglycémie aigue sur 
le continuum de la dysfonction vasculaire restent à ce jour peu décrits. Dans ce 
contexte, un premier objectif de ce travail a été de déterminer le degré et la nature de la 
dysfontion vasculaire au cours du continuum de la pathologie cardiométabolique entre 
une situation physiologique chez des sujets sains, et des situations pathologiques au 
cours du développement de l’obésité, de l’insulino-résistance, du syndrome 
métabolique jusqu’au DT2 sans et avec des complications associées.  
 
La première étude basée sur une revue systématique et une méta-analyse a donc évalué 
les effets d’une hyperglycémie aigue sur la fonction vasculaire. Ce travail a confirmé 
qu’un excès de consommation de sucre pouvait de manière transitoire altérer la fonction 
endothéliale de la macrocirculation (30 études; n=884; standardized mean difference 
[SMD], -1.40; 95% IC, -1.68 à -1.12; P<0.01), sans modifications de la fonction 
endothéliale au niveau microcirculatoire (9 études; n = 181; SMD, -0.63; 95% IC, -1.36 
to 0.11; P=0.09) de la réactivité du muscle lisse vasculaire (6 études; n = 144; SMD, -
0.07; 95% IC, -0.30 to 0.16; P=0.55). Néanmoins, ces résultats étaient à prendre avec 
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précaution puisque les données macro- et micro-vasculaires présentaient une 
hétérogénéité importante et un nombre d’études limité, notamment chez le sujet sain.  
 
Ainsi, notre second travail s’est intéressé à l’aide d’une approche translationnelle chez 
l’homme et l’animal à mieux comprendre les effets d’une hyperglycémie aigüe, induite 
par une consommation de boisson sucrée, sur la fonction vasculaire macro- et 
microcirculatoire. En comparaison avec une consommation d’eau, une boisson sucrée 
de 600 mL chez des sujets jeunes et sains a provoqué une altération de la fonction 
vasculaire au niveau des vaisseaux de conduits (baisse de la réactivité flux-dépendante, 
0.019 ± 0.002 vs. 0.014 ± 0.002 %/s-1, P<0.01) et de la microcirculation (baisse de la 
réactivité de la microcirculation cutanée à une iontophorèse d’acétylcholine, (208.3 ± 
24.3 vs. 144.2 ± 15.7 %, P<0.01). La réactivité du muscle lisse, quels que soient les 
territoires vasculaires considérés, n’a pas été modifiée, confirmant ainsi l’origine 
endothéliale des altérations observées. L’étude sur un modèle de rongeur a par ailleurs 
démontré que cette baisse de fonction vasculaire en réponse à cette consommation aigüe 
de boisson sucrée était liée à une augmentation du stress oxydant vasculaire et une 
diminution de la biodisponibilité du monoxyde d’azote, un agent vasodilatateur majeur 
du système circulatoire. Ainsi, les deux premières études ont démontré que les 
phénomènes hyperglycémiques aigus, induits par une consommation excessive de 
sucre, pouvaient de manière transitoire altérer la fonction endothéliale chez les patients 
atteints de pathologies cardiométaboliques, mais également chez les sujets sains. Ces 
premiers résultats ont également renforcé l’hypothèse que ces mécanismes pouvaient 
être à l’origine du développement d’une dysfonction vasculaire chronique chez les 
patients obèses, syndrome métabolique et DT2.  
 
Ainsi, la troisième étude a cherché à évaluer par une revue systématique associée à une 
méta-analyse, comment la fonction vasculaire évolue le long de ce continuum de 
pathologies cardiométaboliques. 193 études ont été analysées pour inclure 7226 sujets 
sains et 19344 patients présentant une pathologie cardiométabolique. Une méta-analyse 
par réseau a montré, pour la première fois dans la littérature, une dysfonction vasculaire 
endothéliale progressive au cours du développement physiopathologique menant au 
DT2 avec complications. Les analyses post-hoc ont démontré également une évolution 
identique de la réactivité du muscle lisse, et ces résultats étaient retrouvés dans tous les 
territoires vasculaires. Néanmoins, il est apparu qu’une des techniques couramment 
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utilisée dans la littérature pour explorer la fonction vasculaire microcirculatoire 
présentait des méthodologies d’application très variables (protocoles non standardisés, 
ni d’expression homogène des données. De plus, cette technique qui associe une mesure 
de la perfusion microcirculatoire cutanée par Laser Doppler ou Laser speckle contrast 
imaging avec une iontophorèse de drogues vasoactives peut être influencée par des 
effets de vasodilatation non-spécifiques et liés au courant ou au protocole utilisé. 
 
Ainsi, notre quatrième étude a consisté à comparer les différents protocoles existant 
dans la littérature scientifique afin de mieux discriminer les effets propres des drogues 
vasoactives sur la microcirculation des effets non spécifiques, majoritairement courant-
dépendants. Ce travail a permis de proposer une méthodologie reproductible et sans 
effets « courant » sur la microcirculation cutanée évaluée par le Laser speckle contrast 
imaging pour les agents vasoactifs endothélium dépendant (acétylcholine dans de l’eau 
désionisée, 0,02 mA pendant 200 secondes) et indépendant (nitroprussiate de sodium 
dans de l’eau désionisée, 0,02 mA pendant 400 secondes). L’insuline ayant des effets 
spécifiques sur la microcirculation, il nous a semblé également important de valider 
une méthodologie valide et reproductible. Parmi les deux protocoles existant dans la 
littérature, aucun n’a pu démontré d’effets spécifiques à l’insuline, ne permettant ainsi 
aucune recommandation quant à l’utilisation de cette approche pour mesurer les effets 
vasculaires de l’insuline.  
  
En conclusion, l’ensemble de ces études ont démontré une atteinte progressive de la 
fonction vasculaire endothéliale et musculaire lisse au niveau des lits macro- et 
microcirculatoires le long du continuum de la maladie cardiométabolique menant les 
patients d’un stade de surpoids corporelle à un diabète de type 2 avec complications 
macro- et micro-angiopathiques. Ces travaux montrent également, que même une seule 
boisson sucrée provoquant une hyperglycémie aigüe, était capable chez des sujets 
jeunes et en bonne santé d’altérer de manière transitoire la fonction vasculaire 
endothéliale, confirmant ainsi le caractère très précoce de la dysfonction vasculaire de 
la pathologie métabolique. Néanmoins d’autres études sont nécessaires pour mieux 
comprendre comment un stress aigu, telle que l’hyperglycémie aigüe, peut provoquer 
de manière répétée l’installation d’une dysfonction vasculaire chronique. Il est 
également nécessaire de mieux appréhender les mécanismes sous-jacents explicatifs de 
ces altérations en alliant des approches cliniques et expérimentales afin de proposer des 
 XXVIII 
stratégies de prévention adéquates pour améliorer la santé vasculaire dès le début de 
l’installation de la pathologie cardiométabolique. Par conséquent, ces travaux 
permettent de contribuer à un message de santé publique pour mieux appréhender le 
risque cardiovasculaire et ainsi prévenir la morbi-mortalité cardiovasculaire.  
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Chapter 1 – Introduction and overview 
 
The increasing prevalence of obesity and cardiometabolic disease (inclusive of 
metabolic syndrome [MetS], impaired glucose tolerance and type 2 diabetes [T2D]) 
represents one of the greatest public health issues of the modern era. While high 
incidences of obesity and cardiometabolic disease have traditionally affected those in 
developed regions such as North America and Western Europe, these epidemics have 
now become truly global with cases increasing at an alarming rate across developing 
countries.1–3 Recent statistics from the World Health Organization clearly demonstrate 
this trend, indicating that while approximately 39 % of the global adult population (aged 
18 years or more) are currently overweight, obesity rates have more than doubled in the 
past three decades and now affect about 13 % of the world’s adult population.4 
Moreover, while the prevalence of obesity is, on occasion, exceeding 50 % amongst 
adults in developing nations, overweight and obesity rates in children from developing 
countries have also increased from 8.1 % to 12.9 % in boys and 8.4 % to 13.4 % in 
girls.5 At the same time,  the global incidence of diabetes has nearly quadrupled in 
recent decades, increasing from 108 million people worldwide in 1980 to 422 million 
in 2014,3 with approximately 90-95 % of that population being accounted for by those 
with T2D.6 Indeed, while metabolic issues such as insulin resistance may also effect 
those with clinically normal weight, obesity is one of the primary factors driving this 
prevalence of T2D.7 Once defined as ‘adult onset diabetes’, a growing number of T2D 
cases are now also being observed in children and adolescents;8 further potentiating a 
situation where a majority of the world’s population will face complications and/or 
premature death stemming from poor cardiometabolic health. 
 
The urgency of this public health crisis is well recognised and authorities have set 
global targets to halt the rise in obesity and T2D at their 2010 levels by the year 2025.2,3 
However, if post-2000 trends continue, the likelihood of achieving these targets is 
virtually zero for obesity and approximately 1 % for T2D.2,3 Subsequently, the burden 
of obesity and T2D is only projected to worsen.9 Although this trend is driven by a 
complex interaction of numerous lifestyle and socioeconomic factors, it is now well 
accepted that habitual overconsumption of sugar-sweetened beverages (SSB) is the 
dietary factor that is most consistently found to be associated with an increased 
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incidence of obesity, MetS and T2D.1 From the mid-1960’s, the prevalence of obesity 
and cardiometabolic disease has closely paralleled the steady increase in per capita 
calories from SSB consumption in both adults and children of developed nations; a 
trend that has been markedly more rapid in developing nations over the past few 
decades as traditional diets become more westernized.10–12 Overconsumption of SSB 
has also been directly linked with an increased risk of developing cardiovascular 
disease (CVD),10 which remains the single leading cause of mortality, accounting for 
70 % of all deaths amongst those with T2D and 31 % of the overall global mortality 
rate each year.13–15 It is now well accepted that endothelial dysfunction may be 
considered one of the earliest discernible, pathophysiological, precursors to the 
pathogenesis of CVD.16 Indeed, impaired vascular reactivity may also contribute to the 
development of obesity and insulin resistance; in what may, indeed, be considered a 
vicious cycle where each compounds the other.17 
 
In normal vascular function, the endothelium and perivascular adipose tissue 
continuously interact with the vascular smooth muscle (VSM) cells, regulating the 
diameter of the blood vessel under the influence of several vasodilating (nitric oxide 
[NO], prostacyclin [PGI2] and endothelium-derived hyperpolarizing factors [EDHF]) 
and vasoconstricting (endothelin-1 [ET-1], angiotensin II, prostanoids and 
isoprostanes) substances;18,19 ultimately, to maintain optimal vascular tone and organ 
perfusion.20,21 However, during vascular dysfunction, the reactivity of the blood vessel 
is impaired, reducing its capacity to vasodilate when challenged (e.g. when blood flow 
shear stress, exerted on the arterial wall, increases).14 Subsequent increases in overall 
vascular tone, in conjunction with additional hematologic events (e.g. abnormal 
increases in viscosity of the blood),22 may heighten the risk of injury to the arterial 
walls.23 Vascular dysfunction may also be accompanied by increases in the expression 
of plasma and urinary biomarkers that are representative of general endothelial 
dysfunction and inflammation.20 These inflammatory responses, which compound the 
primary vascular dysfunction, are key indicators of atherosclerotic changes and are 
characterized by lesion formation, plaque rupture, and thrombosis; all of which 
represent significant events in the pathogenesis of CVD.24,25 Importantly, it must be 
recognised that the adverse impact of vascular dysfunction is not only limited to the 
coronary circulation. Indeed, similarly to that in those with type 1 diabetes, vascular 
dysfunction also plays a major role in the development of other complications that are 
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associated with T2D, such as diabetic nephropathy, retinopathy, peripheral neuropathy 
and diabetic foot ulceration.26–29  
 
Many studies have compared vascular reactivity between health groups providing 
strong evidence that chronic impairments in vascular reactivity may present early, even 
in those considered overweight and metabolically healthy;30,31 a health condition that is 
often considered less serious than obesity, MetS or T2D. However, even if much of the 
research has shown differences, cross-sectional studies may often lack the power to 
accurately estimate the effect size of vascular impairment between health groups. 
Moreover, whether there is a pathophysiological continuum in the impairment of 
vascular reactivity between early stages of obesity and diabetic complications has never 
been addressed. Furthermore, it has also been suggested that acute hyperglycemia 
induced by the excess consumption of added sugar, such as that in the form of SSB, 
may transiently impair vascular reactivity in humans; contributing to the initial and 
ongoing development of chronic vascular dysfunction. Hyperglycemia-mediated 
vascular dysfunction, whether induced by diet or by dysglycemia in those with poor 
cardiometabolic health, may be explained by increases in oxidative stress that reduce 
the bioavailability of the vasodilator, NO.24,32 Ultimately, though, the effect of acute 
hyperglycemia on vascular reactivity and the mechanisms that may underlie any 
dysfunction remain unclear due to discrepant results in previous research and a lack of 
data, respectively.  
 
It is important from a clinical perspective that vascular impairments are fully 
understood to enhance the timing and, subsequent, effectiveness of treatment strategies 
that aim to improve vascular health; and to ascertain which clinical measures of 
vascular reactivity may best detect primary markers of vascular impairment, long 
before the development of chronic dysfunctions and significant detrimental 
cardiovascular events. Considering this, the primary aim of this research program is to 
examine the extent and nature of vascular impairment across the spectrum of 
cardiometabolic health (i.e. health classifications including overweight, obese, MetS, 
impaired glucose tolerance, T2D and T2D with complications); with a focus on the 
mediating effects of SSB consumption and the validity and accuracy of current methods 
used to quantify vascular reactivity in affected individuals.
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Chapter 2 – Literature review 
 
Publication statement: 
The content of this chapter is comprised of two book chapters that were completed 
during the course of my PhD program in collaboration with the laboratory of Professor 
Aristidis Veves (Microcirculation Laboratory and Rongxiang Xu, MD, Center for 
Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical 
School, Boston, MA, USA). The content has been modified to ensure that it meets the 
flow and formatting of this thesis. 
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diabetic foot. In: Contemporary Diabetes, The Diabetic Foot: Medical and Surgical 
Management, Fourth Edition. Springer; accepted for publication. 
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2.1 Normal structure and physiology of the vascular network 
 
Early research into the role of vascular dysfunction in CVD often assessed vascular 
reactivity directly in the region of interest (e.g. the coronary circulation). Common 
techniques included intracoronary infusion of a vasoactive substance (e.g. 
acetylcholine, nitroprusside etc.), performed in conjunction with a coronary 
angiography or intravascular ultrasound to measure coronary macrovascular reactivity; 
and with Doppler wires or cineangiographic frame counts to assess coronary 
microvascular reactivity.33 Such tools measure changes in vessel diameter or coronary 
blood flow in response to the aforementioned pharmacological stimuli or even exercise, 
which induces shear stress; with decreased responses indicating impaired vascular 
reactivity.33 However, these early methods are considered highly invasive and 
technically challenging; and are not an option in patients who do not require an 
angiography. More recently, vascular research has consistently used non-invasive 
surrogate markers of coronary vascular function, assessing peripheral vascular 
reactivity in conduit arteries and in the microcirculation. Indeed, measures of peripheral 
vascular reactivity may also provide important information about the decline in 
vascular health, directly in the region of interest, in those with T2D and complications 
such as diabetic neuropathy or foot ulceration. Considering this as a whole, the 
following review will focus primarily on aspects of the peripheral circulation. 
 
2.1.1 Anatomy of the vascular network 
The vascular network is typically categorized by size and defined as the 
macrocirculation, which includes both conduit arteries (>1000 µm) and small arteries 
(300 – 1000 µm), or the microcirculation, consisting of smaller arteries, arterioles and 
venules (10 – 300 µm), and capillaries (≈ 6 µm).34 In the cutaneous microcirculation, 
these small arteries, arterioles and venules collectively form two horizontal plexuses in 
the dermis.35 The upper plexus in the papillary dermis, from which nutritive capillary 
loops arise, is connected by ascending arterioles and descending venules to a lower 
network located at the dermal-hypodermal interface.35 Arterio-venous anastomoses 
provide direct connections between the arterial and venous networks.35 Each blood 
vessel has three distinct layers defined as the outer tunica adventitia, the central tunica 
media and the inner tunica intima.36 The adventitia’s proportion of the vascular wall is 
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variable, dependent on the vascular bed and is comprised of elastin, collagen, 
fibroblasts, mast cells, and macrophages.36 Compared to other tissues, the adventitia of 
blood vessels within the cutaneous microcirculation also present a high density of 
sensory, sympathetic and parasympathetic nerve axons that do not penetrate the 
media.37 However, these nerve fibres do pass close to the media, which is comprised 
predominantly of VSM cells, demonstrating the major influence of autonomous neural 
control in cutaneous microvascular function.38  
 
As blood vessels decrease in diameter, the proportion of the vessel wall occupied by 
VSM cells remains similar due to a decrease in the number of VSM cell layers to as 
little as one layer in the arterioles.36 However, the actual volume fraction of VSM cells 
within the media typically increases to 70-85% of the total media volume demonstrating 
an increased ability of microcirculatory blood vessels to control vessel diameter.36 Deep 
to the media and an internal elastic lamina is the intima, which consists of a layer of 
endothelial cells that forms a continuous internal cover over the vascular wall. The 
endothelium, which sometimes forms ridges that project into the lumen, also frequently 
projects through fenestrations of the internal elastic lamina regularly making contact 
with VSM cells of the media.36 This important anatomical feature allows for an 
interaction between the endothelium and VSM cells that is crucial to maintaining 
normal vascular tone. Finally, blood vessels are surrounded by perivascular adipose 
tissue, which may also have vasoactive and vasoprotective roles.39 The composition of 
the perivascular adipose tissue varies by region with the amount surrounding the blood 
vessel increasing with greater general adiposity.40 While the microcirculation contains 
mainly white adipose tissue, the macrocirculation is characterized by white, brown or 
beige adipose tissue.39,40 
 
2.1.2 Normal vascular physiology 
In addition to neural control, vascular tone is modulated by shear stress, metabolic 
mechanisms and the arteriolar myogenic response.20 Shear stress, the force exerted on 
the endothelial wall by vascular blood flow, is considered the predominant regulator of 
vasomotion.18 Together, with other agonists such as insulin, acetylcholine, adenosine 
triphosphate, adenosine, bradykinin and histamine (Figure 2-1), shear stress acts on the 
endothelium to stimulate the synthesis of several vasodilating (NO, PGI2, and EDHF) 
and vasoconstricting (ET-1, angiotensin II, prostanoids, and isoprostanes) substances 
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that are released to the VSM, mediating widening and narrowing of the blood vessel, 
respectively.18,19 Additionally, vasoactive substances such as NO, adiponectin, 
hydrogen sulphide and others yet to be identified, may also be released by the 
perivascular adipose tissue surrounding the blood vessel.39 Although both vasodilators 
and vasoconstrictors are synthesized simultaneously, the net result of these two 
antagonistic effects in normal healthy conditions is usually vasodilation.41 Indeed, the 
balance of this mechanism is not only critical to maintaining normal vascular tone, but 
also essential in promoting optimal vascular health through the regulation of pro-
inflammatory cytokines, leukocyte recruitment, platelet aggregation and adhesion, 
angiogenesis and VSM cell proliferation.18  
 
Given its status in those with insulin resistance, the vasoactive role of insulin is 
important to consider when exploring underlying mechanisms of microvascular 
dysfunction. A key component of insulin’s metabolic action is its ability to dilate 
resistance vessels and pre-capillary arterioles to increase total blood flow and the 
microvascular exchange surface perfused within the skeletal muscle, respectively.42 
Thus, allowing for optimal postprandial-nutrient delivery to the most peripheral 
vascular beds such as those of the skeletal system and cutaneous microcirculation. 
Unique to other agonists, insulin achieves its vasodilatory role by synthesizing NO 
exclusively via a calcium-independent pathway.43 In brief, circulating insulin signals 
the insulin receptor of the endothelial cell, activating G protein-phospholipase 
interactions that stimulate the phosphatidylinositol 3-kinase pathway.43,44 This cascade 
of signalling activates protein kinase B to phosphorylate and activate endothelial NO 
synthase (eNOS), which ultimately synthesizes NO from the amino acid, L-
arginine.44,45 Further to its vasodilatory action, insulin also simultaneously induces 
vasoconstrictive mechanisms via mitogen-activated protein kinase, which stimulates 
the secretion of ET-1.42 
 
Shear stress and agonists of vasomotion, such as acetylcholine, adenosine triphosphate, 
adenosine, bradykinin, and histamine, also stimulate NO synthesis via the 
phosphatidylinositol 3-kinase, calcium-independent pathway.18 However, unlike 
insulin, these agonists also stimulate the synthesis of both NO and PGI2 via a calcium-
dependent, cyclooxygenase (COX) pathway. In brief, agonist-mediated G protein-
phospholipase interactions deplete the endothelial cell calcium concentration, inducing 
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a calcium influx via store-operated channels and potassium channel activity.46 Free 
intracellular calcium then binds to calmodulin and liberates arachidonic acid, activating 
eNOS to synthesize NO and initiating the COX pathway to synthesize PGI2, 
respectively.46,47 Once synthesized in the endothelial cell, NO and PGI2 diffuse to the 
VSM cell where they increase the formation of cyclic guanosine monophosphate 
(cGMP) and cyclic adenosine monophosphate (cAMP), respectively. The actions of 
cGMP and cAMP are identical, mediating a reduction in intracellular calcium 
concentration that induces VSM relaxation. Noting that cGMP also promotes cAMP 
activity to increase the overall sensitivity of the mechanism demonstrates the 
synergistic influence of NO and PGI2 to modulate cutaneous microvascular tone.18 
 
In healthy conditions, NO is the dominant agonist in macrovascular vasodilation,48 
while both NO and PGI2 are the dominant mediators of microvascular dilation. 
However, EDHF, which include epoxyeicosatrienoic acids (EETs), also contribute to 
inducing vasodilation.38 In brief, arichidonic acids that are liberated by an increase in 
endothelial intracellular calcium concentrations also stimulate several cytochromes to 
synthesize EETs in the endothelium.49 Diffusion of EETs to the VSM cell induces 
hyperpolarization and subsequent VSM relaxation via opening of potassium channels 
and closure of calcium channels, which causes a decrease in VSM intracellular calcium 
concentrations. Indeed, normal NO bioavailability suppresses cytochrome activity and 
the subsequent synthesis of EETs. However, when NO activity is disrupted, EETs 
production and its vasodilatory influence may increase in order to maintain normal 
vascular reactivity.49 Although these dynamic systems with multiple regulators allow 
for vasodilation and vasoconstriction to still occur normally in the event of weakening 
of a vasoactive pathway, a significant dysfunction within a central mechanism may still 
substantially impair overall vascular function.18 
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Figure 2-1. Schematic diagram illustrating the interaction between the three main 
vasodilatory pathways in normal healthy vascular function Adapted from Hellsten et 
al.18 ACh, acetylcholine; ATP, adenosine triphosphate; BRK, bradykinin; IRS-1, 
insulin receptor substrate-1; G, G-protein phospholipase; Ca++, free intracellular 
calcium; AA, arichidonic acid; PIK3, phosphatidylinositol 3-kinase; COX, 
cyclooxygenase; Calm, calmodulin; eNOS, endothelial nitric oxide synthase; PGI2, 
prostacyclin; CYP, cytochrome metabolites; NO, nitric oxide; EETs, 
epoxyeicosatrienoic acids; cAMP, cyclic adenosine monophosphate; cGMP, cyclic 
guanosine monophosphate; VSM, vascular smooth muscle; é, increase; ê, decrease; 
−, down-regulates; +, up-regulates. 
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2.2 Methods of assessing peripheral vascular reactivity 
 
The peripheral vascular network has become widely accepted as a model of systemic 
vascular function due, mainly, to its superior accessibility allowing for simple non-
invasive investigations. Indeed, the peripheral circulation may also provide an index, 
specifically, of coronary vascular reactivity. Previous vascular research has typically 
utilized techniques that assess peripheral macrovascular reactivity. However, emerging 
evidence suggests that coronary microvascular disease may explain the occurrence of 
myocardial ischemia, heart failure and CVD mortality following myocardial infarction 
without apparent coronary macrovascular disease; highlighting the microcirculation, 
which represents most of the arterial vascular network and exerts dominant control over 
local blood flow to the nutritive network, as an equally important concentration in the 
study of vascular function. When interpreting data acquired from tests of peripheral 
microvascular and macrovascular reactivity, it must be acknowledged that the 
physiology may vary between vascular regions.45,50 The following section of this 
review will detail common tests of microvascular and macrovascular function in the 
peripheral circulation. 
 
2.2.1 Assessing peripheral macrovascular reactivity 
In recent decades, flow-mediated dilation (FMD) in conjunction with ultrasound 
measurements of the brachial artery has become the standard non-invasive test to assess 
macrovascular endothelial reactivity.51,52 Briefly, this test consists of comparing the 
brachial artery diameter at rest (baseline) to that following occlusion of an artery with 
the patient remaining in a supine position for the duration of the test (Figure 2-2). 
Occlusion is usually of the brachial artery and is achieved by inflating a 
sphygmomanometric cuff below, or sometimes above, the antecubital fossa. The cuff 
is typically inflated to 50 mmHg above systolic blood pressure, or  to 200-300 mmHg, 
for 5 minutes before being rapidly deflated to induce shear stress and subsequent 
vasodilation.53 Ultrasound images are taken pre-occlusion and post-occlusion using a 
high-resolution ultrasound machine with the ultrasound probe positioned in the 
longitudinal plane of the brachial artery above the antecubital fossa.  
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Figure 2-2. Ultrasound images of the brachial artery before and after the flow-mediated 
dilation (FMD) and nitrate-mediated dilation (NMD) procedures. Simultaneous 
electrocardiogram recordings are performed (illustrated by the green line) during each 
phase (pre- and post-occlusion/nitroglycerin administration) of FMD and NMD. 
 
 
Whereas FMD assesses endothelial function, nitrate-mediated dilation (NMD) is often 
used to examine VSM reactivity in the macrocirculation.54 Nitrate-mediated dilation is 
performed using similar protocols to that in FMD, but the occlusion is substituted with 
a pharmacological stimulus, namely a NO donor (e.g. sublingual nitroglycerine) that 
bypasses the endothelium and directly stimulates the VSM cells.54 To ensure ultrasound 
image analyses, which determine brachial artery diameter, are performed at a consistent 
phase of the cardiac cycle, ultrasound recordings should be acquired in conjunction 
with electrocardiogram during both FMD and NMD measurements. The percentage 
change between baseline and post-challenge artery diameter is the key variable of 
interest in both tests and is considered as the maximal vasodilator response; irrespective 
of endothelial function, in NMD only.52 
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Evidence suggests that mechanisms underlying FMD predominantly involve the NO 
pathway as infusion of the NO synthase inhibitor N-monomethyl-L-arginine blunts 
vasodilation following occlusion. In contrast, aspirin infusion had no effect, suggesting 
a decreased role of PGI2 in macrovascular function.48,55 More recently, cytochrome 
P450 (CYP) metabolites and, putatively, other hyperpolarizing factors (e.g. EETs), 
have been suggested to closely interact with the NO pathway in the response to artery 
occlusion.56 It must also be recognized that FMD does not only measure mechanisms 
of conduit artery vascular function per se, but also, indirectly, the limb 
microcirculation, due to the stimulus (i.e. shear stress) being highly dependent on 
maximal forearm resistance.33 To facilitate between-study comparisons and optimize 
the evaluation of macrovascular function, it has been suggested that the change in 
brachial artery diameter should be normalized to the shear stress stimulus.57,58 Despite 
these efforts to optimize and standardize the test,34,52,59 the FMD technique still suffers 
from a lack of homogeneity and high inter-operator variability.  
 
2.2.2 Assessing peripheral microvascular reactivity  
Recent technological advances have allowed researchers to perform non-invasive 
assessment of cutaneous microcirculatory health in specific regions with improved 
accuracy; a development that is of considerable importance given that global 
measurement of microvascular perfusion may not reflect regional deficits observed in 
those with diabetes complications (e.g. diabetic foot ulceration).60 Despite these 
advances, the heterogeneity of the cutaneous vascular anatomy itself represents a key 
challenge for achieving reproducible measurements. 
 
2.2.2.1 Strain gauge plethysmography 
Strain gauge plethysmography, also referred to as venous occlusion plethysmography, 
is an old, minimally invasive method that permits extrapolation of blood flow 
(mL/min), usually from the forearm muscle microcirculation. This test consists of 
inflating a cuff around the upper arm above venous blood pressure but below diastolic 
blood pressure (typically 10 s at 40 mmHg). Venous return from the forearm is then 
briefly interrupted while arterial blood inflow is preserved, resulting in a linear increase 
in forearm blood volume. A second cuff placed around the wrist excludes the hand 
circulation. Changes in forearm blood volume are measured by a strain gauge located 
between the cuffs and connected to a plethysmograph.61 Strain gauge plethysmography 
  44 
is particularly interesting to assess the response to vasodilators, which requires intra-
arterial infusion of drugs and makes the procedure more difficult. Finally, heterogeneity 
in the vascular response due to differences in initial arterial pressures, forearm blood 
flow, or size of the forearm, limits the value of the technique.33 
 
2.2.2.2 Digital plethysmography 
More recently, a digital form of plethysmography has emerged as an additional 
technique for assessing peripheral microvascular reactivity. Briefly, arterial pulse wave 
amplitude is measured before and after brachial artery occlusion, and the signal is 
corrected with simultaneous measurement on the contralateral hand. A marketed 
proprietary device (Endo-PAT, Itamar Medical) has been used to show that digital 
vascular dysfunction correlates with metabolic risk factors, including obesity, diabetes 
mellitus and ratio of total to high-density lipoprotein (HDL) cholesterol.62 Digital 
plethysmography also has the advantage of being operator-independent; however, it is 
only partly dependent on the NO pathway.63  
 
2.2.2.3 Laser Doppler flowmetry 
One of the most common methods adopted by researchers over recent decades to 
quantify changes in cutaneous microvascular reactivity has been laser Doppler 
flowmetry (LDF). The laser Doppler principle is based upon the phenomenon that when 
a laser beam emitted by the device hits moving red blood cells in the cutaneous vessels, 
the light undergoes a change in wavelength (Doppler shift) and the backscatter is 
detected.64 The laser Doppler signal, quantified as the product of mean red blood cell 
velocity and concentration, provides an index of cutaneous perfusion referred to as flux, 
rather than a direct measure of cutaneous blood flow as measured by strain gauge 
plethysmography.65 Using a single-point laser probe and a high sampling frequency of 
approximately 32 Hz, LDF is capable of accurately quantifying rapid variations in 
cutaneous blood flow within a volume of 1 mm3 or smaller. However, considering the 
anatomical heterogeneity of the cutaneous microcirculation and the relatively small 
vascular region that can be assessed, LDF is subject to increased spatial variability and, 
thus, presents relatively poor reproducibility between measurements.65 
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2.2.2.4 Laser Doppler imaging  
Laser Doppler imaging (LDI) is an alternative laser-based technology that scans a tissue 
bed of interest (e.g. the volar surface of the forearm) to produce a 2D image and map 
cutaneous blood flux within that region, with each pixel representing a separate 
perfusion value.65 In contrast to LDF, where the laser unit is in direct contact with the 
skin, LDI emits a laser beam at a set distance above the skin surface. Therefore, given 
that LDI is capable of assessing a large area of the cutaneous microvasculature in a 
single scan, the spatial variability associated with LDF is reduced. However, the image 
rate of LDI is much slower than that of LDF and therefore it is not possible to detect 
rapid changes in cutaneous perfusion. Furthermore, research commonly performs a 
single scan to acquire baseline and post-intervention perfusion values, resulting in 
images that correspond to a single time-point during the assessment of microvascular 
function. Consequently, critical events (e.g. peak responses to tests of vascular 
reactivity) may be completely missed, introducing temporal variability and severely 
limiting the reproducibility and interpretation of LDI data. 
 
2.2.2.5 Laser speckle contrast imaging 
The most recently developed laser-based imaging technology, laser speckle contrast 
imaging (LSCI), allows for near real time analysis of cutaneous blood perfusion.38 
Based on the same fundamental operating principles as LDF and LDI, the LSCI head 
unit emits a laser beam above the skin surface from which speckle pattern images are 
acquired to provide a perfusion index proportional to the mean velocity of red blood 
cells.66 Given that LSCI continuously measures cutaneous microvascular blood 
perfusion over a large area (>100 cm2) using a high sampling frequency, it theoretically 
combines the primary advantages of LDF and LDI, reducing the spatial variability and 
temporal variability associated with each technology, respectively.38,66 Indeed, such 
design features may contribute to the excellent reproducibility of LSCI, when compared 
to that of LDF and LDI.38,65–68 Furthermore, recent research has also established the 
relevance of LSCI for monitoring the health of the superficial microvasculature in those 
with T2D-related vascular complications such as foot ulceration, via human and animal 
models (Figure 2-3).69,70   
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Figure 2-3. Measurement of skin perfusion with laser speckle contrast imaging on the 
plantar region of the foot in a diabetic patient with an active ulcer that is healing 
properly. Colours range from dark blue (no perfusion) to red (high perfusion). 
 
 
2.2.2.6 Capillaroscopy 
Whereas laser Doppler and laser speckle provide an index of general cutaneous 
perfusion, capillaroscopy allows for researchers to noninvasively perform direct in vivo 
assessment of the density, recruitment and blood flow velocity of the capillaries;65 the 
normal function of which are critical to maintaining adequate gas and nutrient exchange 
between the microcirculation and the tissues; and promote optimal tissue health. Using 
a microscope with epi-illumination and imaging systems, capillaroscopy is often 
performed at the periungueal region where nailfold capillary loops are oriented parallel 
to the skin, imaging the width of a few millimetres.71 As capillaroscopy visualizes 
erythrocytes, rather than providing an image of the capillary wall, only capillary loops 
with circulating erythrocytes at the time of assessment will be captured.72 For a nailfold 
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capillary pattern to be considered normal, capillary loops ranging from 6 – 15 µm in 
diameter should be homogenously distributed.72 Although nailfold capillaroscopy has 
been shown to have diagnostic applications in diseases that affect the digital cutaneous 
microcirculation, capillaroscopy outside this periungueal region has not been found to 
have clinical applications. Indeed, capillary loops in these other cutaneous regions are 
oriented perpendicular to the skin and, thus, visualization of capillary perfusion is 
limited to the top of the loop, only providing an index for the density of functioning 
capillaries per region of interest.  
 
2.2.2.7 Transcutaneous oxygen tension 
Given that oxygen is vital to maintaining optimal tissue health and, in those with 
diabetic foot ulceration, to promoting the wound healing processes, assessing the 
oxygenation in the cutaneous microcirculation may be considered as an important index 
of skin blood perfusion. Transcutaneous oxygen tension (TcPO2) is an established 
technique that allows for non-invasive evaluation of the partial pressure of oxygen in 
cutaneous tissue. Correlating well with other T2D-related complications such as 
peripheral arterial disease, TcPO2 may also have value in predicting healing rates in 
those suffering from diabetic foot ulceration and amputation rates in those with 
peripheral arterial disease or ischaemic ulcers.73 In brief, using a probe that is applied 
to the surface of the skin and heated to 45°C in order to induce vasodilation, TcPO2 
measures the transfer of oxygen molecules from the blood vessels to the skin surface 
with a decreased TcPO2 reading indicating reduced oxygenation.73 Given that TcPO2 
only assesses the area of tissue directly under the probe, it may be more clinically 
relevant to perform multiple measurements across varied regions rather than 
conducting a single assessment. Indeed, a regional perfusion index, calculated by 
dividing the foot TcPO2 value by a baseline TcPO2 value measured at the chest, may 
provide more reliable data.60 It must be noted that TcPO2 may be less reliable in warm 
ambient environments and in those who are active smokers, have autonomic neuropathy 
or vascular calcification, with or without peripheral arterial disease; or in those who 
have an active infection, oedema, or callus, due to arteriolar shunting that causes TcPO2 
readings to be less representative of the true state of microvascular health.60,74 The 
‘oxygen challenge’, in which patients are administered 100 % oxygen during the TcPO2 
assessment, has been proposed as a strategy to more accurately detect true values that 
represent peripheral artery diseases in such conditions.60 
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2.2.2.8 Near-infrared spectroscopy 
Cutaneous oxygen concentration can also be non-invasively assessed using near-
infrared spectroscopy, a technique that has traditionally been the most popular method 
of estimating or measuring tissue oxygenation.75 Near-infrared spectroscopy, which 
may also provide an indirect method of evaluating mitochondrial function,76 uses near-
infrared light emitted from a probe placed on the skin and is based on the principles 
that specific wavelengths of red and near-infrared light have the ability to penetrate 
through biological tissue; that absorption of these specific red and near-infrared 
wavelengths are dominated by haemoglobin; and that absorption varies between 
oxygenated and deoxygenated haemoglobin.77 Light emitted by the probes typically 
penetrates the tissue to a depth of 2 cm and is detected by photodetectors, which can 
provide estimations of total haemoglobin, oxyhaemoglobin, deoxyhaemoglobin and 
tissue oxygen saturation.77  
 
Near-infrared spectroscopy may have particularly interesting applications in those with 
T2D-related complications. Traditionally, evaluation of diabetic foot ulceration and 
monitoring of healing rates has been based on surface assessments that involve a 
clinician manually measuring the length and width of the wound; a method that may be 
limited by the fact that irregular wound shapes may lead to inaccurate estimations of 
size and unfavourable recommendations for wound treatment.78 The diffuse photon 
density wave methodology of near-infrared spectroscopy allows for measurement of 
oxyhaemoglobin and deoxyhaemoglobin at depths of up to ~3 cm; and, thus, may 
provide more clinically valuable information about the wound on a subcutaneous level 
(e.g. revascularization) and a more advanced method of evaluating the evolution of 
diabetic foot ulceration.79 The efficacy of diffuse near-infrared spectroscopy was 
evaluated in a recent study that monitored the progression of human diabetic foot 
ulceration longitudinally over 24 weeks, finding that the technique had an 82 % 
predictive value for diabetic foot ulceration outcomes within 4 weeks of wound 
monitoring.78  
 
2.2.2.9 Hyperspectral imaging 
Hyperspectral imaging allows for measurement of cutaneous oxygen saturation over a 
wide area and may also have interesting applications in those with T2D-related 
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complications (Figure 2-4). In the lower limb of patients with diabetic foot ulceration, 
there was a negative association between tissue oxygenation assessed by hyperspectral 
imaging at baseline and healing at 12 weeks.80 An index derived from hyperspectral 
imaging measurements indicated very good sensitivity and specificity for predicting 
healing of ulcerations in a small group of patients with type 1 diabetes,81 which needs 
to be validated on a larger scale. 
 
 
 
Figure 2-4. Measurement of cutaneous oxygenation in a peri-wound area using 
hyperspectral imaging (A) and a corresponding photo of the ulcer (B). The image shows 
poor skin oxygenation around the wound. 
 
 
2.2.3 Challenging microvascular reactivity  
Given that resting skin blood flux is highly variable, most interest in technologies that 
assess the microcirculation has been shown when challenging the functionality of the 
microvessels with various tests of vascular reactivity. Indeed, the combination of a 
variety of mechanical, thermal, electrical, or pharmacological stimuli offers a wide 
range of methods that explore different physiological pathways of the microcirculation, 
with varying reproducibility.38 By analogy, arterial occlusion in FMD has been 
proposed as a test of endothelium-dependent microvascular reactivity. This simple test, 
commonly referred to as post-occlusive reactive hyperemia (PORH), involves sensory 
nerves and CYP metabolites, putatively EETs. Local heating of the skin to a 
temperature of 42-44°C is another interesting, reproducible test characterized by a 
biphasic rise in cutaneous blood flow. The initial peak depends on sensory nerves and 
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involves transient receptor potential vanilloid type 1 channels. This peak is followed by 
a transient nadir, and after 10 to 20 minutes the flux stabilizes. The delayed plateau is 
a good indicator of endothelial function, with an involvement of both NO (accounting 
for approximately two thirds of the response) and EDHF (the other third, half of which 
is dependent on EETs).38  
 
To date, most studies that have assessed microvascular reactivity in humans have used 
iontophoresis coupled with laser Doppler. This non-invasive technique is based on the 
transfer of charged molecules, driven by a low-intensity electrical current, across the 
uppermost layers of the skin. Acetylcholine and sodium nitroprusside are the most 
widely utilized vasoactive drugs and are used to assess endothelium-dependent and 
endothelium-independent vascular reactivity, respectively (Figure 2-5). There are 
several methodological issues that should be considered when using iontophoresis. 
Firstly, the vascular response to acetylcholine iontophoresis has long been primarily 
attributed to a NO-dependent endothelial response, when indeed, the involvement of a 
COX-dependent pathway is likely.38 Recently, acetylcholine-mediated vasodilation in 
human skin has also been shown to involve EDHF.82 Interestingly, the relative 
contribution of NO and PGI2 to acetylcholine-mediated vasodilation varied according 
to the concentration and duration of acetylcholine infusion.82 This suggests that using 
acetylcholine iontophoresis, as a test of NO-dependent vasodilation, is somewhat 
oversimplified. Moreover, additional methodological issues are related to non-specific, 
current-induced vasodilation. This is particularly true in patients with diabetes, in 
whom neuropathy may decrease the vasodilatory response to C-fibre activation (axon 
reflex). Indeed, findings from studies using iontophoresis to assess microvascular 
reactivity are inconsistent; highlighting that there are still no standardized protocols for 
iontophoresis and, consequently, there is an array of methods for iontophoresis being 
utilized in the literature with no consensus as to which are free of non-specific 
vasodilatory effects. Other methods, such as microinjections or microdialysis, allow for 
direct delivery of the vasoactive drug into the dermis. Although they are free from the 
risk of current-induced vasodilation, permitting administration of any kind of 
vasoactive substance, they can be more invasive and difficult to implement. 
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Figure 2-5. (A) The graphed response, in perfusion units, to iontophoresis of 
acetylcholine, which typically induces rapid vasodilation. Laser speckle contrast 
imaging illustrates the increase in cutaneous blood flow from the (B) basal state, to the 
(C) intermediate, and (D) maximal responses to acetylcholine iontophoresis. Note that 
the speckle pattern colour varies by cutaneous region with the brighter green speckles 
within the electrode during and immediately following acetylcholine iontophoresis 
indicating increased cutaneous blood flow as compared to the darker (black and blue) 
colours within the electrodes during basal measurements.  
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2.3 Changes in vascular function across the spectrum of 
cardiometabolic health 
 
Currently, evidence indicates that chronic impairments in vascular reactivity may 
present early, even in those considered overweight or obese, long before the clinical 
onset of T2D or its associated complications (e.g. diabetic neuropathy, nephropathy, 
retinopathy and foot ulceration).31 However, whether there is a pathophysiological 
continuum in vascular impairment between early stages and diabetic complications is 
less clear due, mostly, to a lack of comparisons between all key health classifications 
across the spectrum of cardiometabolic health. The pathogenesis of a chronic vascular 
dysfunction may begin with transient impairments in endothelial function, which can 
be induced by numerous dietary and behavioural factors (e.g. excess sugar, salt and 
lipid consumption, smoking, sedentary behaviour etc.). However, the interaction 
between vascular function and these lifestyle factors are also unclear due to discrepant 
results and, ultimately, a lack of research in this field.  
 
Vascular dysfunction, transient or chronic, reduces the capacity of the blood vessel to 
react to specific stimuli (e.g. when shear stress from blood flow, exerted on the arterial 
wall, increases),14 potentiating a situation in which risk of injury to the arterial walls is 
heightened;23 an event that is significant in the process of atherosclerotic change. In 
addition to contributing to the pathogenesis of CVD, impaired vascular reactivity also 
plays a major role in the development of other complications that are associated with 
T2D, such as diabetic nephropathy, retinopathy, peripheral neuropathy and diabetic 
foot ulceration.26–29 Furthermore, impaired vascular reactivity may also contribute to 
the initial and ongoing development of obesity and/or insulin resistance.17 The 
mechanisms underlying vascular dysfunction, whether endothelium-dependent, 
endothelium-independent, perivascular adipose tissue-dependent or neurovascular, are 
complex and multifactorial; and are directly affected by hyperglycemia, obesity, insulin 
resistance and low-grade inflammation.  
 
2.3.1 Effects of hyperglycemia on vascular physiology 
Although there are numerous dietary factors that may affect vascular reactivity, the 
effect of hyperglycemia on vascular function is of primary importance considering that 
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habitual overconsumption of excess sugar, commonly in the form of SSB, is the factor 
that is most consistently found to be associated with an increased incidence of obesity, 
MetS, T2D and CVD.1 From the mid-1960’s, the prevalence of these cardiometabolic 
diseases have closely paralleled the steady increase in per capita calories from SSB 
consumption in both adults and children of developed nations; a trend that has been 
markedly more rapid in developing nations over the past few decades as traditional 
diets become more westernized.10–12 Moreover, concerning data from the United States 
demonstrates that these dietary habits are being instilled at a young age, with children 
and adolescents aged 2-19 years consuming an average of 80 g of added sugar daily.83 
It is important to note that cardiometabolic disease is primarily characterized by 
dysglycemia, which causes frequent hyperglycemic excursions due to poor glycemic 
control. Furthermore, fasting blood glucose concentrations may also be elevated in 
those with cardiometabolic disease.  
 
Considering that little research has examined the acute effects of excess sugar 
consumption on vascular function, this section of the review will detail mechanisms of 
hyperglycemia-mediated vascular dysfunction that may explain vascular dysfunction 
resulting from both acute hyperglycemia-mediated and dysglycemia-mediated 
hyperglycemic excursions. Traditionally, there have been four pathways to explain the 
mechanisms through which hyperglycemia damages the blood vessels and causes 
impairment to vascular function; namely, an abnormal elevation in oxidative 
phosphorylation in the mitochondria, activation of the polyol pathway and aldose 
reductase, protein kinase C (PKC) activation and the formation of advanced glycation 
end products (AGEs).84 All of these pathways contribute to the production of reactive 
oxygen species (ROS), such as superoxide, in the vascular wall and are also involved 
in nerve damage in diabetes, which itself impairs microvascular reactivity; the latter 
depending on intact sensory nerves.42  
 
When blood glucose concentrations increase, oxidative metabolism initiates oxidative 
phosphorylation of adenosine triphosphate at the electron transport chain of the 
mitochondria, which via the phenomenon of electron leakage causes a superoxide 
generation of ROS.85 These ROS are normally readily detoxified by antioxidant 
systems that suppress oxidative stress;85 however, elevated activity within this 
mechanism, such as that during hyperglycemia, may result in an abnormal increase in 
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the production of ROS to a rate beyond the suppressive capacities of the antioxidant 
systems.86 Furthermore, hyperglycemia may also induce an inflammatory response, 
which itself can contribute to a pro-oxidative stress environment.24 Ultimately, 
increases in oxidative stress may disrupt normal vascular reactivity by decreasing the 
bioavailability of the vasodilator NO through several mechanisms including the 
oxidation of eNOS cofactors (e.g. tetrahydrobiopterin), competitive inhibition of eNOS 
by asymmetric NG,NG-dimethylarginine, and reducing arginine availability in an 
arginase-dependent manner.24 Indeed, these mechanisms contribute to the uncoupling 
of eNOS, which may also promote the production of ROS, compounding the existing 
deleterious effects.24   
 
Endothelial dysfunction may also be induced by increased activity in the polyol 
pathway. Glucose metabolism through the polyol pathway is very low in those 
considered healthy. However, in the presence of cardiometabolic disease-related 
hyperglycemia, glucose conversion to the polyol sorbitol by aldose-reductase is 
increased using NADPH as a cofactor. This may deplete cytosolic NADPH, which is 
necessary for regenerating reduced glutathione, a potent cellular antioxidant.86 
Moreover, NADPH is a cofactor for the synthesis of the vasodilator, NO. Thus, 
cytosolic depletion in the endothelium of this essential cofactor of NO synthesis in 
conjunction with a decreased antioxidant capacity favours eNOS uncoupling, shifting 
NO synthesis activity towards decreased NO production and increased superoxide 
generation.  
 
Protein kinase C is a collection of ubiquitously expressed regulatory enzymes involved 
in cellular signal transduction. It plays a central role in several vascular functions, such 
as the regulation of vascular cell permeability, extracellular matrix synthesis, 
angiogenesis, and the regulation of VSM contractility.87 While increased lipid 
diacylglycerol causes PKC activation to be sustained in diabetes, hyperglycemia also 
increases PKC activation through upregulated transcription.88 Such sustained activation 
of endothelial PKC results in endothelium-dependent vascular dysfunction through 
inhibition of the NO and EDHF pathways. Moreover, it also activates the ET-1 pathway 
and enhances the production of ROS, resulting in increased vascular tone.87  
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Hyperglycemia also induces the formation of intracellular and extracellular AGEs 
through both enzymatic and non-enzymatic reactions. In endothelial cells, AGEs alter 
the structure and function of intracellular and extracellular matrix proteins causing 
abnormal interactions with other matrix proteins and with integrins.86 Moreover, 
activation of receptors for AGEs by extracellular AGEs leads to a signalling cascade 
that stimulates nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. This 
increases the production of ROS, which contributes to eNOS uncoupling, as described 
earlier in this section of the review. The role of NADPH oxidase-derived oxidative 
stress in diabetic kidney disease and in diabetic peripheral neuropathy has been 
established.89 Another target of AGEs receptor signalling is nuclear factor-κB (NF-κB) 
translocation to the nucleus, which increases the transcription of proteins including ET-
1 and intracellular adhesion molecule-1 (ICAM-1); and activates inflammatory 
pathways.90  
 
Generation of ROS appears to be a unifying pathway between hyperglycemia and 
endothelial dysfunction, as well as a key player in endothelial cell damage (Figure 2-
6). Indeed, in addition to reducing the bioavailability of NO, superoxide rapidly reacts 
with NO to form peroxynitrite, which exerts a variety of deleterious effects in 
endothelial cells. Peroxynitrite-mediated alterations include depletion of the eNOS 
cofactor, tetrahydrobiopterin, which further promotes eNOS uncoupling, 
deoxyribonucleic acid (DNA) injury and activation of poly (adenosine diphosphate 
ribose) polymerases (PARP).32 In addition to their role in DNA repair, PARP are 
involved in pro-inflammatory reactions in endothelial cells (e.g. ICAM-1 production in 
response to tumor necrosis factor-α [TNF-α]). Over-activation of PARP by 
peroxynitrite depletes the cell of nicotinamide adenine dinucleotide (NAD+), therefore 
impairing mitochondrial electron transport leading to cell death by necrosis.84 
Interestingly, neutralization of peroxynitrite or inhibition of PARP have demonstrated 
interesting effects in the treatment of microvascular complications in various 
experimental models.84  
 
To counter the adverse effects of increased oxidative stress, protective mechanisms that 
naturally occur in endothelial cells may also be initiated in an effort to maintain 
equilibrium in vasomotion. In the skin of the lower limb, mitochondrial superoxide 
dismutase, which converts superoxide into hydrogen peroxide (accounting for EDHF-
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dependent vasodilation), is overexpressed in patients with recently diagnosed T2D, 
while the subepidermal endothelial cell area is preserved.91 This suggests that increased 
mitochondrial superoxide dismutase is an early mechanism protecting against the 
formation of mitochondrial ROS. In contrast, reduced levels of serum mitochondrial 
superoxide dismutase have been associated with a higher incidence of microvascular 
complications.92–94 Activity within the EDHF pathway may also increase, playing a 
compensatory role and maintaining vascular function in those with cardiometabolic 
disease, when NO-dependent vascular function is impaired. Supporting this, recent 
experimental data in an overweight hyperglycemic mouse model of NO deficient 
conditions suggest that inhibiting the degradation of EETs, which also accounts for 
EDHF activity, prevents the onset of complications associated with chronic vascular 
dysfunction, such as microalbuminuria and renal inflammation.95 Indeed, with chronic 
stress, these protective mechanisms may eventually be overwhelmed, potentiating the 
pathogenesis of worse states of cardiometabolic disease, atherosclerotic change and the 
development of complications associated with T2D. 
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Figure 2-6. Mechanisms linking hyperglycemia to endothelial dysfunction involve 
reactive oxygen species (ROS) as a key agonist. Deleterious pathways appear in red, 
while protective mechanisms are in blue. AGE: advanced glycation end-product; DAG: 
diacylglycerol; EDHF: endothelium-derived hyperpolarizing factor; eNOS: endothelial 
nitric oxide synthase; ET-1: endothelin-1; GAPDH: glyceraldehyde 3-phosphate 
dehydrogenase; GSH: glutathione; NADPH: nicotinamide adenine dinucleotide 
phosphate; NF-κB: nuclear factor-kappa B; NO: nitric oxide; NOX: NADPH oxidase; 
O2·−: superoxide; ONOO·: peroxynitrite; PARP: Poly (ADP-ribose) polymerase; PKC: 
protein kinase C; SOD: superoxide dismutase. 
 
 
2.3.2 The role of insulin resistance and obesity in chronic vascular dysfunction 
It must be acknowledged that while obesity is one of the primary driving factors behind 
the increasing prevalence of T2D,7 insulin resistance may also be observed without 
obesity. This section of the review focuses purely on the interaction of obesity and 
insulin resistance. As described earlier in this review, insulin has a pivotal role in 
regulating cell metabolism and in mediating a wide range of hemodynamic effects 
including increased NO-dependent vasodilation and capillary recruitment.96 In 
endothelial cells, insulin up-regulates gene expression of eNOS, vascular endothelial 
growth factor (VEGF) and ET-1, and down-regulates vascular cellular adhesion 
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molecule-1 (VCAM-1); noting that up-regulation of ET-1 does not exert beneficial 
effects on endothelial function. Interestingly, targeted knockout of the insulin receptor 
in the vascular endothelium of mice led to accelerated atherosclerosis without changes 
in insulin levels or sensitivity, suggesting an overall beneficial effect of insulin on 
endothelial function, independently of its metabolic effects.97 
 
The ability of insulin to enhance endothelium-dependent vasodilation in the lower-limb 
is impaired, even in those considered obese, with a negative correlation between leg 
blood flow during metacholine injection and percentage of body fat.98 Interestingly, 
endothelium-dependent vasodilation is similarly reduced by 40-50% in obese patients 
with or without T2D, while endothelium-independent responses remain preserved.98 In 
contrast, insulin resistance in patients with T2D has been associated with impaired 
endothelium-dependent and endothelium-independent vascular reactivity, 
independently from obesity, in parallel with low-grade inflammation.99 This suggests 
that obesity, which plays a key role in the development of insulin resistance, potentiates 
the deleterious effect of insulin resistance on vascular function. Indeed, elevated free 
fatty acids impaired capillary recruitment and acetylcholine-mediated vasodilation in 
the skin of lean subjects, while they were improved after free fatty acids were lowered 
in obese subjects.100  
 
The main mechanism underlying this effect involves the binding of elevated free fatty 
acids to toll-like receptors, which initiate a pro-inflammatory environment through NF-
κB activation. They also activate PKC, which inhibits signalling of the 
phosphatidylinositol 3-kinase pathway and, subsequently, downregulates eNOS, while 
the mitogen-activated protein kinase pathway is preserved. Hence, decreased NO and 
increased ET-1 disrupts the endothelium’s ability to properly vasodilate in response to 
stimuli. Finally, intracellular oxidation of free fatty acids generates ROS, which 
compounds the aforementioned deleterious mechanisms.7  
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2.3.3 Increases in inflammatory cytokines, growth factors, and biomarkers of 
vascular dysfunction in obesity and cardiometabolic diseases 
 
This review has introduced the interaction between hyperglycemia, insulin resistance 
and the inflammatory response. However, given that low-grade inflammation signals 
the onset of vascular injury and the atherosclerotic changes that contribute to the 
pathogenesis of CVD,101 this section will provide special focus on inflammatory 
cytokines, growth factors and biomarkers of vascular dysfunction that develop with 
prolonged cardiometabolic stress; and that accompany and promote chronic impairment 
of vascular reactivity in obesity and cardiometabolic disease (Table 2-1). Previous 
research demonstrated that serum C-reactive protein (CRP), an inflammatory 
biomarker, correlates negatively with the forearm blood flow response to acetylcholine, 
suggesting a relationship between systemic inflammation and endothelial function.102 
Moreover, hyperglycemia and insulin resistance are both known to contribute to 
microvascular dysfunction trough several mechanisms, including the induction of a 
chronic state of vascular inflammation.17 Thus, highlighting inflammatory biomarkers 
as an acceptable surrogate for tests of vascular reactivity to track cardiovascular health 
in diabetes. 
 
Increased expression of intercellular cell adhesion molecule-1 and vascular cell 
adhesion molecule-1 is observed in diabetic populations and has been shown to 
independently predict myocardial infarction.103–105 Activated by cytokines and 
developing atherosclerotic lesions, the endothelium produces cellular adhesion 
molecules (CAMs) that mediate the attachment and transmigration of leukocytes across 
the endothelial surface, an important event in atherogenesis.105 Found firmly bound to 
the membrane of the endothelial cell in greatest concentration around the borders of 
atherosclerotic lesions and lesion prone areas, CAMs may also be released by activated 
endothelial cells from cell surface adhesions in a soluble form that circulates throughout 
the plasma.106,107 Therefore, the presence of soluble CAMs is thought to reflect their 
increased expression on the endothelial cell surface and provide a valuable marker of 
atherosclerotic changes.106 
 
Further to being acted upon, the endothelium contributes to the inflammatory process 
and, consequently, to the pathophysiology of vascular complications in diabetes. 
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Indeed, proinflammatory molecules such as TNF-α and CRP may promote endothelial 
cells to express an atherogenic phenotype.108 When deciding which inflammatory 
biomarkers to track, it is important to note that TNF-α, CRP, interleukin-1, interleukin-
6, monocyte chemoattractant protein-1, and macrophage migration inhibition factor are 
the main markers that have been proven to provide prognostic information about the 
progression and outcome of CVD in diabetic populations.109 Considering the role of 
perivascular adipose tissue in maintaining normal vascular function, it is important to 
recognise that as an active endocrine and paracrine organ, adipose tissue has a major 
role in releasing these cytokines and biomarkers that mediate a pro-oxidant, pro-
inflammatory phenotype.110,111 
 
Noting that diabetes is also associated with pro-thrombotic and anti-fibrinolytic states, 
several molecules such as plasminogen activator inhibitor-1, tissue factor, fibrinogen, 
P-selectin and von Willebrand factor may provide an indication of endothelial 
function.112 Further to this, assessment of micro-ribonucleic acids and circulating 
microparticles may reveal the status of endothelial apoptosis, mechanical injury, and 
cellular activation by cytokines. Endothelial dysfunction is also associated with 
elevated levels of homocysteine, which may share a relationship with increased 
concentrations of asymmetrical dimethylarginine. Elevated asymmetrical 
dimethylarginine disrupts NO synthesis, decreasing its bioavailability and thus 
impairing endothelial function. Decreased concentrations of tetrahydrobiopterin, an 
essential co-factor in the regulation of eNOS, also provides an indication of reduced 
NO bioavailability and endothelial function.113 More recently, endothelial progenitor 
cells, which are of lower concentration in those with diabetes, were also highlighted as 
viable biomarkers of endothelial dysfunction.108,114,115 
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Table 2-1. Biomarkers of endothelial dysfunction and inflammation in diabetes that 
indicate key events in the pathogenesis of cardiovascular disease 
Biomarker Status in diabetes Diagnostic marker of: 
ICAM-1 é Adhesion of leukocytes 
VCAM-1 é Adhesion of leukocytes 
IL-1 é Inflammation 
IL-6 é Inflammation 
TNF-a é Inflammation 
CRP é Inflammation 
MCP-1 é Inflammation 
MIF é Inflammation 
VEGF é Inflammation 
Homocysteine é Inflammation/hyper-coagulation 
Adiponectin ê Inflammation/endothelial dysfunction 
E-selectin é Inflammation/adhesion of leukocytes 
P-selectin é Procoagulant state/adhesion of leukocytes 
ET-1 é Elevated free fatty acids 
PAI-1 é Altered coagulation process 
Fibrinogen é Altered coagulation process 
vWF é Altered coagulation process 
BH4 ê Decreased NO bioavailability 
EPC é Decreased NO bioavailability 
ADMA é Decreased NO bioavailability 
miRs êé Either enhanced or inhibited eNOS activity 
MPs é Endothelial apoptosis, mechanical injury, and 
cellular activation by cytokines 
 
ICAM-1, intercellular cell adhesion molecule; VCAM-1, vascular cell adhesion 
molecule; IL-1, interleukin-1; IL-6, interleukin-6; TNF-a, tumor necrosis factor-a; 
CRP, C-reactive protein; MCP-1, monocyte chemoattractant protein-1; MIF, 
macrophage migration inhibition factor; VEGF, vascular endothelial growth factors; 
ET-1, endothelin-1; PAI-1, plasminogen activator inhibitor-1; vWF, von Willebrand 
factor; BH4, tetrahydrobiopterin; EPC, endothelial progenitor cells; ADMA, 
asymmetrical dimethylarginine; miRs, micro-ribonucleic acids; MPs, circulating 
microparticles; NO, nitric oxide; eNOS, endothelial nitric oxide synthase; é 
increased/up-regulated; êdecreased/down-regulated. 
 
 
 
2.3.4 The role of diabetic peripheral neuropathy in chronic vascular dysfunction 
The ability of the skin to adequately regulate blood flow in response to temperature 
variations or to a variety of mechanical and chemical stimuli is highly dependent on the 
existence of intact neurovascular function. Indeed, diabetes is also associated with 
nerve dysfunction that contributes to impaired reactivity of the cutaneous 
microvasculature and has long been observed through disturbances in cold and heat 
pain thresholds.116 Although diabetic neuropathy has been classically defined as a 
microvascular complication, the relationship between skin microvascular dysfunction 
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and neuropathy in diabetes is complex and has not yet been fully elucidated. Indeed, 
diabetic peripheral neuropathy is a complication that typically presents later in the 
pathophysiological continuum when diabetes is well established. 
 
From a mechanistic perspective, peripheral neuropathy and endothelial dysfunction 
share similar pathophysiological pathways. Indeed, some of the mechanisms described 
above for endothelial cells are also encountered in neurons.117 For example, increased 
intracellular glucose increases the polyol pathway flux. In addition to depleting the 
cellular NADPH reserve, increased aldose-reductase transformation of glucose leads to 
sorbitol accumulation, which de-differentiate Schwann cells into immature cells.118 
Oxidative stress and AGEs also play an important role in the pathophysiology of 
diabetic peripheral neuropathy.117 It is therefore tempting to think that endothelial 
dysfunction and diabetic peripheral neuropathy are two concomitant phenomenon of 
the same origin.  
 
Pioneering work using electron micrographs of sural nerve capillaries showed that 
endoneural microangiopathy was related to the severity of neuropathy, thus supporting 
a causal relationship between impaired microvasculature and diabetic neuropathy.119 
Recent experimental data provided further insight into the complex relationship 
between endothelial function and neuropathy, suggesting that endothelium impairment 
is sufficient to cause neuropathy trough the involvement of the Desert Hedgehog 
pathway.120 This is consistent with a large observational study conducted in participants 
with prediabetes, diabetes with or without neuropathy, and controls, demonstrating that 
endothelial function was a strong, independent predictor of diabetic peripheral 
neuropathy. It further suggested that endothelial dysfunction mediates the deleterious 
effects of diabetes on cardiovascular risk and diabetic peripheral neuropathy.30  
 
A unifying hypothesis could involve neuronal sensors that are also present at the surface 
of endothelial cells. In recent years, growing evidence has suggested that transient 
receptor potential vanilloid subfamily member-1 may play a key role in vascular health 
and metabolism; with possible involvement in the pathogenesis of T2D.121 Other 
sensors may also be involved. Indeed, pressure-induced vasodilation, an early 
microvascular response that delays the decrease in cutaneous blood flow produced by 
local low pressure, is abnormal at the foot level in diabetic patients with or without 
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diabetic peripheral neuropathy.122,123 This reflects microvascular fragility in the skin 
and involves acid-sensing ion channel-3, a voltage-insensitive cation channel that has 
been shown to be a neuronal sensor for appropriate adjustment to pressure changes in 
the cutaneous microcirculation.124 
 
2.3.5 Anatomical changes to the vascular network in cardiometabolic diseases 
The following section will focus on anatomical changes in the vascular network that 
may present in those with a history of T2D. Structural abnormalities of the arterioles 
were observed in the mid-twentieth century in the retina and the kidneys; and arteriolar 
hyalinization, corresponding to the thickening of the walls of arterioles from amputated 
diabetic limbs, was also described.125 Such arteriolar remodelling was confirmed 
decades later in patients with T2D, who had systemic structural alterations of 
subcutaneous small resistance arteries, as indicated by an increased media-to-lumen 
ratio. These abnormalities are characterized by hypertrophic remodelling and are 
associated with impaired endothelium-dependent vasodilation in vitro. Of note, they 
affect patients with and without hypertension.126 Another structural abnormality, that 
has been inconsistently reported, is the decrease in skin capillary density that was 
observed in the lower limb muscle of patients with diabetes when compared to 
controls.127 Additionally, endo-neural capillary density was also found to be reduced in 
diabetic patients with neuropathy.128 Aside from density, abnormal morphology of 
cutaneous capillaries in the dorsum of the foot such as capillary enlargement, a sign of 
hypoxia, has also been reported.129 
 
One of the most notable structural changes of the microvasculature in diabetes involves 
thickening of the capillary basement membrane. These abnormalities are more 
pronounced in the leg, likely because of the higher hydrostatic pressure and the inability 
of the skin microvasculature of diabetic patients to respond adequately to postural 
changes.130 Capillary basement membrane thickness in the nerve and the skin of the 
lower limb correlates with the extent of neuropathy in diabetes.128 Such thickening of 
the basement membrane may affect oxygen and nutrient exchanges. Moreover, it may 
also limit the compensatory arteriolar dilation in response to reduced perfusion 
pressure.129 Despite these deleterious adaptations, structural microcirculatory changes 
are not likely to have a primary role in the pathophysiology of more severe 
complications associated with T2D, such as diabetic foot ulceration; rather, they 
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potentiate the functional impairment that affects different parts of the cutaneous 
microcirculation, most prominently, the arterioles and arterio-venous anastomoses. 
 
2.3.6 Regional differences in the decline of vascular health  
Popular hypotheses suggest that microvascular dysfunction may precede 
macrovascular dysfunction. However, whether there is a pathophysiological continuum 
in microvascular and macrovascular dysfunction between early stages and diabetic 
complications has never been addressed; and, thus, it remains unclear whether 
microvascular dysfunction precedes or parallels large vessel impairment. In contrast, 
regional difference between anatomical regions (e.g. upper body versus lower body) 
may be clearer. Differences in the cutaneous microcirculation between the upper and 
the lower limb may explain why diabetic ulcers develop on the foot. In healthy subjects, 
absolute perfusion and TcPO2 of non-glabrous skin is similar between the upper and 
the lower limb.131 However, the reactivity of the microvasculature expressed as the 
percentage change from baseline measurement in response to reactivity tests is lower 
in the foot than in the forearm; and this difference is consistent in diabetic patients with 
and without diabetic peripheral neuropathy.131 In patients with T2D, the vasodilatory 
response to acetylcholine iontophoresis was more altered in the foot than in the forearm 
when neuropathy was present; while diabetic peripheral neuropathy was associated 
with reduced microvascular reactivity both on the foot and the forearm.132 Similarly, 
local anaesthesia had no effect on microvascular reactivity on the foot of patients with 
diabetic peripheral neuropathy when assessing sensory nerve-dependent vasodilation, 
showing further impairment in these patients.133 Ultimately, differences between upper 
and lower extremities may be explained by higher hydrostatic pressure in the lower 
limb that leads to microvascular remodelling and a subsequent decrease in the ability 
to respond to stimuli. Furthermore, differences in the density of arterio-venous 
anastomoses between the foot and the forearm may also be an explanation.134 
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2.4 Summary 
 
In normal vascular function, the endothelium and perivascular adipose tissue interact 
with the VSM cells, releasing vasodilating and vasoconstricting substances that 
maintain optimal blood vessel tone and organ perfusion. In recent decades, several 
techniques have been developed that allow researchers to assess changes in vascular 
reactivity, non-invasively in the peripheral vasculature, providing a model of coronary 
vascular health and, in certain cases (e.g. neuropathy and foot ulceration), a measure of 
vascular health directly in the region of interest. While the guidelines for assessing 
macrovascular reactivity appear clear, this review has demonstrated that there is far less 
consensus in the methodology for assessing microvascular reactivity and, subsequently, 
there are a range of techniques presented in the literature. 
 
In vascular dysfunction, the reactivity of the blood vessel is decreased, heightening the 
risk of injury to the vessel wall and, subsequent, atherosclerotic change. Many studies 
have explored vascular reactivity across different populations from healthy subjects to 
patients with T2D, providing evidence that chronic impairments in vascular reactivity 
develop early, even in those considered overweight and metabolically healthy. While 
dysglycemia may have a primary role in the ongoing development of chronic vascular 
dysfunction, it has been suggested that acute hyperglycemia, induced by excess sugar 
consumption, may also cause transient impairments to vascular reactivity. Indeed, any 
hyperglycemic excursion may cause an elevation in oxidative stress that disrupt 
pathways crucial to maintaining normal vascular function (e.g. the NO pathway). 
Ultimately, though, the effect of acute hyperglycemia on vascular function is unclear 
due to discrepant results and a lack of data. Furthermore, whether there is a 
pathophysiological continuum in microvascular and macrovascular dysfunction 
between early stages and diabetic complications has never been addressed. Considering 
that vascular dysfunction is one of the earliest discernible pathophysiological 
precursors to the pathogenesis of CVD and a potentiating factor in the ongoing 
development of obesity and insulin resistance, highlights the importance of this 
research program’s objective to further understand the changes in vascular reactivity 
across the spectrum of cardiometabolic health.
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Chapter 3 – Study one: Acute hyperglycemia impairs 
vascular function in healthy and cardiometabolic diseased 
subjects: systematic review and meta-analysis  
 
Publication statement: 
This chapter is comprised of a manuscript that is published in Arteriosclerosis, 
Thrombosis and Vascular Biology.  
 
Loader J, Montero D, Lorenzen C, Watts R, Meziat C, Reboul C, Stewart S, Walther 
G. Acute hyperglycemia impairs vascular function in healthy and cardiometabolic 
diseased subjects: systematic review and meta-analysis. Arter Thromb Vasc Biol. 
2015:35(9):2060-72. Doi: 10.1161/ATVBAHA.115.305530. 
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3.1 Linking paragraph 
 
It has been suggested that the development of a chronic impairment in vascular 
reactivity, which may potentiate atherosclerotic change and the pathogenesis of obesity 
and cardiometabolic disease, begins with transient impairments induced by a 
combination of dietary and lifestyle factors. Excess sugar consumption is the dietary 
factor that is most consistently associated with the pathogenesis of obesity, 
cardiometabolic disease and CVD. Indeed, it has been suggested that acute 
hyperglycemia, mediated by excess sugar consumption, may transiently impair 
vascular function. However, the overall effect of acute hyperglycemia on vascular 
function is not entirely clear due to discrepant results in previous research. Considering 
this, the first study of this research program consolidates existing data in a systematic 
review and meta-analysis, aiming to determine the effect of acute hyperglycemia on 
vascular function in those considered healthy, obese or in those with cardiometabolic 
diseases.  
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3.2 Abstract 
 
Objectives 
Controversy exists over the effect of acute hyperglycemia on vascular function. In this 
systematic review, we compared the effect of acute hyperglycemia on endothelium-
dependent and endothelium-independent vascular reactivity across healthy and 
cardiometabolic diseased subjects.  
 
Approach and Results 
A systematic search of MEDLINE, EMBASE and Web of Science from inception until 
July 2014 identified articles evaluating endothelium-dependent and endothelium-
independent vascular reactivity during acute hyperglycemia and normoglycemia. Meta-
analyses compared the standardized mean difference (SMD) in endothelium-dependent 
and endothelium-independent vascular reactivity between acute hyperglycemia and 
normoglycemia. Subgroup analyses and meta-regression identified sources of 
heterogeneity. Thirty nine articles (525 healthy and 540 cardiometabolic subjects) were 
analysed. Endothelium-dependent vascular reactivity was decreased (39 studies; n = 
1065; SMD, -1.25; 95% confidence interval [CI], -1.52 to -0.98; P<0.01), whereas 
endothelium-independent vascular reactivity was preserved (6 studies; n = 144; SMD, 
-0.07; 95% CI, -0.30 to 0.16; P=0.55) during acute hyperglycemia compared with 
normoglycemia. Significant heterogeneity was detected among endothelium-dependent 
data (P<0.01). A subgroup analysis revealed that endothelium-dependent vascular 
reactivity was decreased in the macrocirculation (30 studies; n = 884; SMD, -1.40; 95% 
CI, -1.68 to -1.12; P<0.01), but not in the microcirculation (9 studies; n = 181; SMD, -
0.63; 95% CI, -1.36 to 0.11; P=0.09). Similar results were observed according to health 
status. Macrovascular endothelium-dependent vascular reactivity was inversely 
associated with age, blood pressure, and low-density lipoprotein (LDL) cholesterol and 
was positively associated with the post-occlusion interval of vascular assessment.  
 
Conclusions    
To our knowledge, this is the first systematic review and meta-analysis of its kind. In 
healthy and diseased subjects, we found evidence for impairment of macrovascular, but 
not microvascular, endothelium-dependent reactivity during acute hyperglycemia.   
  70 
3.3 Introduction 
 
The prevalence of T2D represents a major public health issue, directly affecting an 
estimated 312 million people worldwide.135 This burden is projected to worsen due, in 
part, to increasingly sedentary lifestyles and unhealthy dietary habits predominantly 
characterized by an excess consumption of added sugars.9,11,136 Habitual consumption 
of added sugars, most commonly in the form of SSB, is strongly associated with an 
increased risk in developing T2D, as well as MetS and obesity.137–140 In addition, 
consumption of added sugars has been linked to an increased risk of developing CVD, 
which is the leading cause of mortality amongst those with cardiometabolic 
disease.135,141,142 Consumption of excess added sugars leads to acute hyperglycemia, 
which is considered a better predictor of future CVD events than fasting glycemia in 
healthy and diabetic populations.24,143 Indeed, such acute hyperglycemic stress has also 
been proposed to contribute to vascular dysfunction,144 which represents one of the 
main precursors to CVD.145  
 
In normal vascular function, the endothelium and VSM cells continuously interact to 
regulate vasodilation and vasoconstriction, maintaining optimal organ perfusion and 
vascular tone.20,21 During acute hyperglycemia, increased oxidative stress has been 
proposed as a key trigger of vascular dysfunction by reducing NO production or NO 
bioavailability.21,146,147 Furthermore, animal and in vitro studies suggest that acute 
hyperglycemia may also impair endothelium-independent reactivity by disrupting its 
pathways and VSM cell apoptosis, causing subsequent VSM cell proliferation and 
desensitization to NO.25,148,149 However, whether endothelium-dependent and 
endothelium-independent vascular reactivity are transiently impaired during acute 
hyperglycemia in humans is unclear because of discrepant results. Given this, we 
conducted a systematic review and meta-analysis of available studies comparing 
endothelium-dependent vascular reactivity alone or in combination with tests of 
endothelium-independent vascular reactivity during acute hyperglycemia in healthy 
and cardiometabolic diseased individuals.  To our knowledge, this represents the first 
systematic review and meta-analysis to assess the effect of acute hyperglycemia on 
vascular function. 
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3.4 Methods 
 
This review was conducted according to the Preferred Reporting Items for Systematic 
Review & Meta-Analysis (PRISMA) statement.150 
 
3.4.1 Data sources and searches  
The systematic search included MEDLINE, EMBASE, and Web of Science databases, 
from their inception until July 2014. The search consisted of combinations of subject 
headings including: ‘postprandial hyperglycemia’, ‘acute hyperglycemia’, ‘oral 
glucose tolerance test’, ‘high glucose’, ‘glucose load’, ‘vasodilation’, ‘vascular 
reactivity’, ‘FMD’, ‘acetylcholine’, ‘endothelium-dependent’, ‘endothelium-
independent’, ‘nitroglycerin’, and ‘sodium nitroprusside’. Searches were limited to 
‘human’ studies only; but were not limited by study design. A manual search of 
reference citations in identified reviews and original articles selected for full text 
retrieval was also performed.54 
 
3.4.2 Study selection 
To be included in this review, studies had to assess endothelium-dependent and 
endothelium-independent vascular reactivity in states of acute hyperglycemia and 
normoglycemia in humans. Blunted FMD and sublingual NMD of the brachial artery 
indicated impaired macrovascular endothelium-dependent and endothelium-
independent reactivity, respectively. A blunted increase in blood perfusion in response 
to PORH or the administration of acetylcholine, metacholine or serotonin intravenously 
or by iontophoresis suggested impairment of microvascular endothelium-dependent 
reactivity. Impairment of endothelium-independent vascular reactivity was 
demonstrated if there was a blunted increase in blood perfusion in response to 
iontophoresis or intravenous administration of sodium nitroprusside. Studies following 
the above criteria, but including other interventions deemed likely to influence vascular 
function, such as exercise training programs combined with hyperglycemic tests, were 
excluded. In the event of multiple publications pertaining to the same research, the first 
published or more comprehensive study was included. If multiple trials inducing acute 
hyperglycemia were conducted for the same sample in a single study, data for the initial 
acute hyperglycemia and normoglycemia trials were included in the meta-analysis. 
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Where vascular reactivity was tested multiple times during a single period of acute 
hyperglycemia, data for vascular reactivity measured during peak hyperglycemia was 
included. Inclusion was limited to studies published in the English language. Study 
selection was performed independently by two investigators (J. L.) and (D. M.). 
Discrepancies in inclusion/exclusion were solved by consensus or through consultation 
with a third reviewer (G. W.). 
  
3.4.3 Data extraction and quality assessment 
The following variables were summarized into a pre-formatted spreadsheet by two 
investigators (J.L.) and (D.M.): authors, year of publication, characteristics of 
participants (n, % female, age, body mass index, blood pressure, fasting insulin, fasting 
glucose, HbA1c %, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, 
smoking, medication and health status) and vascular variables (region assessed, method 
used, length of time for post-occlusion interval of vascular assessment, endothelium-
dependent and endothelium-independent vascular reactivity data). Additionally, the 
type of carbohydrate and dosage used to induce acute hyperglycemia were recorded. If 
data were unclear or were not available in the published reports, the corresponding 
and/or first author was contacted by email to request this information. A Systematic 
Appraisal for Observational Research (SAQOR),151 previously applied in meta-
analyses of observational studies evaluating vascular function,152,153 was performed to 
provide assessment of study quality. The SAQOR was scored out of 12, quality deemed 
better with a greater score. The Grading of Recommendations Assessment, 
Development & Evaluation (GRADE) was performed to provide assessment of the 
quality of evidence for outcomes investigated by this meta-analysis.154 The GRADE 
for each outcome was classified as high quality, moderate quality, low quality, or very 
low quality. Results from studies designed as randomized controlled trials began as 
high-quality evidence, whereas observational studies began as low-quality evidence. 
Quality of evidence decreased due to: (1) study limitations; (2) inconsistency of results; 
(3) indirectness of evidence; (4) imprecision; or (5) reporting bias. Quality of evidence 
was upgraded if there was: (1) a large magnitude of effect; (2) a dose-response gradient; 
or if (3) plausible biases would decrease the magnitude of an apparent treatment effect. 
Data extraction (J.L. and D.M.) and assessment of study quality (J.L. and C.L.) were 
performed independently by two investigators. Discrepancies were solved through 
consultation with a third reviewer (G.W.). 
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3.4.4 Data synthesis and analysis 
The meta-analyses and meta-regression analyses were performed using Review 
Manager (RevMan 5.3; Cochrane Collaboration, Oxford, UK) and Comprehensive 
Meta-Analysis software (Comprehensive Meta-Analysis 2.2.064; Biostat, Englewood 
NJ, USA), respectively. The primary outcomes were the SMD in endothelium-
dependent and endothelium-independent vascular reactivity between acute 
hyperglycemic and normoglycemic states. The SMD summary statistic allowed for 
standardization of values obtained using different methodologies into uniform scales to 
complete the meta-analyses.155 Each SMD was weighted according to the inverse 
variance method and they were pooled with a random-effects model.151 A negative 
SMD corresponded to decreased vascular reactivity in the acute hyperglycemic state 
compared to the normoglycemic state.  
 
Heterogeneity between studies was assessed using the chi-squared test for 
heterogeneity and the I2 statistic. In case of considerable heterogeneity (I2>75 %) after 
subgroup analyses, the adequacy of pooling study estimates was determined in light of 
the consistency of the direction and size of the intervention effect.155 In addition, pre-
defined potential moderating factors (n, age, gender, body mass index, systolic blood 
pressure, diastolic blood pressure, fasting insulin, fasting glucose, HbA1c %, total 
cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, length of time for post-
occlusion interval of vascular assessment, methodological quality score, year of 
publication) influencing the SMD in endothelium-dependent vascular reactivity were 
evaluated ad-hoc by subgroup and meta-regression analyses. In all meta-regression 
models, studies were weighted by the inverse variance of the dependent variable. 
Potential moderating factors were individually entered as independent variables in 
regression models with the SMD in endothelium-dependent vascular reactivity as the 
dependent variable. Publication or other biases were evaluated by funnel plots, the Begg 
and Mazumdar’s rank correlation test, and Egger’s regression test.156 A P-value of less 
than 0.05 was considered statistically significant. 
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3.5 Results 
 
3.5.1 Study selection and characteristics 
A flow-chart of study selection is shown in Figure 3-1. The systematic search resulted 
in the inclusion of 39 from 394 potential articles.157–195 Fourteen of these articles 
reported vascular data for multiple subgroups of a given or diverse health status; thus, 
they were assessed as individual studies.157,160–163,166,172,173,180,187,191–194 The main 
characteristics and clinical data for these studies are shown in Table 3-1 and Table 3-2, 
respectively. Three potentially relevant studies were not available for full text reading 
and, thus, could not be included.196–198 All studies assessed endothelium-dependent and 
endothelium-independent vascular reactivity during acute hyperglycemia and 
normoglycemia in a total of 1065 individuals classified as healthy (n = 525), obese (n 
= 72), or having impaired glucose tolerance (n =104), T2D (n = 229), hypertension (n 
= 94), MetS (n = 30), or type 1 diabetes (n = 11). 
 
Figure 3-1. Flow Diagram of the study selection process. AH, acute hyperglycemia; 
NG, normoglycemia.  
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Table 3-1. The main characteristics of the studies included in the meta-analysis 
Study, year of 
publication 
Study 
design 
Health 
status Medication 
Quality 
Score Vascular 
region 
Inducing AH EDVR during 
AH 
EIVR 
during 
AH (0 – 12) Method Dose 
Grasser et al,169 2014 RCT Healthy None 9 Micro Energy drink Sucrose/glucose 39.1g ↑ ACh NA 
Nakayama et al,178 2013 OBS Healthy None 6 Macro Sugar drink Maltose 75g ↓ FMD NA 
Mah et al,177 2013 RCT Healthy None 11 Macro OGTT Glucose 75g ↓ FMD NA 
Wang et al A,187 2013 RCT Healthy None 9 Macro OGTT Glucose 75g ↓ FMD NA 
Zhang et al A,194 2013 RCT Healthy None 10 Macro OGTT Glucose 75g ↓ FMD NA 
De Marchi et al,165 2012 RCT Healthy None 8 Micro OGTT Glucose 75g ↓ ACh ↔ SNP 
Grassi et al,170 2012 RCT Healthy None 9 Macro OGTT Glucose 75g ↓ FMD NA 
Suzuki et al,184 2012 OBS Healthy None 8 Macro OGTT Glucose 75g ↓ FMD NA 
Ceriello et al A,163 2011 RCT Healthy None 6 Macro OGTT Glucose 75g ↓ FMD NA 
Mah et al,176 2011 RCT Healthy None 11 Macro OGTT Glucose 75g ↓ FMD NA 
Watanabe et al,188 2011 OBS Healthy None 11 Macro OGTT Glucose 75g ↓ FMD NA 
Baynard et al A,160 2009 OBS Healthy 3 statin, 1 
hydrochlorothiazide, 
 1 angiotensin II 
receptor blocker, 
1 angiotensin 
converting enzyme 
inhibitor 
9 Macro Test meal Carbohydrate 80g ↓ FMD NA 
Ceriello et al (1) A,162 
2008 
OBS Healthy None 8 Macro IV infusion Glucose 15mmol/L ↓ FMD NA 
Ceriello et al (2) A,161 
2008 
RCT Healthy None 8 Macro IV infusion Glucose 15mmol/L ↓ FMD NA 
Natali et al A,180 2008 OBS Healthy Unknown 11 Micro OGTT Glucose 75g ↔ ACh ↓ SNP 
Weiss et al,189 2008 RCT Healthy None 10 Macro Candy/sugar 
drink 
Carbohydrate 101g ↓ FMD NA 
Xiang et al (1) A,192 2008 RCT Healthy None 11 Macro OGTT Glucose 75g ↔ FMD NA 
Xiang et al (2) A,191 2008 OBS Healthy None 11 Macro OGTT Glucose 75g ↓ FMD ↔ 
NMD 
Xiang et al (2) B,191 2008 OBS Healthy None 11 Macro OGTT Glucose 75g ↔ FMD ↔ 
NMD 
Dengel et al A,166 2007 OBS Healthy None 11 Macro OGTT Glucose 75g ↑ FMD NA 
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Zhu et al,195 2007 RCT Healthy None 7 Macro OGTT Glucose 75g ↓ FMD NA 
Arora et al A,157 2006 OBS Healthy None 10 Micro OGTT Glucose 75g ↓ PORH NA 
Fujimoto et al,168 2006 OBS Healthy None 10 Macro OGTT Glucose 75g ↓ FMD NA 
Tushuizen et al,186 2006 RCT Healthy None 11 Macro Test meal Carbohydrate 55g ↓ FMD NA 
Napoli et al,179 2004 RCT Healthy None 6 Micro Test meal Carbohydrate 60g ↔ ACh ↔ SNP 
Siafarikas et al,182 2004 RCT Healthy None 9 Macro OGTT Glucose 75g ↔ FMD NA 
Ihlemann et al,171 2003 RCT Healthy None 7 Micro OGTT Glucose 75g ↓ Serotonin ↓ SNP 
Bagg et al,158 2000 RCT Healthy None 9 Macro IV infusion Dextrose 10% 238mL ↔ FMD NA 
Title et al,185 2000 RCT Healthy None 11 Macro OGTT Glucose 75g ↓ FMD NA 
Kawano et al A,173 1999 OBS Healthy None 10 Macro OGTT Glucose 75g ↔ FMD NA 
Williams et al,190 1998 OBS Healthy None 10 Micro IV infusion Glucose 16.7mmol/L ↔ 
Metacholine 
NA 
Lavi et al,175 2009 RCT Obese None 8 Macro Sugar drink Glucose 50g ↓ FMD NA 
Dengel et al B,166 2007 OBS Obese None 11 Macro OGTT Glucose 75g ↑ FMD NA 
Wang et al B,187 2013 RCT IGT None 9 Macro OGTT Glucose 75g ↓ FMD NA 
Natali et al B,180 2008 OBS IGT Unknown 11 Micro OGTT Glucose 75g ↔ ACh ↓ SNP 
Xiang et al (1) B,192 2008 RCT IGT None 11 Macro OGTT Glucose 75g ↓ FMD NA 
Arora et al B,157 2006 OBS IGT None 10 Micro OGTT Glucose 75g ↓ PORH NA 
Kawano et al B,173 1999 OBS IGT None 10 Macro OGTT Glucose 75g ↓ FMD NA 
Wang et al C,187 2013 RCT T2DM None 9 Macro OGTT Glucose 75g ↓ FMD NA 
Ceriello et al B,163 2011 RCT T2DM 6 metformin 
discontinued 4 weeks 
prior 
5 excluded angiotensin 
converting enzyme 
inhibitor 
6 Macro OGTT Glucose 75g ↓ FMD NA 
Chittari et al,164 2011 OBS T2DM 17 oral agents 10 Macro OGTT Glucose 75g ↓ FMD NA 
Kato et al A,172 2010 RCT T2DM None 9 Macro Cookie Carbohydrate 75g ↓ FMD NA 
Kato et al B,172 2010 RCT T2DM None 9 Macro Cookie Carbohydrate 75g ↓ FMD NA 
Kato et al C,172 2010 RCT T2DM None 9 Macro Cookie Carbohydrate 75g ↓ FMD NA 
Ceriello et al (1) B,162 
2008 
OBS T2DM None 8 Macro IV infusion Glucose 15mmol/L ↓ FMD NA 
Ceriello et al (2) B,161 
2008 
RCT T2DM None 8 Macro IV infusion Glucose 15mmol/L ↓ FMD NA 
Ceriello et al (2) C,161 
2008 
RCT T2DM None 8 Macro IV infusion Glucose 10mmol/L ↓ FMD NA 
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Ceriello et al (2) D,161 
2008 
RCT T2DM None 8 Macro IV infusion Glucose 10mmol/L ↓ FMD NA 
Natali et al C,180 2008 OBS T2DM Unknown 11 Micro OGTT Glucose 75g ↔ ACh ↓ SNP 
Stirban et al,183 2006 RCT T2DM 13 insulin, 11 aspirin, 9 
ACE inhibitors,  
1 angiotensin receptor 
blockers,  
6 
hydroxymethylglutaryl-
CoA inhibitors,  
5 Beta-blockers, 5 
diuretics,  
3 calcium channel 
blockers 
11 Macro Test meal Carbohydrate 48g ↓ FMD NA 
Kim et al,174 2003 OBS T2DM None 9 Micro IV infusion Glucose 
12/mg/kg/min 
↓ PORH NA 
Kawano et al C,173 1999 OBS T2DM None 10 Macro OGTT Glucose 75g ↓ FMD NA 
Shige et al,181 1999 OBS T2DM None 8 Macro Test meal Sucrose 75g ↓ FMD ↔ 
NMD 
Zhang et al B,194 2013 RCT Hypertensive None 10 Macro OGTT Glucose 75g ↓ FMD NA 
Zhang et al A,193 2012 RCT Hypertensive None 11 Macro OGTT Glucose 75g ↓ FMD NA 
Zhang et al B,193 2012 RCT Hypertensive None 11 Macro OGTT Glucose 75g ↓ FMD NA 
Ballard et al,159 2013 RCT MetS None 11 Macro Rice milk Mixed sugars 23g ↓ FMD NA 
Baynard et al B,160 2009 OBS MetS 3 metformin, 2 
sulfonylurea, 4 Statin 
11 Macro Test meal Carbohydrate 80g ↓ FMD NA 
Dye et al,167 2012 OBS T1DM Insulin monotherapy 9 Micro IV infusion Dextrose 200mg/dL ↓ PORH NA 
Some studies presented multiple health groups comparing normoglycemia and acute hyperglycemia vascular function and were therefore evaluated as individual 
studies (distinguished by A, B, C, or D). Authors who published multiple studies in a single year were distinguished by (1) or (2). ↓, indicates significant decrease 
of vascular function during acute hyperglycemia compared to normoglycemia; ↔, no significant difference in vascular function between acute hyperglycemia 
and normoglycemia; ↑, significant increase of vascular function during acute hyperglycemia compared to normoglycemia; ACE, angiotensin-converting enzyme; 
ACh, acetylcholine; AH, acute hyperglycemia; EDVR, endothelium-dependent vascular reactivity; EIVR, endothelium-independent vascular reactivity; FMD, 
flow-mediated dilation; IGT, impaired glucose tolerance; IV, intravenous; MetS, metabolic syndrome; NA, vascular data not available; NMD, nitroglycerin-
mediated dilation; OBS, observational study; OGTT, oral glucose tolerance test; PORH, post-occlusive reactive hyperemia; RCT, randomized controlled trial; 
SNP, sodium nitroprusside; T1DM, type 1 diabetes mellitus; and T2DM, type 2 diabetes mellitus.  
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Table 3-2. Clinical data for each study included in this meta-analysis 
Study, year of publication Health status 
n  
(% 
female) 
Age BMI Blood pressure (mmHg) Fasting plasma 
insulin (pmol/l) 
Fasting plasma 
glucose (mmol/l) 
HbA1c 
(%) 
Cholesterol (mmol/l) Triglycerides 
(years) (kg/m2) SBP DBP MAP Total HDL LDL (mmol/l) 
Grasser et al,169 2014 Healthy 25 (48) 22.5±3 23.3±10 114±10 87±5 96±7 NA NA NA NA NA NA NA 
Nakayama et al,178 2013 Healthy 23 (0) 44±10 23±2.1 111±8 71±6 84±7 NA 5.1±0.4 NA NA NA NA NA 
Mah et al,177 2013 Healthy 16 (0) 21.8±3.2 24.8±NA 117±4 79±4 92±4 142.5±94.4 5.3±0.4 NA 3.7±0.8 NA NA 3.3±5 
Wang et al A,187 2013 Healthy 33 (64) 51.36±7.15 24.76±3.6 NA NA NA NA 5.4±0.5 6±0.3 5.5±0.6 1.4±0.4 3.7±0.6 1.5±0.5 
Zhang et al A,194 2013 Healthy 31 (48) 47.87±10.95 23.9±2.1 124±8 79±5 94±6 NA 4.8±1.1 NA 4.7±0.4 1.4±0.3 2.9±0.4 1.3±0.3 
De Marchi et al,165 2012 Healthy 34 (50) 32.4±3.5 19±3 119±4 79±9 92±7 34.8±6.6 5.1±0.6 NA 4.3±0.7 1.5±0.2 NA 1.5±0.1 
Grassi et al,170 2012 Healthy 12 (58) 28±2.7 23.2±4.2 NA NA NA NA 4.2±0.4 NA NA 1.5±0.4 2.5±0.4 0.7±0.3 
Suzuki et al,184 2012 Healthy 14 (57) 33.4±11.9 20.7±2.3 106±9 64±6 78±7 NA 4.8±0.6 5.4±0.3 5±0.6 1.7±0.4 2.7±0.5 0.8±0.4 
Ceriello et al A,163 2011 Healthy 12 (50) 50.5±8.66 28.5±10.7 117±19 78±8 91±11 73.4±15.2 4.5±1.4 4.8±0.7 4.5±2.1 1.4±0.7 2.5±1 0.9±0.7 
Mah et al,176 2011 Healthy 16 (0) 21.6±3.2 28.7±NA 117±4 79±4 92±4 147±96 5.3±0.4 NA 3.6±0.7 NA NA NA 
Watanabe et al,188 2011 Healthy 14 (43) 33.4±11.9 20.7±2.3 106±9 64±6 78±7 29.7±11.9 4.7±0.4 NA 5±0.6 1.7±0.4 2.7±0.5 0.8±0.4 
Baynard et al A,160 2009 Healthy 10 (NA) 53±3.32 32.7±3.5 117±13 72±3 87±6 NA 4.6±0.3 5.2±0.4 5.2±1 1.3±0.3 3.2±0.95 1±0.3 
Ceriello et al (1) A,162 2008 Healthy 22 (45) 50.5±11.73 28.5±14.5 117±26 78±10 91±15 NA 4.5±1.4 4.8±0.9 4.5±2.8 1.4±0.9 2.5±1.4 0.9±0.9 
Ceriello et al (2) A,161 2008 Healthy 10 (40) 50.3±8.22 27.5±9.8 115±14 76±11 89±12 NA 4.5±1 4.8±0.6 4.8±1.9 1.4±1.6 2.4±1.3 0.9±1.6 
Natali et al A,180 2008 Healthy 20 (70) 49±8.94 27.9±4 129±13 78±9 95±10 NA 5.3±NA 5.6±0.5 4.9±0.9 1.2±0.2 3.3±0.8 1.1±0.5 
Weiss et al,189 2008 Healthy 13 (62) 48±17 24±2.2 114±14 66±7 82±10 NA 5.5±1.4 NA NA NA NA NA 
Xiang et al (1) A,192 2008 Healthy 26 (46) 50±6 24.2±2.3 114±7 72±6 86±7 NA 4.6±0.5 NA 4.4±0.9 1.2±0.1 1.9±0.7 1.4±1.2 
Xiang et al (2) A,191 2008 Healthy 17 (41) 39±12.37 24.1±6.6 115±20 68±12 84±15 NA 5.1±1.7 5.1±0.4 4.7±2.7 1.2±0.7 1.9±2.4 1.4±3.8 
Xiang et al (2) B,191 2008 Healthy 15 (47) 40±11.62 23.7±7.4 111±20 24±7 53±12 NA 4.6±1.9 4.8±0.8 4.5±1.9 1.2±0.7 1.9±1.8 1.4±3 
Dengel et al A,166 2007 Healthy 15 (53) 11.3±1.55 17.5±1.9 110±12 59±8 76±9 41.2±15.1 4.8±0.3 NA 3.8±0.8 1.2±0.3 2.3±0.6 0.8±0.4 
Zhu et al,195 2007 Healthy 11 (0) 22.6±2.3 22.5±1.5 113±7 79±6 90±6 NA 5.2±0.2 NA 4±0.8 1.4±0.2 2.1±0.6 0.9±0.3 
Arora et al A,157 2006 Healthy 10 (0) 27±N/A 22.4±NA 122±NA 68±NA 86±NA NA 4.8±NA NA 4.1±NA 1.8±NA 2.2±NA 1.1±NA 
Fujimoto et al,168 2006 Healthy 10 (0) 30±2 NA 111±12 65±8 80±9 NA 5.1±0.6 NA 4.3±0.7 1.2±0.3 NA 1.2±0.7 
Tushuizen et al,186 2006 Healthy 17 (0) 25.4±3 23.6±1.8 116±8 75±7 89±7 33±10 4.8±0.3 5.1±0.2 4±0.6 1.4±0.2 2.2±0.6 0.8±0.3 
Napoli et al,179 2004 Healthy 10 (40) 23±3.16 23.6±1.9 124±6 60±3 81±4 NA 5±NA NA NA NA NA NA 
Siafarikas et al,182 2004 Healthy 32 (66) 19.1±1.7 22.9±4.2 NA NA NA NA NA 5±0.3 4±0.8 1.3±0.4 2.2±0.7 1.2±0.7 
Ihlemann et al,171 2003 Healthy 10 (40) 53±6.96 22.7±1.9 144±17 75±11 98±13 NA NA 5.2±0.3 5.2±0.6 1.7±0.3 3.2±0.6 0.8±0.3 
Bagg et al,158 2000 Healthy 10 (20) 26±6 22±2 111±10 65±8 80±9 34.2±11.4 5.2±0.3 NA 4.7±1 NA NA NA 
Title et al,185 2000 Healthy 10 (40) 25.5±3.1 24±3 118±8 72±7 87±7 NA 5.3±0.7 NA 5.1±1.1 1.3±0.1 3.3±0.9 1.2±0.5 
Kawano et al A,173 1999 Healthy 17 (35) 52.6±7.42 NA NA NA NA 51.6±9.9 5±0.3 NA 4.9±0.4 1.2±0.1 3±0.4 1.5±0.2 
Williams et al,190 1998 Healthy 10 (30) 33±6.32 NA NA NA NA NA 3.9±1.2 3.6±0.6 4.2±0.7 1.1±0.2 2.6±0.7 1±0.4 
Lavi et al,175 2009 Obese 56 (0) 47.9±5.8 32.1±4.3 134±13 82±6 99±8 NA 5.4±0.2 NA 5.1±0.7 1.1±0.2 3.2±0.7 1.7±0.9 
Dengel et al B,166 2007 Obese 16 (56) 10.1±1.6 19.3±6.4 120±12 65±8 83±9 61.6±33.2 4.8±0.2 NA 4.2±0.6 1.1±0.2 2.6±0.5 1±0.6 
Wang et al B,187 2013 IGT 33 (64) 52.88±9.2 27.8±3.1 NA NA NA NA 6.1±0.5 6.5±0 5.5±1 1.2±0.3 3.1±0.8 1.8±0.9 
Natali et al B,180 2008 IGT 16 (63) 52±20 29.5±4.8 122±12 79±8 93±9 NA 5.7±NA 5.9±1.2 5.6±1.4 1.3±0.5 3.7±1.3 1.3±0.6 
Xiang et al (1) B,192 2008 IGT 21 (48) 51±6 24.8±3.1 110±8 72±6 85±7 NA 5.9±0.9 NA 5.2±1.1 1.2±0.2 2.3±0.7 2±1.1 
Arora et al B,157 2006 IGT 10 (0) 65±N/A 23.2±NA 134±NA 72±NA 93±NA NA 5.3±NA NA 4.3±NA 1.2±NA 2.1±NA 2.6±NA 
Kawano et al B,173 1999 IGT 24 (38) 58.5±7.84 NA NA NA NA 66±11.8 5.8±0.8 NA 5.3±1 1.1±0.1 3.4±0.5 1.7±0.2 
Wang et al C,187 2013 T2DM 43 (42) 53.4±8.99 25.7±2.9 NA NA NA NA 7.5±1.2 7.4±0.1 5.8±1.7 1.2±0.3 3.2±0.7 2.2±1.2 
Ceriello et al B,163 2011 T2DM 16 (44) 51.3±10.4 29.5±13.2 123±26 80±14 95±18 107.3±15.2 7.8±8.8 8.4±1.2 5.1±3.2 1.2±0.3 2.6±0.4 1.2±1.6 
Chittari et al,164 2011 T2DM 21 (43) 46.4±9.62 30.1±5 NA 76±8 NA NA 7.8±1.8 7.8±1.4 4.5±0.9 1.2±0.5 2.5±0.9 1.6±0.5 
Kato et al A,172 2010 T2DM 10 (50) 68±7.7 26.8±3.2 144±29 89±19 107±22 45±17.4 6.1±0.8 5.8±0.6 5.5±0.4 1.4±0.3 3.5±1.3 1.5±0.1 
Kato et al B,172 2010 T2DM 10 (30) 67.6±6.2 25.8±2.5 141±26 88±23 106±24 57.6±33.6 6.1±1 6±0.3 5.2±0.7 1.5±0.3 3.7±1.8 1.3±0.2 
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Kato et al C,172 2010 T2DM 10 (30) 67.8±8.6 25.8±3.3 141±29 88±12 106±17 39.6±24.6 6.6±1 6.1±0.6 5.3±0.7 1.4±0.3 3.9±2 1.4±0.2 
Ceriello et al (1) B,162 2008 T2DM 27 (48) 51.3±13.51 29.5±17.2 123±33 80±19 95±24 NA 7.8±11.4 7.7±1.6 5.1±4.2 1.2±0.3 2.6±0.4 1.2±1.6 
Ceriello et al (2) B,161 2008 T2DM 10 (50) 50.3±6.96 27.5±10.1 118±17 77±12 91±14 NA 6.8±7 7.3±1 5±2.5 1.3±0.2 2±0.5 1±1.9 
Ceriello et al (2) C,161 2008 T2DM 10 (50) 50.2±14.23 28.4±13 121±7 79±9 93±8 NA 7.7±1.3 7.9±1.6 5±2.2 1.2±0.3 2.7±0.4 1.3±0.95 
Ceriello et al (2) D,161 2008 T2DM 10 (60) 51±17.71 28.6±11.7 122±11 80±12 94±12 NA 6±1 7.7±1.9 5.1±2.9 1.2±0.3 2.6±0.8 1.2±2.2 
Natali et al C,180 2008 T2DM 17 (71) 58±8.25 29.3±4.1 139±17 81±8 100±11 NA 8.3±NA 7.2±2.1 4.9±1.2 1±0.3 3.29±1.1 1.5±0.4 
Stirban et al,183 2006 T2DM 13 (NA) 56.9±10.1 30.3±3.2 136±22 79±13 98±16 NA NA 8.5±1.8 NA NA NA NA 
Kim et al,174 2003 T2DM 8 (50) 55.9±3.7 25.4±3.2 134±7 82±6 99±7 NA 7.2±2.6 6.6±0.8 5.5±0.3 1.3±0.2 NA 2.1±0.6 
Kawano et al C,173 1999 T2DM 17 (29) 62.2±4.95 NA NA NA NA 84±22.3 7.1±0.3 NA 5.6±0.4 1.1±0.1 3.7±0.4 1.9±0.2 
Shige et al,181 1999 T2DM 7 (29) 49.3±8 26±5 128±9 72±9 91±9 47.4±16.8 7.1±1.3 NA 4.9±13 1±0.2 NA 1.6±0.6 
Zhang et al B,194 2013 Hypertensive 34 (50) 47.44±10.96 24.7±3.5 156±9 96±8 116±8 NA 4.7±0.6 NA 4.7±0.5 1.3±0.2 3±0.4 1.3±0.3 
Zhang et al A,193 2012 Hypertensive 26 (50) 47.92±8.05 24.6±2.6 160±8 97±6 118±7 NA 5.3±0.5 NA 4.7±0.6 1.4±0.3 2.6±0.4 1.4±0.2 
Zhang et al B,193 2012 Hypertensive 34 (47) 49.29±8 24.8±2.5 159±9 99±6 119±7 NA 5.2±0.6 NA 4.9±0.5 1.3±0.3 2.7±0.5 1.3±0.3 
Ballard et al,159 2013 MetS 19 (26) 28.5±9.59 35±3.9 125±11 85±8 98±8 55±25.7 6±0.9 NA 4.7±0.9 1±0.1 2.8±0.2 1.9±0.9 
Baynard et al B,160 2009 MetS 11 (NA) 52±3.16 34.4±5 123±7 78±3 93±4 NA 6.1±1.3 5.9±1.1 5.1±1 1±NA 3.1±0.7 2.4±1.3 
Dye et al,167 2012 T1DM 11 (36) 14.5±3.32 21.5±9.6 105±7 61±10 76±9 NA NA 8.3±1.2 NA NA NA NA 
Data are expressed as mean ± standard deviation or n. Some studies presented multiple health groups comparing normoglycemia and acute 
hyperglycemia vascular function and were therefore evaluated as individual studies (distinguished by A, B, C, or D). Authors who published 
multiple studies in a single year were distinguished by (1) or (2). BMI indicates body mass index; DBP, diastolic blood pressure; HDL, high-
density lipoprotein; IGT, impaired glucose tolerance; LDL, low-density lipoprotein; MAP, mean arterial pressure; MetS, metabolic syndrome; 
NA, data not available; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; and SBP, systolic blood pressure.  
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3.5.2 Quality assessment and potential bias 
The quality of the studies was moderate-to-high. The mean score was 9.4 ± 1.5 of a 
possible 12 points (Table 3-1). The quality of evidence for outcomes demonstrating the 
effect of acute hyperglycemia on vascular reactivity was low-to-moderate (Table 3-3). 
As for the evaluation of potential bias, the funnel plot (Figure 3-2), Begg and 
Mazumdar’s rank correlation test, and the Egger’s regression test suggested the 
presence of publication bias or other biases for the SMD in endothelium-dependent 
vascular reactivity in the studies included in the meta-analysis (P<0.01 and P<0.01, 
respectively). There was no evidence of publication or other biases when assessing the 
SMD in endothelium-independent vascular reactivity in the studies included in the 
meta-analysis. 
 
 
Figure 3-2. Funnel plot of the standardized mean difference (SMD) in macrovascular 
endothelial function in studies included in the meta-analysis. Funnel plot asymmetry: 
P=0.0002 and P=0.00005 according to Begg and Mazumdar’s rank correlation test and 
Egger’s test, respectively. 
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Table 3-3. Effect of acute hyperglycemia on vascular reactivity in healthy and cardiometabolic populations: Quality of Evidence 
Outcome Among 
Participants 
Design (No. 
of Studies) Risk of Bias Inconsistency Indirectness Imprecision Other Considerationsa 
Quality of 
Evidence 
(GRADE) 
Decreased EDVR RCT (23) Serious† Not serious Not serious Not serious Publication bias likely¶ Low 
Decreased EDVR OBS (16) Not serious Not serious Not serious Not serious None Low 
Decreased macro- EDVR RCT (19) Serious† Not serious Not serious Not serious Publication bias likely¶ Low 
Decreased macro- EDVR OBS (11) Not serious Not serious Not serious Not serious None Low 
Preserved micro- EDVR RCT (4) Very serious† Serious§ Not serious Very serious✜ Publication bias likely¶ Very low 
Preserved micro- EDVR OBS (5) Serious≠ Not serious Not serious Serious✜ None Very low 
Preserved EIVR RCT (3) Serious† Not serious Not serious Not serious None Moderate 
Preserved EIVR OBS (3) Not serious Not serious Not serious Not serious None Low 
EDVR indicates endothelium-dependent vascular reactivity; endothelium-independent vascular reactivity; GRADE, Grading of Recommendations 
Assessment, Development and Evaluation; OBS, observational study; and RCT, randomized controlled trial. 
*Large magnitude of effect, dose-response, plausible biases decreasing the magnitude of effect, publication bias. 
†Method for allocation of concealment and participant/assessor blinding unclear or not performed. Incomplete outcome data and selective reporting 
when assessing endothelium-dependent vascular reactivity, macrovascular endothelium-dependent vascular reactivity and microvascular 
endothelium-dependent vascular reactivity or endothelium-independent vascular reactivity during acute hyperglycemia.  
≠No control population included, failure to adequately control for confounding, and incomplete follow up when assessing microvascular 
endothelial function.  
§Large I2 and point estimates vary widely across studies assessing microvascular endothelial function suggesting benefit, harm and no effect of 
acute hyperglycemia.  
✜The 95 % confidence interval of the pooled risk ratio includes both positive and negative effects of acute hyperglycemia. 
¶Publication bias is strongly suspected due to the presence of asymmetry in funnel plots for randomized control trials assessing endothelial, 
macrovascular endothelial, and microvascular endothelial function during hyperglycemia.  
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3.5.3 Endothelial function  
After data pooling, endothelium-dependent vascular reactivity was significantly 
decreased during acute hyperglycemia when compared with normoglycemia (39 
studies; n = 1065; SMD, -1.25; 95% CI, -1.52 to -0.98; P<0.01; Figure 3-3). There was 
no difference between health groups in the SMD in endothelium-dependent vascular 
reactivity (P=0.13), but significant heterogeneity was detected (I2=87 %, P<0.01). 
Subgroup analysis of the SMD in endothelium-dependent vascular reactivity revealed 
that macrovascular endothelium-dependent reactivity was significantly decreased 
during acute hyperglycemia when compared with normoglycemia (30 studies; n = 884; 
SMD, -1.40; 95% CI, -1.68 to -1.12; P<0.01; Figure 3-4), whereas no significant 
decrease was found in the studies that assessed microvascular endothelium-dependent 
reactivity (9 studies; n = 181; SMD, -0.63; 95% CI, -1.36 to 0.11; P=0.09; Figure 3-5). 
Heterogeneity was detected in the SMD in endothelium-dependent reactivity for both 
macrovascular (I2=84 %, P<0.01) and microvascular reactivity studies (I2=90 %, 
P<0.01). Of note, the heterogeneity in microvascular endothelium-dependent reactivity 
was primarily explained (~40 %) by a single study;165 and the exclusion of such study 
did not significantly alter the pooled effect size (8 studies; n = 147; SMD, -0.18; 95% 
CI, -0.53 to 0.17; P=0.30). 
 
3.5.4 Endothelium-independent vascular reactivity  
After data pooling, endothelium-independent vascular reactivity was preserved during 
acute hyperglycemia versus normoglycemia (6 studies; n = 144; SMD, -0.07; 95% CI, 
-0.30 to 0.16; P=0.55; Figure 3-6). There was no significant difference between health 
groups in the SMD in endothelium-independent vascular reactivity (P=0.49) and no 
heterogeneity was observed (I2=0 %, P=0.85). Due to a limited availability of data, it 
was not possible to analyse endothelium-independent reactivity in the macrocirculation 
and microcirculation separately. 
 
3.5.5 Meta-regression analyses 
The SMD in macrovascular endothelium-dependent reactivity was inversely associated 
with age (β=-0.03; P<0.01), systolic blood pressure (β=-0.04; P<0.01), diastolic blood 
pressure (β=-0.05; P<0.01), mean arterial pressure (β=-0.05; P<0.01) and LDL 
cholesterol (β=-0.93; P<0.01; Figure 3-7). In turn, it was positively associated with the 
post-occlusion interval of vascular assessment (β=0.36; P=0.01).  
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Figure 3-3. Forest plot of the standardized mean difference (SMD) in endothelium-
dependent vascular reactivity between acute hyperglycemic and normoglycemic states 
for all included health groups. Squares represent the SMD in endothelium-dependent 
vascular reactivity of each study. The diamond represents the pooled SMD in 
endothelium-dependent vascular reactivity by health group and overall. Some studies 
presented multiple subgroups according to health status; thus, they were evaluated as 
individual studies (distinguished by A, B, C or D). Authors who published multiple 
studies in a single year had studies distinguished by numerical values (1 and 2). AH 
indicates acute hyperglycemia; CI, confidence interval; IV, inverse variance; and NG, 
normoglycemia. 
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Figure 3-4. Forest plot of the standardized mean difference (SMD) in macrovascular 
endothelium-dependent reactivity between acute hyperglycemic and normoglycemic 
states for all included health groups. Squares represent the SMD in endothelium-
dependent vascular reactivity of each study. The diamond represents the pooled SMD 
in endothelium-dependent vascular reactivity by health group and overall. Some studies 
presented multiple subgroups according to health status; thus, they were evaluated as 
individual studies (distinguished by A, B, or C). Authors who published multiple 
studies in a single year had studies distinguished by numerical values (1 and 2). AH, 
acute hyperglycemia; CI, confidence interval; IV, inverse variance; and NG, 
normoglycemia. 
 
!
Supplemental Figure II. Forest plot of SMD in acrovascular endothelial function between acute 
hyperglycemic and ormoglycemic states for all health groups included. IV, inverse variance; AH, 
acute hyperglycemia; NG, normoglycemia. Squares represent the SMD in endothelial function of each 
study. The diamond represents the pooled SMD in endothelial function by health group and overall. 
Some studies presented multiple subgroups according to health status, thus they were evaluated as 
individual stu ies (disti guished by A, B, C or D). Authors who p blished multiple studies in a single 
year had studies distinguished by numerical values (1 and 2)  
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Figure 3-5. Forest plot of the standardized mean difference (SMD) in microvascular 
endothelium-dependent reactivity between acute hyperglycemic and normoglycemic 
states for all included health groups. Squares represent the SMD in endothelium-
dependent vascular reactivity of each study. The diamond represents the pooled SMD 
in microvascular endothelium-dependent vascular reactivity by health group and 
overall. Some studies presented multiple subgroups according to health status; thus, they 
were evaluated as individual studies (distinguished by A, B, or C). Authors who 
published multiple studies in a single year had studies distinguished by numerical values 
(1 and 2). AH, acute hyperglycemia; CI, confidence interval; IV, inverse variance; and 
NG, normoglycemia. 
 
SUPPLEMENTAL MATERIAL!
!
!
 
Supplemental Figure I. Forest plot of SMD in microvascular endothelial function between acute 
hyperglycemic and normoglycemic states for all health groups included. IV, inverse variance; AH, 
acute hyperglycemia; NG, normoglycemia. Squares represent the SMD in endothelial function of each 
study. The diamo d represents the pooled SMD in endothelial function by health group a  verall. 
Some studies presented multiple subgroups according to health status, thus they were evaluated as 
individual studies (distinguished by A, B, C or D)!
!
!
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Figure 3-6. Forest plot of the standardized mean difference (SMD) in endothelium-
independent vascular reactivity between acute hyperglycemic and normoglycemic states 
for all included health groups. Squares represent the SMD in endothelium-independent 
vascular reactivity of each study. The diamond represents the pooled SMD in 
endothelium-independent vascular reactivity by health group and overall. Some studies 
presented multiple subgroups according to health status; thus, they were evaluated as 
individual studies (distinguished by A, B, or C). Authors who published multiple studies 
in a single year had studies distinguished by numerical values (1 and 2). AH, acute 
hyperglycemia; CI, confidence interval; IV, inverse variance; and NG, normoglycemia. 
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Figure 3-7. Meta-regression plots of the standardized mean difference (SMD) in 
macrovascular endothelium-dependent reactivity according to the difference in (A) age 
(β=-0.03, P=0.005), (B) systolic blood pressure (SBP; β=-0.04, P=0.0004), (C) diastolic 
blood pressure (DBP; β=-0.05, P<0.00001), (D) mean arterial pressure (MAP; β=-0.05, 
P=0.00001), (E) low-density lipoprotein cholesterol (LDL; β=-0.93, P=0.005) and (F) 
post-occlusion interval of vascular assessment (β=0.36, P=0.01). The size of each circle 
is proportional to the study’s weight.  
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Therefore, macrovascular endothelial dysfunction observed 
during acute hyperglycemia may partially e mediated by 
a decrease in shear stress stimulus reflecting microvascular 
dysfunction.74 The fact that VSM function was preserved dur-
ing acute hyperglycemia indicates that endothelial dysfunc-
tion precedes VSM dysfunction, further supporting its role 
as a primary mechanism of CVD pathogenesis. Although 
disruptions in NO bioavailability mediated by acute hyper-
glycemia and the resulting endothelial dysfunction may ini-
tially be transient, if repeated often enough, they may lead 
to cumulative adverse outcomes, including proinflammatory 
responses and VSM cell proliferation.12,75 It has been sug-
gested that acute hyperglycemia may induce VSM cell pro-
liferation by disrupting VSM cell apoptosis, which is a key 
mechanism to prevent increased neointimal formation and 
stenosis.19 Moreover, decreased NO delivery by the endothe-
lium to the VSM may contribute to VSM cell proliferation 
through increased periods of higher vasoconstrictive tone.75 
Ultimately, VSM cell proliferation may signal the beginning 
of a detectable and significant VSM dysfunction, represent-
ing a critical event in vascular remodeling and the develop-
ment of CVD.76
Given that CVD is the single leading cause of death, 
accounting for 30% of the annual global mortality rate,77 and 
that even healthy populations are subject to vascular dys-
function during acute hyperglycemia, there is a clear need to 
further investigate the effects of acute hyperglycemia on the 
underlying mechanisms of vascular function in vivo. Because 
of a surge in added sugar consumption in recent decades, 
predominantly in the form of sugar-sweetened beverages,2 
humans are more often in a state of acute hyperglycemia and 
therefore are more frequently inducing endothelial dysfunc-
tion. Considering this, future research should quantify what 
frequency and dosage of sugar consumption mediate athero-
sclerotic vascular changes in healthy and cardiometabolic 
diseased populations. Previously, certain ethnicities have 
demonstrated decreased vascular function at rest compared 
with white subjects.78 Whether this exacerbates any vascular 
dysfunction mediated by acute hyperglycemia is still unknown 
and requires further research. To provide more comprehensive 
conclusions on how macrovascular and microvascular func-
tions are affected by acute hyperglycemia, future research 
should consider shear stress as a covariate of conduit artery 
flow-mediated dilation data during statistical analyses.79,80 
Furthermore, noting that vascular function is not entirely 
mediated by NO,12 future research may also investigate the 
effect of sugar-sweetened beverage consumption on numerous 
mechanisms of vasodilation (eg, NO, endothelium-derived 
Figure 5. Metaregression plots of standardized mean difference (SMD) in macrovascular endothelial function (EF) according to the dif-
ference in (A) age (β=−0.03; P=0.005), (B) systolic blood pressure (SBP; β=−0.04; P=0.0004), (C) diastolic blood pressure (DBP; β=−0.05; 
P<0.00001), (D) mean arterial pressure (MAP; β=−0.05; P=0.00001), (E) low-density lipoprotein cholesterol (LDL; β=−0.93; P=0.005), and 
(F) postocclusion interval of vascular assessment (β=0.36; P=0.01). The size of each circle is proportional to the study’s weight.
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3.6 Discussion 
 
To our knowledge, this is the first systematic review and meta-analysis to assess the 
effect of acute hyperglycemia on vascular function. Data from 39 studies assessing 
endothelium-dependent vascular reactivity alone or in combination with tests of 
endothelium-independent vascular reactivity during acute hyperglycemia in healthy 
and cardiometabolic diseased individuals were pooled and analysed. The meta-analysis 
provided evidence that the average effect of acute hyperglycemia on endothelial 
function is impaired function, whereas endothelium-independent vascular reactivity 
was preserved in healthy and diseased individuals. Due to evidence of heterogeneity, 
the interpretation of the pooled effects of hyperglycemia on endothelium-dependent 
vascular reactivity should be made cautiously. Considerable heterogeneity was 
identified for most subgroups suggesting the variability across studies was due to not 
only sampling variability, but also differences in treatment effect within each study.199 
Nevertheless, the large effects sizes and 95 % CIs consistently favoured 
normoglycemia, providing evidence of treatment effect.199 Exploration of 
heterogeneity with meta-regression indicated that the variability across studies could 
be explained by differences in age, blood pressure, LDL cholesterol and the post-
occlusion interval of vascular assessment. 
 
Currently, there is no consensus on the effect of acute hyperglycemia on endothelium-
dependent vascular reactivity and endothelium-independent vascular reactivity as 
studies assessing vascular reactivity during acute hyperglycemia have presented 
confounding results. This meta-analysis demonstrated evidence of macrovascular 
endothelial dysfunction during acute hyperglycemia in healthy people, as well as in 
patients with cardiometabolic disease, suggesting that the pathogenesis of CVD may 
begin, among others, with acute hyperglycemia-mediated transient decreases in 
endothelial function long before the onset of morbidities such as obesity, hypertension, 
or T2D.  Interestingly, the inverse relationship between macrovascular endothelial 
function and several traditional cardiovascular risk factors demonstrates the degree to 
which acute hyperglycemia mediates macrovascular endothelial dysfunction correlates 
with increases in age, blood pressure, or LDL cholesterol levels. This is consistent with 
previous research revealing that elderly, hypertensive and subjects with dyslipidemia 
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all exhibited significantly impaired endothelium-dependent vasodilation at rest 
compared with healthy populations,200–202 indicating that any existing macrovascular 
endothelial dysfunction may therefore be compounded by an acute hyperglycemic 
stress. The fact that microvascular endothelial dysfunction during acute hyperglycemia 
was not detected contradicts previously published data that associates decreased 
microvascular function with incident T2D and suggests a role for microvascular 
dysfunction in the pathogenesis of T2D.203 Although macrovascular endothelial 
function was affected in healthy populations and in those with cardiometabolic disease, 
in this meta-analysis, endothelium-independent vascular reactivity remained preserved 
during acute hyperglycemia when compared to normoglycemia. In contradiction to 
previous findings in animal and in vitro studies, which found VSM impairment 
mediated by VSM cell proliferation may occur in as little as 6 hours.148,187  
 
Macrovascular endothelial dysfunction observed during acute hyperglycemia by 
methods assessing endothelium-dependent vascular reactivity primarily implicate 
decreased NO bioavailability as a central mechanism of endothelial dysfunction in 
healthy and cardiometabolic diseased populations.48 This may be attributed to acute 
hyperglycemia increasing oxidative stress and its role in disrupting pathways of NO 
synthesis.24 The fact that even healthy people exhibited impaired macrovascular 
endothelial function during acute hyperglycemia demonstrates how acutely NO 
bioavailability may be affected by excess sugar consumption. The magnitude of 
macrovascular endothelial dysfunction induced by acute hyperglycemia may be 
compounded when cardiovascular risk factors such as increased age, blood pressure or 
LDL cholesterol are present. This may be partly due to the fact that health groups 
exhibiting these clinical markers demonstrate decreased NO bioavailability and 
therefore impaired endothelial function, even at rest.200–202 Although NO is the 
predominant vasodilator in macrocirculation, it has been demonstrated to have 
significantly less influence in the microcirculatory system.204 The increased influence 
of other chemical mediators of vasodilation such as endothelial derived hyperpolarizing 
factor and prostaglandin I2,205 may, however, explain why microvascular endothelium-
dependent vascular reactivity remained preserved during acute hyperglycemia.  
Consideration should also be given to the spatial variability associated with the 
techniques used in several of the studies using skin microcirculation as a model of 
assessing microvascular reactivity.206 The large spatial variability in single-point LDF 
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for example, may have limited findings.67 Despite this, final conclusions on the effect 
of acute hyperglycemia on microvascular reactivity should not be made due to the 
limited availability of microcirculation data. Furthermore, it must be acknowledged that 
shear stress was not considered when performing analyses of FMD data in many 
studies. Shear stress, which is responsible for inducing synthesis of the NO release that 
causes FMD, is dependent on variability of the hyperemic blood flow response in the 
microcirculation.207 Therefore, macrovascular endothelial dysfunction observed during 
acute hyperglycemia may partially be mediated by a decrease in shear stress stimulus 
reflecting microvascular dysfunction.207 The fact that endothelium-independent 
vascular reactivity was preserved during acute hyperglycemia indicates that endothelial 
dysfunction precedes impairment to endothelium-independent vascular reactivity, 
further supporting its role as a primary mechanism of CVD pathogenesis. Although 
disruptions in NO bioavailability mediated by acute hyperglycemia and the resulting 
endothelial dysfunction may initially be transient, if repeated often enough, may lead 
to cumulative adverse outcomes, including proinflammatory responses and VSM cell 
proliferation.24,54 It has been suggested that acute hyperglycemia may induce VSM cell 
proliferation by disrupting VSM cell apoptosis, which is a key mechanism to prevent 
increased neointimal formation and stenosis.25 Moreover, decreased NO delivery by the 
endothelium to the VSM, may contribute to VSM cell proliferation through increased 
periods of higher vasoconstrictive tone.54 Ultimately, VSM cell proliferation may 
signal the beginning of a detectable and significant impairment in endothelium-
independent vascular reactivity, representing a critical event in vascular remodelling 
and the development of CVD.208  
 
Given that CVD is the single leading cause of death, accounting for 30 % of the annual 
global mortality rate,209 and that even healthy populations are subject to vascular 
dysfunction during acute hyperglycemia, there is a clear need to further investigate the 
effects of acute hyperglycemia on the underlying mechanisms of vascular function, in 
vivo. Due to a surge in added sugar consumption in recent decades, predominantly in 
the form of SSB,136 humans are more often in a state of acute hyperglycemia and 
therefore are more frequently inducing endothelial dysfunction. Considering this, future 
research should quantify what frequency and dosage of sugar consumption mediate 
atherosclerotic vascular changes in healthy populations and in those with 
cardiometabolic diseases. Previously, certain ethnicities have demonstrated decreased 
  91 
vascular reactivity at rest compared with white subjects.210 Whether this exacerbates 
any vascular dysfunction mediated by acute hyperglycemia is still unknown and 
requires further research. To provide more comprehensive conclusions as to how 
microvascular and microvascular function are affected by acute hyperglycemia, future 
research should consider shear stress as a covariate of conduit artery FMD data during 
statistical analyses.34,58 Furthermore, noting that vascular reactivity is not entirely 
mediated by NO,24 future research may also investigate the effect of consuming SSB 
on numerous mechanisms of vasodilation (e.g. NO, endothelium derived 
hyperpolarizing factor, prostaglandin I2) and vasoconstriction (e.g. ET-1), the influence 
of which vary from the microcirculation to the macrocirculation.  
  
There are a number of inherent limitations to our analyses that require comment. As 
previously discussed, significant heterogeneity was observed among studies that 
assessed endothelium-dependent vascular reactivity. Studies published in languages 
other than English were not included and the quality of evidence for outcomes assessed 
in this meta-analysis was low-to-moderate. Sub-analyses of microcirculatory and 
endothelium-independent data were limited due to the low number of studies assessing 
microvascular reactivity and endothelium-independent vascular reactivity in 
normoglycemic and acute hyperglycemic states. Furthermore, some studies used 
methods of assessing the microcirculation that can be easily influenced by spatial 
variability and thus may limit results when assessing microvascular function. The risk 
of publication or other biases were detected when assessing the SMD in endothelial 
function. However, the quality of studies was evaluated by specific tools for the quality 
assessment of observational research,151,153 revealing a predominantly low bias risk. It 
must be acknowledged that the ethnicity of the populations was poorly reported by 
studies included in this meta-analysis and, thus, conclusions on the effect of ethnicity 
cannot be drawn from these data.  Finally, many studies using FMD as a method of 
assessing macrovascular endothelial function did not report shear stress. Therefore, it 
was not possible to comprehensively conclude whether macrovascular endothelial 
dysfunction found during acute hyperglycemia is due to intrinsic abnormalities of 
macrovascular endothelial function or if it is partially attributable to microvascular 
dysfunction and decreased stimulus for conduit artery dilation.58 
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In conclusion, based on studies included in this meta-analysis, current evidence 
suggests that acute hyperglycemia decreases macrovascular endothelial function with 
no changes in microvascular endothelial function and systemic endothelium-
independent vascular reactivity across healthy and cardiometabolic diseased 
populations. This further supports endothelial dysfunction mediated by decreased NO 
availability as a primary mechanism in the pathogenesis of CVD, which may begin long 
before vascular remodelling is detectable or the onset of cardiometabolic diseases. 
Noting that microvascular data were limited, the microcirculatory system should 
therefore not be dismissed as a possible site of vascular dysfunction. Considering this, 
future studies should investigate the effects of consuming SSB on the underlying 
mechanisms of human vascular reactivity at microvascular and macrovascular levels. 
These studies will provide a better understanding of how acute hyperglycemia induces 
vascular dysfunction and how it contributes to the pathogenesis of CVD from healthy 
populations to those with cardiometabolic diseases.     
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Chapter 4 – Study two: Effects of sugar-sweetened beverage 
consumption on microvascular and macrovascular function 
in a healthy population 
 
Publication statement: 
This chapter is comprised of a manuscript that is published in Arteriosclerosis, 
Thrombosis and Vascular Biology.  
 
Loader J*, Meziat C*, Watts R, Lorenzen C, Sigaudo-Roussel D, Stewart S, Reboul 
C, Meyer G, Walther G. Effects of sugar-sweetened beverage consumption on 
microvascular and macrovascular function in a healthy population. Arter Thromb Vasc 
Biol. 2017:37(6):1250-60. Doi: 10.1161/ATVBAHA.116.308010. 
 
*Both authors contributed to this work. It must also be acknowledged that the 
experimental models of this study were primarily executed by Cindy Meziat; and, thus, 
some of the data included in Chapter 4 has been previously published in her Doctoral 
Thesis. However, as first author of this study, I had significant involvement in the 
production of all aspects of this manuscript, including those of an experimental nature. 
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4.1 Linking paragraph 
 
Study one of this research program provided evidence that acute hyperglycemia, 
induced by excess sugar consumption, transiently impairs endothelial function in the 
macrocirculation, but not in the microcirculation; while systemic endothelium-
independent vascular reactivity remains unaffected. This effect was consistent in those 
with cardiometabolic diseases and in those considered healthy, suggesting that acute 
hyperglycemia induces endothelial dysfunction across the spectrum of cardiometabolic 
health; and, subsequently, that it has a significant role in the initial and ongoing 
development of chronic vascular dysfunction, obesity, MetS and T2D. However, study 
one summarized that this evidence, describing the effect of acute hyperglycemia on 
endothelial function, was inconclusive due to the fact that previous research had 
inadequately reported macrovascular data. Indeed, changes in FMD were not adjusted 
for possible differences in shear stress between assessments and, therefore, it was not 
possible to confirm whether the acute hyperglycemia-mediated dysfunction was local 
to the macrocirculation or if was simply due to a lack of stimulus for vasodilation, 
possibly caused by an impairment in microvascular endothelial function. Additionally, 
the availability of microvascular data was limited, suggesting that further research was 
needed. Considering this, study two aimed to clarify the vascular impact of acute 
hyperglycemia by examining the effect of commercial SSB consumption, the 
predominant source of sugar in our diets, on endothelium-dependent vascular reactivity 
and endothelium-independent vascular reactivity in the microcirculation and 
macrocirculation. 
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4.2 Abstract 
 
Objective      
To assess vascular function during acute hyperglycemia induced by consuming 
commercial SSB and its effect on underlying mechanisms of the NO pathway. 
 
Approach and results      
In a randomized, single-blind, crossover trial, twelve healthy male participants 
consumed 600 mL (20 oz.) of water or a commercial SSB across two visits. Endothelial 
function and endothelium-independent vascular reactivity were assessed in the 
microcirculation using LSCI coupled with iontophoresis and in the macrocirculation 
using brachial artery ultrasound with FMD and NMD. Compared to water, SSB 
consumption impaired microvascular and macrovascular endothelium-dependent 
reactivity as indicated by a decrease in the vascular response to acetylcholine 
iontophoresis (208.3 ± 24.3 vs. 144.2 ± 15.7 %, P<0.01) and reduced FMD (0.019 ± 
0.002 vs. 0.014 ± 0.002 %/s-1, P<0.01), respectively. Systemic endothelium-
independent vascular reactivity remained preserved. Similar decreases in endothelial 
function were observed during acute hyperglycemia in an in vivo rat model. However, 
function was fully restored by treatment with the antioxidants, N-acetylcysteine and 
apocynin. Additionally, ex vivo experiments revealed that while the production of ROS 
was increased during acute hyperglycemia, the bioavailability of NO in the endothelium 
was decreased, despite no change in the activation state of eNOS.  
 
Conclusions       
To our knowledge, this is the first study to assess the vascular effects of acute 
hyperglycemia induced by commercial SSB consumption alone. These findings suggest 
that SSB-mediated endothelial dysfunction is partly due to increased oxidative stress 
that decreases NO bioavailability. 
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4.3 Introduction 
 
Commercial SSB are one of the most frequently consumed drinks worldwide.136,211 As 
such, they represent a major source of added sugar in the modern diet. Habitual 
consumption of SSB induces frequent episodes of acute hyperglycemia and is linked to 
an increased risk of developing obesity, MetS, and T2D.12,211,212 Furthermore, excessive 
SSB consumption is also associated with a higher incidence of advanced forms of 
CVD,211 which remains the single leading cause of death representing 31 % of the 
global mortality rate.209 Impaired vascular reactivity is considered to be a main 
precursor to the pathogenesis of CVD and may be present long before atherosclerotic 
vascular changes occur.145  
 
Normal vascular function involves a continuous interaction between the endothelium 
and VSM that is regulated by numerous vasodilators and vasoconstrictors.205,213 In a 
recent systematic review and meta-analysis, our research group provided evidence that 
acute hyperglycemia induced by an oral sugar load transiently impairs endothelial 
function in not only patients with cardiometabolic disease, but also in those considered 
healthy.214 It has been suggested that such endothelial dysfunction may be attributed to 
increased oxidative stress mediated by acute hyperglycemia.24,176 Indeed, NO 
bioavailability in the vascular wall is highly sensitive to redox modulation of the 
cellular environment.215,216 However, due to a limited availability of microcirculatory 
data and discrepant reporting of macrovascular data, the impact of acute hyperglycemia 
on vascular reactivity remains inconclusive and the underlying mechanisms not fully 
understood.  
  
In this context and considering the surge in commercial SSB consumption, as well as 
its potential link to a sustained epidemic of CVD, this present study aimed to provide a 
comprehensive assessment of the effect of SSB-mediated acute hyperglycemia on 
microvascular and macrovascular reactivity in a healthy population. Additionally, 
considering that experimental exploration of healthy vascular tissue in humans is 
difficult to perform, due to ethical barriers, this study also aimed to further investigate 
the underlying mechanisms of the interaction between acute hyperglycemia and 
endothelial function via an in vivo and ex vivo rat model.   
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4.4 Methods 
 
This study was comprised of two separate protocols in order to comprehensively 
investigate the effect of acute hyperglycemia induced by consuming SSB on vascular 
function. Protocol one was a clinical study conducted at the Australian Catholic 
University, Melbourne, which assessed the effect of SSB consumption on 
microvascular and macrovascular reactivity in healthy humans. Protocol two was 
conducted at Avignon University, France, providing deeper exploration into the effect 
of acute hyperglycemia on underlying mechanisms of vascular function through in vivo 
and ex vivo experimental rat models.  
 
4.5 Protocol One - Clinical Study 
 
4.5.1 Participants and screening 
Healthy non-smoking, sedentary (<2 hours/week of exercise) males (n = 12) aged 18-
55 years were recruited. Participants were excluded if they had any history of CVD; a 
5 % weight gain or loss in the 6 months prior to beginning the protocol; or if they were 
currently using or being treated with any vasoactive medications. All participants 
provided informed written consent. The Human Research Ethics Committee at the 
Australian Catholic University, Australia, approved this protocol. This study was 
registered with the Australian New Zealand Clinical Trial Registry: 
#ACTRN12614000614695. 
 
4.5.2 Study design 
Following overnight fasting (≥10 hours), participants presented to the cardiovascular 
laboratory on two occasions to perform this randomized, single-blind, crossover trial. 
To standardize responses between trials, participants were instructed to maintain their 
current level of physical activity and to abstain from strenuous exercise for 48 hours, 
alcohol consumption for 24 hours, and caffeine consumption in the 12 hours prior to 
each trial. Clinical measurements were performed at the beginning of the first trial to 
collect anthropometric and hemodynamic data; and to assess fasting blood glucose 
concentrations. At visit one, participants were randomized using an online sequence 
generator,217 by a researcher not involved in data collection or data analyses (J.L.), to 
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consume either 600 mL (20 oz.) of water or 600 mL of a commercial SSB from an 
opaque container. At visit two, the participants returned to consume 600 mL of the 
beverage type that was not consumed at visit one. Participants were allowed five 
minutes to consume each beverage. Blood glucose concentrations, blood pressure, heart 
rate and vascular function were assessed throughout each visit (Figure 4-1). A 600 mL 
volume of each beverage was administered, as it represents the common volume of SSB 
commercially available for purchase by the public. 
 
 
Figure 4-1. Study design: sequence of testing. In a fasted state (≥10 h) participants 
rested for 20 minutes before consuming 600 mL (20 oz.) of water or sugar-sweetened 
beverage (SSB) within a 5 minute period. Participants then rested for a further 15 
minutes before iontophoresis of acetylcholine (ACh) and sodium nitroprusside (SNP) 
were performed. Immediately following the conclusion of iontophoresis, flow-
mediated dilation (FMD) and nitrate-mediated dilation (NMD) were also performed. 
Blood glucose (GL), blood pressure (BP), and heart rate (HR) were measured after the 
20 minutes resting period, 15 minutes after consuming the test beverage, at the end of 
iontophoresis, at the end of FMD and at the end of NMD. All 12 participants were 
administered water or the commercial SSB in a randomized order. 
 
 
4.5.3 Clinical measurements 
Height and mass were measured using a stadiometer and a calibrated scale, 
respectively. Body mass index was calculated as mass (kg) divided by height² (m). 
Blood glucose concentrations were assessed with a handheld blood glucose monitoring 
system (Freestyle Optium, Abbott Diabetes Care Ltd, UK). Systolic and diastolic blood 
pressure, and heart rate were measured using a digital sphygmomanometer (Dinamap, 
GE Medical Systems, Milwaukee, USA). Blood pressure variables were expressed as 
mean arterial pressure (mmHg) calculated by [(2 X diastolic blood pressure) + systolic 
blood pressure]/3. 
 
-20 
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0 
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20 40 75 
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4.5.4 Vascular reactivity 
Microvascular and macrovascular measurements were conducted in a temperature-
controlled room maintained at 22-24°C and proceeded 15 minutes following the 
consumption of water or the commercial SSB, during the measured time period of acute 
hyperglycemia. Each participant remained in a supine position from the moment they 
finished consuming the 600 mL test beverage until measurements of vascular reactivity 
were complete. Microvascular reactivity was assessed on the ventral surface of the right 
forearm using iontophoresis in conjunction with LSCI. Assessment of macrovascular 
reactivity commenced next on the upper right arm using brachial artery ultrasound 
coupled with FMD and NMD. Blood glucose concentrations and hemodynamic 
changes were monitored throughout. 
 
4.5.4.1 Assessment of cutaneous microvascular reactivity 
Iontophoresis delivers a pharmacologically charged solution to the skin allowing for 
non-invasive assessment of cutaneous microvascular endothelium-dependent reactivity 
and endothelium-independent reactivity.218 The vascular response to iontophoresis was 
quantified by LSCI using a 70mW system (PeriCam PSI System®, Perimed, Järfälla, 
Sweden) with a laser wavelength of 785 nm and laser head working distance set at 15 
cm. The LSCI head unit emits and detects light scattered in the tissue that is partially 
backscattered by moving blood cells, causing a change in frequency from which 
microvascular blood flux is calculated.219 Laser speckle measurements were recorded 
continuously at a frequency of 18 Hz using an interfaced computer with data acquisition 
software (PimSoft 1.2.2.0®, Perimed, Järfälla, Sweden). Two adhesive drug delivery 
electrodes (LI 611, Perimed, Järfälla, Sweden) were installed on the ventral surface of 
the right forearm, avoiding any hair, broken skin, areas of increased skin pigmentation 
and visible veins. A dispersive electrode (PF 384, Perimed, Järfälla, Sweden) was 
positioned approximately 15 cm from each drug delivery electrode to complete the 
electrical current circuit. The arm was then immobilized with a vacuum cushion prior 
to commencing the protocol to ensure the participant was positioned as recommended.  
Following two minutes of baseline measurement of basal blood flux, iontophoresis of 
acetylcholine 2 % dissolved in sodium chloride 0.9 % (saline) and sodium nitroprusside 
1 % dissolved in saline were performed to assess cutaneous microvascular 
endothelium-dependent reactivity and endothelium-independent reactivity, 
respectively. An anodal current of 0.02 mA for acetylcholine and a cathodal current of 
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0.02 mA for sodium nitroprusside were administered simultaneously for 200 and 400 
seconds, respectively, using a Micropharmacology system (PF 751 PeriIont USB 
Power Supply, Perimed, Järfälla, Sweden), avoiding nonspecific vasodilation observed 
with higher cathodal electrical charges.220 Laser speckle contrast imaging was 
performed throughout. The manufacture’s software was used to set regions of interest 
at 30 mm2 that were adjusted retrospectively to find the area of max blood flux during 
iontophoresis. Data were exported to Microsoft Excel and analysed off-line. Cutaneous 
microvascular blood flux values were averaged for the 30 seconds immediately prior to 
the beginning of iontophoresis for baseline and for the five seconds at the maximal 
blood flux plateau. Data were reported as blood flux at rest, peak blood flux in response 
to iontophoresis, and the relative percentage increase in cutaneous blood flux from 
baseline measurements; and expressed as perfusion units (PU) and cutaneous vascular 
conductance (CVC), which is the flux in PU divided by the mean arterial pressure 
(mmHg), to account for differences in blood pressure between tests.38  
 
4.5.4.2 Assessment of macrovascular reactivity 
All macrovascular measurements were performed as previously described using high-
resolution vascular ultrasonography (Vivid I, GE Medical Systems, Milwaukee, USA), 
with a 10-MHz multi-frequency probe.221 Briefly, B-mode images and Doppler signals 
were simultaneously recorded with ECG data. Arterial diameter was measured on B-
mode images in the region of the artery running perpendicular to the ultrasound beam. 
The operator searched for the largest diameter, strong wall signals and the longitudinal 
section of the artery in each image. Time-averaged mean velocity (cm.s-1) was 
recorded, at the same level, by pulsed wave Doppler with a 45-60° insonation angle. 
Measurements were corrected for the insonation angle, and the pulsed Doppler sample 
volume was adjusted to cover the entire width of the vessel. The high-pass Doppler 
frequency filter was kept at the lower value ensuring rejection of arterial wall motion 
artefacts, with a cut-off value usually below 100 Hz. The same, well-trained operator 
(G.W.) performed all measurements. To assess macrovascular endothelium-dependent 
vreactivity, brachial FMD was performed according to the International Brachial 
Reactivity Task Force Guidelines.52 A pneumatic cuff was placed around the right 
forearm distal to the elbow and the ultrasound probe was positioned approximately 
midway between the antecubital and axillary regions before baseline measurements of 
basal brachial artery diameter were performed. The cuff was then inflated to 250 mmHg 
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for five minutes before sudden cuff deflation induced reactive hyperemia and 
measurements of brachial artery diameter were performed again. Fifteen minutes later, 
baseline measurements of basal brachial artery diameter were repeated before NMD 
was performed to assess macrovascular endothelium-independent vascular reactivity. 
As described previously, this procedure involves sublingual delivery of 0.4 mg of 
glyceryl trinitrate (Nitrolingual® Pumpspray, G. Pohl-Boskamp GmbH & Co, KG, 
Germany).222,223 Data were analysed off-line as the mean of five consecutive 
measurements using dedicated software (EchoPac 6.0, GE Healthcare, Horten, 
Norway). Volume blood flow (mL.min-1) was measured as the mean of the five cardiac 
cycles with the highest systolic velocity following cuff release and reported for the 
basal state and during peak reactive hyperemia; and expressed as the percentage change 
from basal measurements. Shear rate (s-1) was calculated as (4 x mean systolic 
velocity)/mean diameter to estimate the shear stress induced by hyperemia; and was 
expressed as the change from basal measurements (Peak shear rate minus basal shear 
rate).224 Flow-mediated dilation and NMD in response to PORH and nitrate 
administration, respectively, were expressed as the percentage change in brachial artery 
diameter from baseline measurements, with and without respect to the change in shear 
rate.  
 
4.6 Protocol Two - Experimental exploration 
 
4.6.1 Animals 
Thirty seven male Wistar rats (12 weeks old, 300 ± 50 g; Laboratoire Janvier, France) 
were housed in controlled conditions at 23-24°C with a normal 12 hour light/dark cycle, 
free access to water and a commercial standard diet conforming to current French 
legislation. The local Research Ethics Committee at Avignon University approved this 
protocol (84004).  
 
4.6.2 Study design 
Each rat was randomized into one of three treatment groups using an online sequence 
generator prior to in vivo assessment of cutaneous microvascular function (Figure 4-
2).217 Rats designated as normoglycemic controls received an intra-peritoneal injection 
of a 1.5 mL bolus of saline one hour prior to vascular assessment; while rats designated 
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to perform a glucose tolerance test were treated with either an intra-peritoneal injection 
of a 1.5 mL bolus of saline one hour prior to vascular assessment or a 1.5 mL bolus of 
the antioxidant, N-acetylcysteine, at 50 mg.kg-1 body weight, 48 hours and one hour 
prior to vascular assessment. These treatments prior to the glucose tolerance test 
allowed for assessment of the vascular effect of acute hyperglycemia alone, as well as 
the interaction between oxidative stress and microvascular function during acute 
hyperglycemia. Following overnight fasting (12-16 hours) and the designated treatment 
preparations, each rat was inspected to ensure that the skin on the back was hairless and 
the hind legs were intact. Experiments were performed in a temperature-controlled 
enclosure set at 34°C to maintain the skin temperature of each rat at 36-37°C. The rats 
were anesthetized with an intra-peritoneal injection of sodium pentobarbital at 60 
mg.kg-1 and were maintained in a prone position for the duration of the experiment.  
Figure 4-2. Study design of experimental exploration: In a fasted state (≥12 hours), 
following pre-treatments with saline (NaCl) or N-acetylcysteine (NAC), rats were 
anesthetized using sodium pentobarbital (60mg.kg-1). Rats then received an intra-
peritoneal injection of NaCl or glucose (2g/kg) before acclimatizing for 10 minutes in 
an incubator to maintain skin temperature at 37°C. Iontophoresis of acetylcholine 
(ACh) and sodium nitroprusside (SNP) were then performed. Rats were randomized 
into each treatment group. 
 
 
4.6.3 Glucose tolerance test  
Rats designated to receive the glucose tolerance test were administered an intra-
peritoneal injection of a 1.5 mL bolus of 40 % glucose solution at 2g.kg-1 body weight. 
Rats designated as normoglycemic controls received a second intra-peritoneal injection 
of saline in lieu of the glucose tolerance test. Blood samples were collected from the 
tail for measurement of blood glucose concentrations at 0, 10, 15, 20, 30, 60, 120 
Supplemental Material Figure I. Study design of experimental exploration: In a fasted 
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and sodium nitroprusside (SNP) were then performed. Rats were randomized into each 
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minutes following the induction of acute hyperglycemia or administration of the control 
(saline) solution. 
 
4.6.4 In vivo vascular exploration 
Cutaneous microvascular function was assessed 10 minutes following the induction of 
acute hyperglycemia or the administration of the control (saline) treatment using a LDF 
system (Periflux PF5000; Perimed, Järfälla, Sweden) and a thermostatic LDF probe 
(PF 481; Perimed) with an effective surface area of 0.95 cm²; in conjunction with 
iontophoresis. Two adhesive drug delivery electrodes containing acetylcholine 2 % 
dissolved in saline and sodium nitroprusside 2 % dissolved in saline were positioned 
on the inferior-posterior surface of the right and left leg of each rat. Each adhesive drug 
delivery electrode was inserted with a LDF probe. Dispersive electrodes were placed 
on the front paws to complete the electrical current circuit and were connected to a 
battery powered iontophoresis device (Perilont, Perimed, Järfälla, Sweden). For 60 
seconds prior to the commencement of iontophoresis, baseline cutaneous blood flux of 
the leg was measured using LDF. A single pulse of a 0.1 mA anodal and cathodal 
current was administered for 20 seconds for acetylcholine and sodium nitroprusside, 
respectively,225 followed by a further 20 minutes of LDF measurements. Data was 
exported to Microsoft Excel and analysed off-line. Cutaneous blood flux values were 
averaged for the 10 seconds immediately prior to the beginning of iontophoresis for 
baseline measurements and for the period at the maximal blood flux plateau. Data were 
reported as PU expressed as the percentage increase in cutaneous blood flux relative to 
baseline measurements.  
 
4.6.5 Ex vivo vascular exploration 
Following in vivo assessment, rats were anesthetized using an intra-peritoneal injection 
of sodium pentobarbital at 120 mg.kg-1 and the intact thoracic aorta was quickly 
removed and placed in cold Krebs-Henseleit bicarbonate buffer (composition in mM: 
NaCl 118; NaHCO3 25; Glucose 11; KCl 4.8; KH2PO4 1.2; MgSO47H2O 1.1; CaCl2 
1.25). Following removal of adherent tissue, the thoracic aorta was cut into 2-3 mm 
rings and suspended between two wire hooks. The suspended rings were then mounted 
in an organ chamber with 5 mL of Kreb’s solution with a pH level of 7.4 at 37°C and 
continuously gassed with 95 % oxygen and 5 % carbon dioxide, under a resting tension 
of 2 g. The rings were connected to an isometric force transducer (EMKA technologies, 
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EMKA Paris, France) and linked to an amplifier (EMKA technologies, EMKA Paris, 
France), as well as a computer acquisition system that recorded changes in isometric 
force. The rings were then allowed to equilibrate for 45 minutes. During this period, 
the tension was verified every 15 minutes and washed with Kreb’s solution. Following 
the equilibration period, the rings were pre-contracted with phenylephrine (10-6 M) and 
relaxed with acetylcholine (10-5 M) to functionally confirm the muscular and 
endothelium integrity. Each ring was then pre-contracted with phenylephrine (10-6 M). 
When a plateau in the effect of pre-contraction was reached, endothelial function was 
examined by challenging the aortic rings with two cumulative concentration-response 
curves to administration of acetylcholine (10-10 to 10-5 M), firstly in the normoglycemic 
state and then during acute hyperglycemia. Acute hyperglycemia was induced by one 
hour of incubation in a hyperglycemic Kreb’s solution at glucose concentrations of 30 
mM, 100 mM and 200 mM. The interaction between microvascular function and 
oxidative stress was further examined during acute hyperglycemia, induced by 
incubation in hyperglycemic Kreb’s solution (100 mM), in aortic rings that were pre-
treated with N-acetylcysteine (20 mM) for 30 minutes, or with apocynin (100 µM) for 
15 minutes. Data acquisition was performed using IOX (EMKA technologies, EMKA 
Paris, France). The relaxation response was expressed as a percentage of the pre-
contraction induced by phenylephrine.  
 
4.6.6 Western blotting analysis 
Proteins from aorta homogenates were separated on polyacrylamide-sodium dodecyl 
sulphate gels and transferred onto polyvinylidene difluoride membranes. The 
membranes were incubated overnight with primary antibodies, anti-eNOS III and anti-
eNOS-PSer1177 (1:1000 and 1:500, respectively; BD Transduction Laboratory), at 4°C 
in 10 % milk with Tris-buffered saline containing 0.05 % Tween 20. The eNOS-PSer1177 
protein content was expressed relative to the eNOS content and the eNOS protein 
content was expressed relative to the glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) content (anti-GAPDH antibody 1: 5000; incubated in 3 % 
bovine serum albumin, Santa Cruz Biotechnology). Low-temperature SDS-PAGE (LT-
PAGE) was performed for detection of eNOS dimers. Briefly, total proteins, were 
prepared in 1 × SB buffer without 2-mercaptoethanol. The samples were then subjected 
to SDS-PAGE with 6 % gel. Gels and buffers were equilibrated at 4°C before 
electrophoresis; and the buffer tank was placed in an ice bath during electrophoresis to 
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maintain the temperature of the gel at <15°C. Subsequent to LT-PAGE, the gels were 
transferred, and the blots were probed as a routine Western blot. Immunodetection was 
performed using an ECL or ECL Plus System (Supersignal West Pico 
Chemiluminescence Substrate, Thermo Scientific); and the membranes were exposed 
to X-ray films for visualization.  
 
4.6.7 Measurement of reactive oxygen species 
Production of ROS in both normoglycemic and hyperglycemic aortic ring preparations 
were evaluated by electron paramagnetic resonance in fresh frozen aortic homogenates 
as previously described.226,227 Aortic ring preparations were then treated with 1 mM 
CMH (1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethyl-pyrrolidine solution) (1:1 
v/v), put in the electron paramagnetic resonance glass capillary tube (Noxygen Science 
Transfer and Diagnostics, Germany) and placed inside the e-scan spectrometer (Bruker, 
Germany) for data acquisition. Production of ROS was normalized to the protein 
content of each sample and then expressed in µmol/mn/mg.  
 
4.6.8 Measurement of Nitrites 
Quantification of nitrite in aortic lysates was performed using the Measure-iT™ High-
Sensitivity Nitrite Assay Kit (Invitrogen) according to the manufacturer’s instructions. 
 
4.6.9 Statistical analyses 
Sample size was calculated using the results of a similar intervention, which 
demonstrated that FMD decreased from 6.96 ± 1.56 % to 4.0 ± 2.6 % during acute 
hyperglycemia when compared to the normoglycemic state.176 Considering this, it was 
estimated that a total of six participants would be needed to detect a difference between 
trials, with a one-tailed α of 0.05 and a 1-β of 0.80. All clinical microvascular and 
macrovascular data were exported and coded by a researcher (J.L.) not involved in data 
collection and analyses in order to blind the investigator. Following checks of 
distribution, clinical data was then analysed using repeated measures analysis of 
variance (ANOVA) with a post-hoc Tukey’s multiple comparison test to assess 
differences over time in vascular, hemodynamic and blood glucose responses to water 
or SSB consumption. A one-way ANOVA with a Fisher post hoc test was performed 
to determine differences in the cutaneous microvascular blood flow response to the 
induction of acute hyperglycemia in rats designated with normoglycemic, acute 
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hyperglycemic only, or acute hyperglycemic-N-acetylcysteine treatments. Differences 
in ex vivo vascular reactivity between the hyperglycemic and normoglycemic 
conditions were determined using a two-way ANOVA with Bonferroni post hoc tests. 
All statistical analyses were performed using MedCalc software (bvba, Mariakerke, 
Belgium) and significance was accepted at P<0.05. All values are reported as mean ± 
SEM. 
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4.7 Results 
 
Twelve healthy male participants were recruited and completed this randomized, 
single-blind, crossover trial between June 9th and July 4th, 2014 (Figure 4-3). To 
examine the acute vascular effects of commercial SSB consumption in humans, 
variables of blood glucose concentration, heart rate, arterial pressure and vascular 
function were assessed after the ingestion of 600 mL (20 oz.) of a commercial SSB and 
compared to values measured following water consumption. Nutritional information 
for each beverage is presented in Table 4-1. 
 
 
 
 
Figure 4-3. Flow diagram illustrating participant recruitment and randomized 
allocation to sugar-sweetened beverage (SSB) or water consumption interventions; and 
the participant retention to the conclusion of the crossover trial.  
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Table 4-1. The nutritional composition of each test beverage 
 WATER SSB 
Volume, mL 600 600 
Energy, kJ 0 1200 
Protein, g 0 0.30 
Fat    
- Total, g 0 0 
- Saturated, g 0 0 
Carbohydrate, g 0 72.4 
- Sugars, g 0 72.4 
Calcium, mg 18 N/A 
Magnesium, mg 6 N/A 
Sodium, mg 24 108 
Zinc, mg 0.06 N/A 
Ingredients Tap water Carbonated water, sugar, 
reconstituted lemon juice (5 %), 
food acids (330,331, natural 
flavour, preservatives (211, 223), 
natural colour (safflower extract) 
Nutrient composition of water was obtained from the United States Department of 
Agriculture Nutrient Database Standard Reference Release 28.228 Nutrient composition 
for the commercial sugar-sweetened beverage (SSB) was obtained from the nutrition 
information label on packaging. Participants consumed 600 mL of water or commercial 
SSB 15 minutes prior to the beginning of vascular assessment. Participants completed 
trials on separate days for each test beverage in a randomized order. 
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4.7.1 Participant characteristics 
Participants included in the study were aged 31 ± 1.9 years with a body mass index of 
24.68 ± 0.71 kg/m2. At each visit, prior to the consumption of the test beverage, basal 
measurements of fasting blood glucose (4.95 ± 0.15 vs. 4.78 ± 0.16 mmol/L, P>0.05), 
heart rate (64.08 ± 3.1 vs. 62.25 ± 3.2 beats.min-1, P>0.05), and mean arterial pressure 
(80.50 ± 1.66 vs. 79.86 ± 1.48 mmHg, P>0.05) were found to be similar (Figure 4-4). 
 
                        
Figure 4-4. Changes in (A) blood glucose concentrations, (B) mean arterial pressure 
(MAP), and (C) heart rate over time in response to consumption of 600 mL of water or 
commercial sugar-sweetened beverage (SSB). *P<0.05 vs. baseline; †P<0.05 vs. water.  
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4.7.2 Sugar-sweetened beverage consumption increased blood glucose concentration 
with no major effect on heart rate or blood pressure. 
Ingestion of the SSB significantly elevated blood glucose concentrations above basal 
values 20 minutes (7.77 ± 0.38 vs. 4.78 ± 0.16 mmol/L, P<0.05) following the 
beginning of consumption, with peak hyperglycemia (8.85 ± 0.36 mmol/L, P<0.05) 
recorded at 40 minutes (Figure 4-4A). A progressive decrease in blood glucose 
concentrations was observed between 40 and 75 minutes thereafter. However, blood 
glucose concentrations at 75 minutes were still significantly greater than basal blood 
glucose values (6.39 ± 0.3 vs. 4.78 ± 0.16 mmol/L, P<0.05) and all blood glucose values 
measured over time following water consumption. Blood glucose concentrations did 
not deviate from basal measurements following water consumption. Acute 
hyperglycemia had no major effect on mean arterial pressure. However, a slight but 
significant reduction in mean arterial pressure was observed during peak 
hyperglycemia when compared to that at the baseline measurement (P<0.05) (Figure 4-
4B).  No variations in heart rate were observed during acute hyperglycemia (Figure 4-
4C). 
 
4.7.3 Sugar-sweetened beverage consumption decreased microvascular and 
macrovascular endothelial function 
All assessments of microvascular and macrovascular function were completed between 
20 and 75 minutes following the beginning of SSB consumption, during acute 
hyperglycemia. Vascular function was assessed in the same time period following water 
consumption to allow for comparison between the two test beverages.  
 
4.7.3.1 Assessment of cutaneous microvascular reactivity 
Cutaneous microvascular endothelium-dependent reactivity and endothelium-
independent reactivity were assessed using LSCI in conjunction with iontophoresis of 
acetylcholine and sodium nitroprusside, respectively. Prior to the beginning of 
iontophoresis, there were no differences in baseline measurements of basal cutaneous 
blood flux between each visit (23.6 ± 1.8 vs. 26.4 ± 1.6 PU P=0.23) (Table 4-2). An 
increase in cutaneous blood flux was observed following iontophoresis of acetylcholine 
and sodium nitroprusside (Figure 4-5A). However, the relative percentage increase in 
cutaneous blood flux in response to acetylcholine iontophoresis was significantly lower 
during SSB-mediated acute hyperglycemia when compared to that during 
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normoglycemia following water consumption (129.76 ± 11.18 vs. 196.78 ± 20.61 %, 
respectively, P<0.01) (Figure 4-5B). Even after accounting for differences in blood 
pressure between visits by converting cutaneous blood flux from PU to CVC, the 
relative increase in cutaneous blood flux mediated by acetylcholine iontophoresis was 
still lower following ingestion of the SSB than that measured after water consumption 
(144.2 ± 15.7 vs. 208.3 ± 24.3 %, respectively, P<0.01). In contrast, the vascular 
responses to iontophoresis of sodium nitroprusside were similar following the 
consumption of each test beverage.  
 
Table 4-2. Microvascular and macrovascular reactivity in response to water and 
commercial SSB consumption in healthy subjects 
 WATER  SSB P-value 
n 12  12  
Microcirculation     
Basal CBF (PU) 23.6 ± 1.8  26.4 ± 1.6 p=0.231 
Peak ACh CBF (PU) 70.9 ± 8.0  63.0 ± 6.4 p=0.346 
Peak SNP CBF (PU) 101.2 ± 6.0  101.9 ± 7.4 p=0.934 
ACh CVC increase (%) 208.3 ± 24.3  144.2 ± 15.7* p=0.008 
SNP CVC increase (%) 360.3 ± 26.7  355.9 ± 29.3 p=0.926 
Skin resistance (Ω) 399.4 ± 41.3  395.6 ± 30.2 p=0.872 
Macrocirculation      
Basal brachial artery diameter (mm) 4.7 ± 0.1  4.7 ± 0.1 p=0.684 
Basal brachial blood flow (ml.min-1)  48.0 ± 5.7  53.0 ± 6.5 p=0.673 
Peak brachial blood flow (ml.min-1) 408.3 ± 27.6  445.1 ± 34.5 p=0.194 
∆shear rate (%/s-1) 484.3 ± 32.8  501.6 ± 37.1 p=0.506 
FMD/∆shear rate (%/s-1) 0.019 ± 0.002   0.014 ± 0.002* p<0.001 
Brachial hyperemia (%) 886.4 ± 132.3  855.5 ± 107.7 p=0.693 
Values are mean ± SEM. SSB indicates sugar-sweetened beverage; CBF, cutaneous 
blood flux; PU, perfusion units; ACh, acetylcholine; SNP, sodium nitroprusside; CVC, 
cutaneous vascular conductance; FMD, flow-mediated dilation. ∆shear rate means peak 
brachial shear rate minus resting brachial shear rate. P-value was estimated by repeated 
measures ANOVA followed by post-hoc Tukey’s multiple comparison tests. *P<0.05 
vs. water. 
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Figure 4-5. Microvascular reactivity in healthy participants following consumption of 
600 mL of water or a commercial sugar-sweetened beverage (SSB). (A) Top: Laser 
speckle contrast imaging electrode position on the right forearm. Bottom: 
Representative curve of cutaneous blood flux (CBF) during acetylcholine (ACh) 
iontophoresis. (B) The percentage increase from baseline in CBF in response to 
iontophoresis of ACh and sodium nitroprusside (SNP). *P<0.01 vs. water.  
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4.7.3.2 Macrovascular measurements 
Endothelium-dependent and endothelium-independent vascular reactivity were then 
assessed in the macrocirculation using ultrasound of the brachial artery in conjunction 
with FMD and NMD, respectively. Following the consumption of each test beverage, 
there were no differences in basal brachial artery diameter or blood flow between visits 
(4.7 ± 0.1 vs. 4.7 ± 0.1 mm, P=0.68; and 48.0 ± 5.7 vs. 53.0 ± 6.5 ml.min-1, P=0.67, 
respectively) (Table 4-2). Increases in brachial blood flow and the ∆shear rate induced 
during hyperemia were also similar between each visit (408.3 ± 27.6 vs. 445.1 ± 34.5 
ml.min-1, p=0.19; and 484.3 ± 32.8 vs. 501.6 ± 37.1 %/s-1, P=0.51, respectively). 
However, FMD was significantly reduced (-23.86 ± 5.33 %) during SSB-mediated 
acute hyperglycemia when compared to that during normoglycemia following water 
consumption; when expressed solely as the percentage change in diameter (6.53 ± 0.61 
vs. 8.56 ± 0.54 %, respectively, P<0.01) (Figure 4-6) and as the percentage change in 
diameter with respect to the change in shear rate (0.014 ± 0.002 vs. 0.019 ± 0.002 %/s-
1, respectively, P<0.01). In contrast, there were no differences in the responses to NMD 
between each visit.  
             
Figure 4-6. Macrovascular reactivity in healthy participants following consumption of 
600 mL of water or commercial sugar-sweetened beverage (SSB). The percentage 
change from baseline brachial artery diameter in response to flow-mediated dilation 
(FMD) and nitrate-mediated dilation (NMD). *P<0.01 vs. water.  
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4.7.4 Endothelial dysfunction following SSB consumption may be associated with an 
acute hyperglycemic-mediated increase in oxidative stress that decreases NO 
bioavailability 
Given that both FMD and the vascular response to acetylcholine iontophoresis were 
reduced during SSB-mediated acute hyperglycemia, whilst the vascular responses to 
nitrate administration were preserved, clinical findings clearly suggest that acute 
hyperglycemia impairs microvascular and macrovascular reactivity via an 
endothelium-dependent pathway. However, considering that further experimental 
exploration within vascular tissues of healthy humans is, for ethical reasons, very 
difficult to perform, the underlying mechanisms by which acute hyperglycemia 
mediates endothelial dysfunction were evaluated further, both in vivo and ex vivo, using 
an experimental rat model. Furthermore, as it is not possible to administer rats with an 
intra-peritoneal injection of commercial SSB, this study used an intra-peritoneal 
injection of glucose to examine the underlying mechanisms of SSB-mediated 
endothelial dysfunction. Importantly, previous research has revealed that acute changes 
in vascular reactivity following SSB consumption are more related to the glucose, than 
the fructose, in sucrose;229 and that fructose has a minimal effect on endothelial function 
in rats.230 Moreover, the adverse vascular effects of glucose consumption in humans 
has been further demonstrated in this study with supplementary data indicating that 
macrovascular endothelial function is decreased during glucose-mediated acute 
hyperglycemia, compared to that during normoglycemia, when expressed as the 
percentage change in diameter (6.17 ± 0.66 vs. 9.92 ± 1.26 %, respectively, P<0.05) 
and as the percentage change in diameter with respect to the change in shear rate (0.011 
± 0.001 vs. 0.018 ± 0.003 %/s-1, respectively, P=0.07) (Figure 4-7). 
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Figure 4-7. The vascular response to flow-mediated dilation (FMD) during 
normoglycemia and glucose-mediated acute hyperglycemia, induced by consumption 
of 72.4 g of glucose diluted in 600 mL of water, in six healthy males when expressed 
as (A) the percentage change in diameter and (B) the percentage change (Δ) in diameter 
with respect to the change in shear rate. *P<0.05 vs. normoglycemia. 
 
 
4.7.4.1 In vivo experimental exploration 
Acute hyperglycemia was induced in each rat using an intra-peritoneal injection of 
glucose that mediated a hyperglycemic plateau between 10 and 20 minutes following 
administration, with peak hyperglycemia occurring at 15 minutes (Figure 4-8A). To 
allow for comparisons between the acute hyperglycemic and normoglycemic 
conditions, a group of control rats received a placebo injection of sodium chloride 0.9 
% (saline). During the acute hyperglycemic plateau, iontophoresis of acetylcholine and 
sodium nitroprusside were performed inducing a significant increase in cutaneous 
microvascular blood flux (Figure 4-9A). However, similar to the findings obtained in 
human trials, the relative increase in cutaneous blood flux in response to iontophoresis 
of acetylcholine was decreased during acute hyperglycemia when compared to 
normoglycemic controls, whilst the vascular response to sodium nitroprusside 
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iontophoresis remained preserved (Figure 4-9B). Such endothelial dysfunction may be 
primarily caused by an acute hyperglycemic-mediated increase in oxidative stress.231 
Considering this, a third group of rats were treated with a dose of the antioxidant, N-
acetylcysteine, during normoglycemia and prior to the induction of acute 
hyperglycemia. Treatment with N-acetylcysteine had no effect on vascular function 
during normoglycemia. However, although the acute hyperglycemic responses to the 
intra-peritoneal injection of glucose between N-acetylcysteine-treated and untreated 
rats were similar (Figure 4-8B), the increase in cutaneous blood flux in response to 
acetylcholine iontophoresis was fully restored in rats treated with the antioxidant 
(Figure 4-9B); supporting the implication of increased oxidative stress in acute 
hyperglycemia-mediated endothelial dysfunction.  
 
                   
 
Figure 4-8. (A) Time course of blood glucose concentrations following glucose 
injection (2 g/kg, 1.5 ml) in rats. (B) Time course of blood glucose concentrations 
following glucose injection in rats pre-treated with saline only (HG) or N-
acetylcysteine (HG-NAC). *P<0.05 vs. baseline.  
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Figure 4-9. Implication of oxidative stress in endothelial dysfunction during acute 
hyperglycemia. (A) Representative curve of cutaneous microvascular blood flux (CBF) 
during normoglycemia (NG) and acute hyperglycemia (HG) in response to 
acetylcholine (ACh) iontophoresis in rats (B) The percentage increase from baseline in 
CBF in response to iontophoresis of acetylcholine and sodium nitroprusside following 
administration of sodium chloride 0.9 % (saline) in NG rats and following the induction 
of HG in rats pre-treated with saline in order to examine the effect of HG alone, or in 
rats pre-treated with N-acetylcysteine (NAC) to evaluate implication of oxidative stress 
in endothelial dysfunction. (C) A dose response curve to ACh during NG and HG (100 
mM) in pre-contracted aortic rings and during HG (100 mM) in pre-contracted rings 
pre-incubated in NAC (20 mM) or in apocynin (100 µM) (D) Production of reactive 
oxygen species (ROS) evaluated by electron paramagnetic resonance in NG aortic 
preparations; and aortic preparations pre-incubated with HG Kreb’s solution (glucose 
concentration: 30 mM).  (E) Expression and activation of endothelial nitric oxide 
synthase (eNOS) by phosphorylation (P) at serine 1177 analysed by western blotting in 
NG aortic preparations and aortic preparations pre-incubated in HG Kreb’s solution 
(100 mM). (F) eNOS dimer/monomer ratio analysed by detecting SDS-resistant eNOS 
dimers using low-temperature SDS-PAGE in the aortas of NG and HG rats. (G) Nitrite 
concentration in NG aortic preparations and aortic preparations pre-incubated with HG 
Kreb’s solution or HG (100 mM). *P<0.05. 
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4.7.4.2 Ex vivo experimental exploration 
Given that endothelial function is highly dependent on NO bioavailability, which itself 
is dependent on eNOS and its activation by phosphorylation at serine 1177 
(eNOSser1177), ex vivo experiments were then performed on rat aortic tissue to 
investigate the interaction between oxidative stress and the NO pathway; and whether 
this interaction contributes to the endothelial dysfunction observed during acute 
hyperglycemia. Similar to that observed following SSB consumption in human trials 
and the intraperitoneal injection of glucose in in vivo experimental exploration, acute 
hyperglycemia induced by the hyperglycemic solution decreased the relaxation 
response to acetylcholine administration in pre-contracted aortic rings in a dose-
dependent manner (Figure 4-10). However, pre-treatment with the non-specific 
antioxidant, N-acetylcysteine restored the relaxation response in aortic rings during 
acute hyperglycemia. Interestingly, similar results were observed when apocynin, a 
specific inhibitor of NADPH oxidase,232 was administered (Figure 4-9C). Although 
these results were supported by electron paramagnetic resonance assessments, which 
measured an elevation in the production of ROS during acute hyperglycemia when 
compared to the normoglycemic condition (Figure 4-9D), western blotting revealed that 
acute hyperglycemia had no effect on the expression of eNOS or its activation in aortic 
rings (Figure 4-9E). Moreover, eNOS dimerization, evaluated by the SDS resistant 
dimer/monomer ratio, was not impacted by acute hyperglycemia (Figure 4-9F). Despite 
this, there was still a marked reduction in the bioavailability of NO in the aortic tissue, 
indicated by a lower concentration of nitrites, during acute hyperglycemia (Figure 4-
9G). 
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Figure 4-10.  (A) Dose response curve to acetylcholine (ACh) in normoglycemic (NG) 
pre-contracted aortic ring preparations; and pre-contracted aortic preparations 
incubated with incremental concentrations of a hyperglycemic (HG) Kreb’s solution 
(glucose concentrations: 30, 100 and 200 mM). (B) Up: Concentration of ACh 
administered to induce 50 % of maximal relaxation response to ACh in NG aortic ring 
preparations; and aortic preparations pre-incubated with incremental concentrations of 
a HG Kreb’s solution (glucose concentrations: 30, 100 and 200 mM). Down: Maximal 
relaxation of aortic ring preparations in response to administration of ACh expressed 
as the percent relaxation relative to the measured pre-contraction with phenylephrine 
(10-6 mM). *P<0.05.  
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Supplemental Material Figure IV.  (A) Dose response curve to acetylcholine (ACh) in 
normoglycemic (NG) pre-contracted aortic ring preparations; and pre-contracted aortic 
preparations incub ted with incremental concentrations of a hyperglycemic (HG) Kreb’s 
solution (glucose con ntrations: 30, 100 and 200 mM). (B) Up: Concentration f ACh 
administered to induce 50 % of maximal relaxation response to ACh in NG aortic ri g 
preparations; and aortic preparations pre-incubated with incremental concentrations of a 
HG Kreb’s solution (glucose concentrations: 30, 100 and 200 mM). Down: Maximal 
relaxation of aortic ring preparations in response to administration of ACh expressed as 
the percent relaxation relative to the measured pre-contraction with phenylephrine (10-6 
mM). *P<0.05.  
A B 
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4.8 Discussion 
 
The present study aimed to assess the effect of acute hyperglycemia induced by the 
ingestion of a commercial SSB on vascular function in healthy sedentary participants. 
It was found that SSB consumption decreased both microvascular and macrovascular 
endothelium-dependent reactivity, whereas endothelium-independent vascular 
reactivity remained unaffected during acute hyperglycemia. Considering these 
findings, in vivo and ex vivo explorations were then performed in an experimental rat 
model to further investigate the interaction between acute hyperglycemia and vascular 
function; and examine the underlying mechanisms that may mediate such endothelial 
dysfunction. Similar to that observed in human trials, acute hyperglycemia impaired 
endothelial function in both in vivo and ex vivo experimental rat models. Interestingly, 
endothelial function was fully restored during acute hyperglycemia in rats that were 
pre-treated with the antioxidant, N-acetylcysteine; and in aortic rings that were pre-
treated with either N-acetylcysteine or a specific inhibitor of NADPH oxidase, 
apocynin. Further to this, it was found that acute hyperglycemia was associated with 
increased production of arterial ROS and reduced bioavailability of NO. Collectively, 
these findings suggest that acute hyperglycemia induces endothelial dysfunction by 
mediating an increase in oxidative stress that disrupts the NO pathway.  
 
It is currently unknown how acute hyperglycemia induced by commercial SSB 
consumption affects vascular function due to limited and discrepant data. Previous 
research has most commonly assessed vascular function during acute hyperglycemia 
induced by a typical oral glucose load using measures of macrovascular reactivity, such 
as brachial artery ultrasound with FMD.214 However, emerging evidence suggests that 
coronary microvascular disease may explain the occurrence of myocardial ischemia, 
heart failure and CVD mortality following myocardial infarction without apparent 
coronary macrovascular disease;233 highlighting the need to assess the microcirculation, 
which represents most of the arterial vascular network and exerts dominant control over 
local blood flow,38 in conjunction with the macrocirculation when investigating 
mechanisms that contribute to the pathogenesis of CVD. The results of this present 
study are consistent with those in previous research, which demonstrated that 
commercial SSB consumption mediates a decrease in macrovascular endothelial 
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function as indicated by reduced FMD during acute hyperglycemia.189 Importantly, it 
should be noted that this previous study induced acute hyperglycemia by administering 
a commercial SSB in conjunction with a high caloric commercial candy bar. In contrast, 
the microcirculatory findings contradict a separate study, which found that 
consumption of commercial SSB enhances microvascular endothelial function, as 
indicated by an increased cutaneous blood flux response to iontophoresis of 
acetylcholine during acute hyperglycemia.169 However, in this study, acute 
hyperglycemia was induced using a commercial SSB that is defined as an energy drink 
containing caffeine, which is an ingredient that has been found to increase 
microvascular reactivity in healthy participants.234 Considering the possible 
confounding vascular effects of these additional foods or ingredients, this present 
research is, to our knowledge, the first to examine the effects of acute hyperglycemia 
induced by commercial SSB consumption alone on microvascular and macrovascular 
reactivity. The results of this study also contribute to clarifying the effect of acute 
hyperglycemia on systemic vascular endothelial function, which in a recent systematic 
review and meta-analysis was found to be inconclusive due to limited microvascular 
data and discrepant reporting of shear stress data in studies that used FMD to assess 
changes in vascular function from normoglycemic to hyperglycemic states.214 Given 
that this present study found a decrease in FMD during acute hyperglycemia with no 
reduction in shear stress, a disruption of the NO pathway may be implicated in SSB-
mediated endothelial dysfunction.34,58  
  
Current evidence suggests that acute hyperglycemia induces endothelial dysfunction by 
mediating an abnormal elevation in oxidative stress that disturbs normal underlying 
mechanisms of NO synthesis.235,236 In the postprandial state, oxidative metabolism 
initiates oxidative phosphorylation of adenosine triphosphate at the electron transport 
chain of the mitochondria, which via the phenomenon of electron leakage causes 
superoxide generation of ROS.85 Moreover, it has been clearly reported that increased 
glycemia is responsible for the activation of NADPH oxidase, which also contributes 
to production of the superoxide anion.24 Although these ROS are normally readily 
detoxified, elevated activity within this mechanism such as that following commercial 
SSB consumption increases production to a rate beyond suppressive capabilities of the 
antioxidant systems.86 The implication of oxidative stress in acute hyperglycemia-
mediated endothelial dysfunction is further supported by ex vivo findings in this present 
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study, which demonstrated that acute hyperglycemia increased ROS in rat aortic rings. 
Moreover, treatment with the antioxidants, N-acetylcysteine and apocynin, were found 
to attenuate the impaired relaxation response to acetylcholine iontophoresis observed 
during acute hyperglycemia. Importantly, the applicability of this oxidative stress-
dependent mechanism to acute hyperglycemia-mediated endothelial dysfunction in 
living organisms was also demonstrated in this study, which revealed for the first time 
in an in vivo experimental rat model that antioxidant treatment also fully restores 
cutaneous microvascular endothelium-dependent reactivity during acute 
hyperglycemia. This study also found that eNOSser1177 and the eNOS dimer/monomer 
ratios remained preserved during acute hyperglycemia, while the concentration of 
nitrites was decreased. Such experimental findings provide evidence that SSB-
mediated endothelial dysfunction is due, at least in part, to decreased bioavailability of 
NO that is not caused by a disruption to the synthesis of NO via the eNOS pathway. 
Indeed, the reaction between NO and free radical superoxide results in the formation of 
peroxynitrite, a potent cytotoxic molecule.237 This nitro-oxidative stress could be a 
primary mechanism responsible for the decrease in NO bioavailability that was 
observed in our model of acute hyperglycemic stress. 
  
Despite not being affected in this present study, previous research has demonstrated 
impaired endothelium-independent vascular reactivity mediated by VSM cell 
proliferation in as little as 6 hours following the induction of hyperglycemia in animal 
and in vitro studies,148 suggesting a need to extend the typical assessment period of 
vascular function following SSB consumption in future research. Moreover, 
considering the global rate of commercial SSB consumption and its role in transient 
endothelial dysfunction, even in a healthy population, research must also quantify the 
relative loading of SSB over time that mediates significant vascular remodelling and 
contributes to the pathogenesis of CVD in humans.214 In addition to examining the 
underlying mechanisms of NO-mediated microvascular reactivity, future research may 
also assess the effect of SSB consumption on other main vasoactive mediators such as 
prostaglandin I2, endothelium derived hyperpolarizing factor, and ET-1, all of which 
have varying influence between the microcirculation and macrocirculation.176,205,238 
Finally, these studies need to be conducted across a variety of ethnicities, some of which 
have previously demonstrated decreased vascular reactivity even at rest; and, therefore, 
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may be more severely impacted by the deleterious vascular-related effects of acute 
hyperglycemia than that observed in Caucasian populations.210,239 
  
Several inherent limitations must be considered when interpreting this data. Whereas 
the main sugar in SSB is sucrose, which is comprised of glucose and fructose, only 
glucose was used to induce acute hyperglycemia in the experimental rat model that 
aimed to explain the effects of SSB consumption on underlying mechanisms of vascular 
reactivity. However, it has been suggested that acute deleterious cardiovascular effects 
of sucrose are more related to glucose rather than fructose;176,229 with previous findings 
also demonstrating that fructose has no significant effect on endothelial function in 
rats.230 Nevertheless, although endothelium-independent vascular reactivity remained 
preserved following SSB consumption in this present study, previous research has 
found that fructose can decrease the endothelium-independent vascular relaxation 
response to the administration of sodium nitroprusside in rats;230 and, therefore, it can’t 
be completely discounted that fructose may also contribute, to some extent, to the 
observed SSB-mediated endothelial dysfunction. It must also be considered that 
ingredients other than sucrose that comprise commercial SSB were not evaluated 
individually in this research and, therefore, it is not known how they may contribute to 
the observed SSB-mediated endothelial dysfunction. Indeed, increases in plasma 
sodium may also contribute to a decrease in NO bioavailability.240 Additionally, it was 
not possible to blind participants to the intervention by using a sugar-free placebo such 
as a commercial diet soda due to previous research suggesting that even artificial 
sweeteners may interact with taste receptors stimulating insulin secretion, which may 
induce a vascular response.241 Given that changes in blood insulin concentration in 
response to SSB consumption were not monitored in this study, it was not possible to 
explore what effect SSB consumption may have on mechanisms of insulin-mediated 
vasodilation. Finally, vascular reactivity was assessed in a focused sample and, 
therefore, the effect of SSB consumption may vary across health groups, ethnicities and 
genders.   
  
In conclusion, this present study is, to our knowledge, the first to assess vascular 
function during acute hyperglycemia induced by SSB consumption alone. The findings 
of this study demonstrate that commercial SSB consumption induces microvascular and 
macrovascular endothelial dysfunction in a healthy population. Furthermore, data from 
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the experimental rat model suggest that this commercial SSB-mediated endothelial 
dysfunction is partly due to increased oxidative stress, which reduces NO 
bioavailability. Ultimately, these results inform international public health policy on 
the adverse effects of both commercial SSB and general excess sugar consumption; and 
how they contribute so acutely, even in those considered healthy, to the upregulation of 
mechanisms that are the primary precursors to the pathogenesis of CVD.242 
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Chapter 5 – Study three: The continuums of impairment in 
vascular reactivity across the spectrum of cardiometabolic 
health: a systematic review and network meta-analysis 
 
Loader J, Khouri C, Taylor F, Stewart S, Lorenzen C, Walther G, Roustit M.  
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5.1 Linking paragraph 
 
To this point, this program of research has demonstrated that acute hyperglycemia 
induces transient endothelial dysfunction across the spectrum of cardiometabolic 
health; and, subsequently, that it has a significant role in the initial and ongoing 
development of chronic vascular dysfunction, obesity, MetS and T2D. However, 
whether there is a continuum in microvascular and macrovascular dysfunction between 
early stages and diabetic complications is still not clear. Indeed, comprehensive 
understanding of the development of vascular dysfunction is highly important to 
improve the timing and, subsequent, effectiveness of prevention and treatment 
strategies. Considering this, the following study examined vascular reactivity across the 
spectrum of cardiometabolic health, from those considered healthy, to those with 
obesity, MetS, impaired glucose tolerance, T2D and T2D with complications; by 
combining direct and indirect comparisons in a systematic review and network meta-
analysis. 
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5.2 Abstract 
 
Objective      
Impaired vascular reactivity has a key role in the development of obesity, insulin 
resistance and cardiovascular disease. However, as its exploration has mostly been 
conducted via cross-sectional studies, it isn’t entirely clear how vascular reactivity 
changes from early stages right through to diabetic complications. Considering this, the 
objective of this study was to assess vascular reactivity across the spectrum of 
cardiometabolic health.  
 
Approach and results      
A systematic search of MEDLINE and EMBASE from inception until March 2017 
identified articles that evaluated endothelium-dependent and endothelium-independent 
vascular reactivity in two or more health groups of interest (healthy, overweight, obese, 
impaired glucose tolerance, MetS and T2D with or without complications). Pairwise 
meta-analyses and network meta-analyses compared indexes of vascular reactivity 
between each health group. One hundred and ninety-three articles (7226 healthy 
subjects and 19,344 patients considered overweight, obese and/or insulin resistant) 
were included. The network meta-analyses revealed a progressive impairment in 
vascular reactivity (FMD data) from the clinical onset of an overweight status (-0.41 
%, 95% CI -0.98, 015) to the development of vascular complications in those withT2D 
(-4.26 %, 95% CI -4.97, -3.54). Meta-regressions revealed that for every 1 mmol/l 
increase in fasting blood glucose concentration, FMD decreased by 0.52 %. 
 
Conclusions       
To our knowledge, this study is the first to demonstrate a continuum where the severity 
of impairment in vascular reactivity progressively increases throughout the 
pathogenesis of obesity and/or insulin resistance, through to the development of 
diabetic complications. 
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5.3 Introduction 
 
It is well established that endothelial dysfunction is an early predictor of cardiovascular 
events in at-risk patients.243–245 Impairments in vascular reactivity, stemming from such 
endothelial dysfunction, as well as possible disruptions to endothelium-independent 
activity and maladaptation to the VSM, increase susceptibility to endothelial injury and, 
thus, promote atherosclerotic change. Furthermore, impaired vascular reactivity may 
also contribute to the development of obesity and insulin resistance; in what may, 
indeed, be considered a vicious cycle where each compounds the other. 246,247 It is 
therefore important from a clinical perspective that the interaction between 
cardiometabolic health and vascular reactivity is fully understood to enhance the timing 
and, subsequent, effectiveness of treatment strategies that aim to improve vascular 
health and CVD outcomes.  
 
Currently, numerous cross-sectional studies provide evidence that, in comparison to 
healthy controls, vascular reactivity is significantly impaired early in the development 
of obesity and/or insulin resistance. Although such data may suggest that impaired 
vascular reactivity precedes the development of overt disease, many cross-sectional 
studies often lack the power to accurately estimate the effect size of impairment 
between groups. Moreover, given that no single study has compared vascular reactivity 
across the full spectrum of cardiometabolic health, whether there is a continuum in the 
impairment of macrovascular and microvascular reactivity between early stages and 
diabetic complications has not yet been properly addressed.  
 
Therefore, considering the large number of vascular studies that have been conducted, 
the primary objective of this present research is to combine direct and indirect 
comparisons of vascular reactivity in a network meta-analysis to test this hypothesis 
and to further understand the development of vascular dysfunction.  
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5.4 Methods 
 
The protocol for this systematic review and network meta-analysis was registered on 
PROSPERO (Registration number: CRD42017053411) and was conducted according 
to the PRISMA statement.248 
 
5.4.1 Population and outcomes 
Seven health groups that represent key stages in the pathogenesis of T2D were included 
in this study: healthy, overweight, obese, impaired glucose tolerance, MetS, T2D and 
T2D with complications. Complications of interest, in those with T2D, were 
microvascular (diabetic neuropathy, retinopathy or nephropathy), macrovascular 
(peripheral artery disease or coronary artery disease), or both (diabetic foot ulceration). 
Considering that definitions for these conditions have evolved over time and between 
countries and, thus, vary between research, a homogenous classification for each health 
group was applied to all studies included in this network meta-analysis by comparing 
the average value of the key clinical characteristics (e.g. body mass index, fasting blood 
glucose concentration etc.) from each health group against the World Health 
Organization guidelines for classification of overweight and obesity;249 the joint interim 
statement of the International Diabetes Federation Task Force on Epidemiology and 
Prevention, harmonizing the criteria for defining MetS;250 and the American Diabetes 
Association criteria for impaired glucose tolerance and diabetes.251   
 
The objective of this study was to assess differences in endothelium-dependent and 
endothelium-independent vascular reactivity between each of the seven health groups 
of interest. Outcomes of interest included commonly used tests of vascular reactivity in 
the microcirculation and macrocirculation. Microvascular endothelium-dependent 
reactivity could be evaluated using post-occlusive reactive hyperemia, pressure-
induced vasodilation, local thermal hyperemia, or the administration of acetylcholine, 
delivered intravenously or by iontophoresis. Microvascular endothelium-independent 
reactivity may have been assessed with the administration of sodium nitroprusside, also 
delivered intravenously or by iontophoresis. The microvascular response to each test of 
reactivity could be measured with strain gauge plethysmography or a laser-based 
perfusion monitoring technology (e.g. LDF, LDI or LSCI).38 Macrovascular 
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endothelium-dependent reactivity and endothelium-independent reactivity were 
assessed using FMD and NMD, respectively;33 each in conjunction with ultrasound of 
the brachial artery. 
 
5.4.2 Data sources and searches  
The systematic search was performed in MEDLINE and EMBASE databases from their 
inception until March 13th, 2017, using a combination of subject headings for health 
status (obesity, prediabetes, MetS and T2D) and methods of assessing vascular 
reactivity (FMD, NMD, brachial artery ultrasound, post-occlusive reactive hyperemia, 
iontophoresis, skin microdialysis, intradermal injection, pressure-induced vasodilation, 
local thermal hyperemia, current-induced vasodilation, nerve-axon reflex, LDF, LDI, 
LSCI, Doppler wires, strain gauge plethysmography and venous occlusion 
plethysmography). Searches were limited to ‘human’ studies only; but were not limited 
by study design. The search strategy is presented in Supplemental Table 5-S1. A 
manual search of reference citations in identified reviews and original articles selected 
for full text retrieval was also performed. 
 
5.4.3 Study selection 
Two investigators (J. L. and F.T) independently performed study selection using 
Covidence©, an online, Cochrane approved, software for conducting systematic 
reviews.252 Discrepancies in inclusion/exclusion were solved through consultation with 
a third (G. W.) or fourth reviewer (M.R.). To be included in this review, each study had 
to assess vascular function in the basal state, in two or more of the health groups of 
interest. Only data from vascular assessments completed on those aged ≥18 years were 
included. The complete inclusion and exclusion criteria are available as supplemental 
methods. 
 
5.4.4 Data extraction and quality assessment 
Characteristics of the population, outcomes and covariates of interest were summarized 
from each study into a pre-formatted spreadsheet by two investigators (J.L. and M.R.). 
If data were unclear or were not available in the published manuscripts, the 
corresponding or first author was contacted by email to request this information. To 
minimize heterogeneity, research using methods of assessing microvascular function 
that were not often used in the literature (i.e. in <5 studies) were excluded from the 
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network meta-analyses. The full list of variables extracted and details about data 
extraction are available as supplemental methods.   
 
A SAQOR, previously applied in meta-analyses of observational studies evaluating 
vascular function,54,214 was performed to provide assessment of study quality. The 
SAQOR was scored out of 17; quality deemed better with a greater score. The GRADE 
was performed to provide assessment of the quality of evidence for outcomes 
investigated by this meta-analysis.154 The GRADE for each outcome was classified as 
high quality, moderate quality, low quality, or very low quality. More details about the 
GRADE quality assessment are available as supplemental methods. 
 
5.5.5 Data synthesis and analysis 
All statistical analyses were performed using R statistical software (version 3.2.4), 
using the Metafor, Meta and Netmeta packages. Considering that macrovascular 
endothelium-dependent and endothelium-independent reactivity were each assessed 
with a single method, FMD and NMD, respectively, macrovascular data was 
synthesized using the mean difference. In contrast, microvascular reactivity was 
assessed with various techniques; and, thus, the SMD summary statistic was used. 
Direct, pairwise meta-analyses were performed first to assess pooled mean differences 
or SMD, as well as 95% CI, in macrovascular and microvascular data, respectively, 
between healthy controls and each other health group   . A DerSimonian and Laird 
random-effects model was used when substantial heterogeneity was detected (I² 
statistic, >50 %; or p-value of the Q statistic, <0.10). A negative mean difference or 
negative SMD indicated that vascular reactivity was impaired in that health group when 
compared to another. 
  
A frequentist network meta-analysis was then performed using the graph theoretical 
method developed by Rucker et al. A network evidence plot was produced with the 
nodes indicating the health groups being assessed and the thickness of lines referring 
to the number of direct comparisons between each health group (e.g. the thicker the 
line, the more direct comparisons). The hypotheses of homogeneity and consistency 
were explored by the Q statistic and netheat plots. Additionally, the node splitting 
method assessed the consistency between direct and indirect comparisons, with a p-
value of <0.05 deemed inconsistent. A Hasse diagram, using partial order sets (posets), 
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was used to rank the severity of impairment in vascular reactivity for each health group 
included in the network meta-analysis. Publication bias was evaluated by funnel plot 
asymmetry and by using Egger's regression test, with a p-value of <0.05 suggesting 
publication bias when more than 10 studies were available in each health group.  
 
Several post hoc meta-regressions were performed on the following potential effect 
modifiers of macrovascular reactivity using a Bayesian approach: age, body mass 
index, brachial artery diameter at rest, blood pressure, fasting glucose, HbA1c %, total 
cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. The Bayesian network 
meta-analysis was performed using four chains, 10,000 burn-in and 50,000 iterations 
using gemtc package (version 0.8-2). Convergence was assessed using the Gelman-
Rubin-Brooks plot.  
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5.5 Results 
 
5.5.1 Study selection and characteristics 
The systematic search resulted in the inclusion of 193 from a total of 4641 potential 
articles (Figure 5-1). From the 193 studies included in the analyses, vascular reactivity 
was assessed in a total of 26,570 patients that were considered healthy (n = 7226), 
overweight (n = 7605) or obese (n = 1758), or that were diagnosed with MetS (n = 
2405), impaired glucose tolerance (n = 936), T2D (n = 5254) or T2D with vascular 
complications (n = 1386).  The main characteristics for each study are presented in 
Supplemental Table 5-S2. Flow-mediated dilation of the brachial artery was the most 
frequently used test of vascular reactivity (n = 120), while an array of tests was used to 
assess microvascular reactivity. 
 
  
Figure 5-1. Flow diagram of the study selection process. 
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5.5.2 Quality assessment and potential bias 
The quality score and risk of bias for each study are reported in Supplemental Table 5-
S2. The mean quality score was 14.3 ± 2.1 out of a possible 17 points. Quality 
assessments graded two studies with a high risk of bias, 53 with moderate risk of bias, 
and 138 with low risk of bias. Overall, the quality of evidence for outcomes 
demonstrating the impairment of vascular reactivity throughout the pathogenesis of 
T2D and its complications was low-to-very low (Supplemental Table 5-S3 to 5-S6). 
Evaluation of funnel plot asymmetry and the Egger’s regression test suggested a 
possible publication bias for microvascular and macrovascular endothelium-dependent 
reactivity in those with T2D, compared with healthy controls (Supplemental Figure 5-
S2). No major asymmetry was found in data for other health groups. 
 
5.5.3 Pairwise meta-analyses results 
Results of the pairwise meta-analyses, summarized in Table 5-1, demonstrate that 
macrovascular endothelium-dependent reactivity is impaired in all health groups when 
compared to healthy controls. In contrast, endothelium-independent vascular reactivity 
is not significantly affected in overweight and obese subjects. In the microcirculation, 
abnormal endothelium-dependent and endothelium-independent vascular reactivity 
were detected in obese patients and in all health groups with cardiometabolic disease, 
except for patients with impaired glucose tolerance. 
 
5.5.4 Network meta-analyses 
The networks of available comparisons for endothelium-dependent and endothelium-
independent vascular reactivity, in the microcirculation and macrocirculation, are 
represented in Figure 5-2. These network meta-analyses indicate a progressive 
impairment of endothelium-dependent reactivity in both the microcirculation and 
macrocirculation, throughout the pathogenesis of T2D and its related complications 
(Table 5-2 and 5-3, Figure 5-3). A similar pattern was observed for endothelium-
independent vascular reactivity in large vessels, while fewer differences were seen in 
the microcirculation. Forest plots for comparisons of endothelium-dependent and 
endothelium-independent vascular reactivity between all health groups, using each 
health group as the reference, are represented in Supplemental Figure 5-S2; 
demonstrating similar patterns in the impairment of endothelium-dependent and 
endothelium-independent vascular reactivity at each comparison. 
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Figure 5-2. The networks of available comparisons between each health group from 
studies included in the network meta-analysis; for (A) macrovascular and (B) 
microvascular endothelium-dependent reactivity; as well as (C) macrovascular and (D) 
microvascular endothelium-independent reactivity. The thickness of lines refers to the 
number of direct comparisons between each health group; with thicker lines indicating 
more comparisons. Where there is no line joining two health groups, there was no 
previous direct comparison of vascular reactivity between those health groups in the 
literature. IGT, impaired glucose tolerance; MetS, metabolic syndrome; T2D, type 2 
diabetes; T2DC, type 2 diabetes with complications. 
 
 
The consistency between direct and indirect comparisons was assessed by the node-
splitting method (Supplemental Table 5-S7 to 5-S10). Although several comparisons 
had significant heterogeneity between direct and indirect evidence, the difference was 
primarily driven by the magnitude of the effect size and not by the direction of effect, 
suggesting consistency in this study’s results. Furthermore, only four comparisons 
differed in direction: type 2 diabetes vs type 2 diabetes with complications, in 1) 
macrovascular endothelium-dependent reactivity and 2) macrovascular endothelium-
A B
C D
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independent vascular reactivity; 3) healthy vs obese, in macrovascular endothelium-
independent vascular reactivity; and 4) obese vs overweight, in microvascular 
endothelium-independent vascular reactivity.  Netheat plots confirmed the overall 
consistency in the results (Supplemental Figure 5-S3). 
 
Considering the risk of bias related to the outcome assessment, sensitivity analyses, 
only including studies in which the outcome assessors were blinded to the health group 
classification, were conducted (Supplemental Figure 5-S4). Indeed, a similar trend in 
the impairment of endothelium-dependent vascular reactivity was observed, but the 
effect size was smaller. For example, in patients with T2D, the mean difference for 
FMD was about 20% lower when outcome assessment was blinded. Similar results 
were found for endothelium-independent vascular reactivity. 
 
 
 
Figure 5-3. Forest plots of the mean difference (MD) in (A) macrovascular 
endothelium-dependent reactivity and (C) macrovascular endothelium-independent 
reactivity; and the standardized mean difference (SMD) in (B) microvascular 
endothelium-dependent reactivity and (C) microvascular endothelium-independent 
reactivity between each health group considered overweight or obese, or with 
cardiometabolic disease, as compared to the healthy group in the network meta-
analyses. CI, confidence interval; IGT, impaired glucose tolerance; MetS, metabolic 
syndrome; T2D, type 2 diabetes; T2DC, type 2 diabetes with complications. 
 
A B
C D
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5.5.5 Meta-regressions  
Given that methods for assessing macrovascular endothelium-independent reactivity 
and microvascular reactivity remain largely unstandardized and that data, in some 
cases, were limited, meta-regressions were only performed on FMD data. Among the 
11 potential effect modifiers, only fasting blood glucose was significantly correlated to 
FMD (Supplemental Table 5-S11); suggesting that the severity of impairment in 
macrovascular reactivity worsened as fasting blood glucose concentrations increased 
(Supplemental Figure 5-S5). Indeed, for every 1 mmol/l increase of fasting blood 
glucose concentration, there is a 0.52 % decrease in FMD.  
 
5.5.6 Microvascular versus macrovascular dysfunction 
To explore whether the pattern of impairment in vascular reactivity is similar between 
the microcirculation and the macrocirculation, when compared across all 
cardiometabolic health groups, ranks for macrovascular endothelium-dependent 
reactivity were plotted against ranks for microvascular endothelium-dependent 
reactivity (Supplemental Figure 5-S6A). They were subsequently computed as posets. 
Overall, the ranks were similar between the macrocirculation and the microcirculation: 
healthy status preceded impaired glucose tolerance and an overweight status, which 
preceded both MetS and obesity, which preceded T2D, which finally preceded T2D 
with vascular complications, as demonstrated in the Hasse diagram (Supplemental 
Figure 5-S6B).  
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Table 5-1. Meta-analysis results of pairwise comparisons versus healthy controls 
 Macrovascular Microvascular 
 Endothelium-dependent Endothelium-independent Endothelium-dependent Endothelium-independent 
 n MD (95% CI) I² n MD (95% CI) I² n SMD (95% CI) I² n SMD (95% CI) I² 
Overweight 9 -1.26 (-1.75, -0.77) 0 6 -1.38 (-3.48, 0.72) 51 6 0.04 (-0.30, 0.38) 45 1 -0.17 (-1.88, 1.53) . 
Obese 22 -0.88 (-1.51, -0.26) 65 10 -1.68 (-3.83, 0.47) 75 20 -0.70 (-0.99, -0.41) 78 9 -0.65 (-1.13, -0.18) 68 
IGT 2 -1.09 (-1.40, -0.77) 0 2 -1.02 (-2.02, 0.02) 44 3 -0.73 (-1.50, -0.03) 70 1 -0.79 (-1.72, 0.14) . 
MetS 9 -1.78 (-3.17, -0.40) 94 3 -1.21 (-2.00, -0.43) 0 10 -1.05 (-1.49, -0.61) 78 7 -0.58 (-0.96, -0.19) 65 
T2D 38 -3.67 (-4.34, -3.00) 93 19 -2.34 (-3.32, -1.37) 68 25 -1.27 (-1.63, -0.91) 81 10 -0.31 (-0.55, -0.06) 0 
T2DC 7 -3.29 (-4.68, -1.90) 90 1 -4.40 (-6.37, -2.43) . 9 -1.07 (-1.35, -0.78) 41 3 -1.27 (-2.01, -0.52) 0 
Values presented in bold font are significantly different from healthy subjects. n, number of studies; MD, mean difference; CI, confidence interval; 
SMD, standardized mean difference; I², results of heterogeneity statistic; IGT, impaired glucose tolerance; MetS, metabolic syndrome; T2D, type 
2 diabetes; T2DC, type 2 diabetes with complications.  
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Table 5-2. Network meta-analysis results for macrovascular reactivity. Results are mean difference (95% CI)  
Macrovascular endothelium-dependent reactivity 
Healthy -0.41 (-0.98, 0.15) -1.33 (-1.98, -0.67) -1.75 (-2.80, -0.70) -1.99 (-2.73, -1.24) -3.22 (-3.69, -2.75) -4.26 (-4.97, -3.54) 
-0.98 (-1.79, -0.17) Overweight -0.91 (-1.67, -0.16) -1.34 (-2.33, -0.34) -1.57 (-2.31, -0.84) -2.80 (-3.29, -2.32) -3.84 (-4.57, -3.12) 
-0.34 (-1.39, 0.71) 0.64 (-0.52, 1.81) Obese -0.42 (-1.59, 0.74) -0.66 (-1.57, 0.25) -1.89 (-2.61, -1.17) -2.93 (-3.84, -2.02) 
-1.50 (-2.95, -0.06) -0.52 (-2.00, 0.96) -1.17 (-2.89, 0.56) IGT -0.24 (-1.40, 0.93) -1.47 (-2.50, -0.44) -2.51 (-3.68, -1.33) 
-1.47 (-2.48, -0.46) -0.49 (-1.42, 0.43) -1.13 (-2.43, 0.16) 0.03 (-1.61, 1.67) MetS -1.23 (-1.99, -0.47) -2.27 (-3.21, -1.33) 
-2.68 (-3.36, -1.99) -1.69 (-2.35, -1.04) -2.34 (-3.45, -1.23) -1.17 (-2.63, 0.29) -1.20 (-2.18, -0.23) T2D -1.04 (-1.69, -0.38) 
-3.14 (-4.20, -2.08) -2.16 (-3.12, -1.20) -2.80 (-4.18, -1.43) -1.64 (-3.31, 0.03) -1.67 (-2.92, -0.42) -0.47 (-1.36, 0.43) T2DC 
Macrovascular endothelium-independent reactivity 
Values presented in bold font are significantly different. CI, confidence interval; IGT, impaired glucose tolerance; MetS, metabolic syndrome; 
T2D, type 2 diabetes; T2DC, type 2 diabetes with complications. 
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Table 5-3. Network meta-analysis results for microvascular reactivity. Results are SMD (95% CI)  
Microvascular endothelium-dependent reactivity 
Healthy -0.20 (-0.48, 0.08) -0.66 (-0.90, -0.41) -0.63 (-1.10, -0.16) -1.01 (-1.39, -0.63) -1.10 (-1.31, -0.89) -1.49 (-1.83, -1.14) 
-0.04 (-0.42, 0.34) Overweight -0.46 (-0.79, -0.13) -0.43 (-0.90, 0.04) -0.81 (-1.27, -0.35) -0.90 (-1.16, -0.64) -1.29 (-1.67, -0.90) 
-0.48 (-0.84, -0.13) -0.45 (-0.90, 0.01) Obese 0.03 (-0.48, 0.54) -0.35 (-0.79, 0.09) -0.44 (-0.72, -0.17) -0.83 (-1.23, -0.42) 
-0.54 (-1.12, 0.04) -0.50 (-1.05, 0.04) -0.06 (-0.71, 0.59) IGT -0.38 (-0.98, 0.22) -0.47 (-0.94, 0.00) -0.86 (-1.41, -0.30) 
-0.55 (-0.94, -0.16) -0.51 (-1.04, 0.01) -0.07 (-0.59, 0.45) -0.01 (-0.70, 0.68) MetS -0.09 (-0.51, 0.32) -0.48 (-0.98, 0.03) 
-0.50 (-0.80, -0.19) -0.46 (-0.74, -0.18) -0.01 (-0.43, 0.41) 0.04 (-0.50, 0.58) 0.05 (-0.42, 0.52) T2D -0.38 (-0.73, -0.04) 
-0.87 (-1.32, -0.42) -0.84 (-1.26, -0.42) -0.39 (-0.93, 0.15) -0.33 (-0.97, 0.31) -0.32 (-0.90, 0.26) -0.38 (-0.77, 0.01) T2DC 
Microvascular endothelium-independent reactivity 
Values presented in bold font are significantly different. CI, confidence interval; IGT, impaired glucose tolerance; MetS, metabolic syndrome; 
T2D, type 2 diabetes; T2DC, type 2 diabetes with complications. 
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5.6 Discussion 
 
The objective of this study was to compare vascular reactivity across the spectrum of 
cardiometabolic health, from healthy populations, through those with obesity, impaired 
glucose tolerance, MetS and T2D, to those with T2D with complications. Combining 
direct and indirect comparisons from 193 studies, the findings of this network meta-
analyses indicate a progressive impairment in microvascular and macrovascular 
endothelium-dependent reactivity throughout the pathogenesis of T2D and its 
complications. A similar pattern was also observed in endothelium-independent 
vascular reactivity in the macrocirculation, but not in the microcirculation; which 
remained relatively unaffected across the health groups.  
 
When interpreting these findings, however, it is important to acknowledge from the 
outset that this network meta-analysis does not properly address whether impairment 
in the microcirculation precedes that of the large vessels, a widely accepted 
hypothesis.233 Indeed, while FMD of the brachial artery is a more standardized 
procedure than most methods of assessing vascular reactivity, it must be noted that a 
majority of studies (116 of the 120 included in this network meta-analysis) did not 
account for changes in shear rate during their data analyses. Subsequently, it is not 
possible to comprehensively conclude that the impairment in macrovascular 
endothelium-dependent reactivity is due to intrinsic abnormalities of macrovascular 
function, or if they are partially attributable to downstream abnormalities (e.g. 
microvascular dysfunction) and/or simply a decrease in the stimulus for conduit artery 
dilation.58 Considering this, future vascular studies and the accurate interpretation of 
their data would be improved by adopting previously standardized methodology for 
evaluating vascular reactivity. In a similar vein, it must also be noted that the 
progressive decline in FMD is associated with a decrease in NMD, suggesting that 
impaired vascular reactivity could be caused by one or several factors; including 
abnormalities in endothelial function, endothelium-independent function or structural 
changes within the blood vessel itself. Regardless, this study is the first to demonstrate 
a continuum where the severity of impairment in vascular reactivity progressively 
increases throughout the pathogenesis of obesity and/or insulin resistance, through to 
the development of diabetic complications. Furthermore, this data reinforces that 
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chronic impairments in vascular reactivity present early in the decline of 
cardiometabolic health, long before the clinical onset of overt diseases. The impact of 
such chronic vascular impairment on the pathogenesis of CVD, even in these early 
stages, may be significant with data indicating that the risk of coronary heart disease is 
increased in those who are metabolically healthy, but are considered obese.254 
 
Notably, meta-regression analyses of FMD data and potential effect modifiers found 
one significant, negative correlation, that between FMD and fasting blood glucose 
concentration; indicating that as fasting blood glucose concentration increases by 1 
mmol/l, FMD decreases by 0.52 %. Indeed, hyperglycemia is one of several other 
factors, including insulin resistance, obesity and low-grade inflammation, which may 
influence vascular function throughout the decline of cardiometabolic health. Elevated 
generation of ROS appears to be a unifying pathway between each of these factors and 
impaired vascular reactivity.7 Oxidative stress may induce endothelial dysfunction by 
disrupting the synthesis of the potent vasodilator, NO; thus, reducing its 
bioavailability.7 Additionally, hyperglycemia-mediated increases in the concentration 
of the superoxide anion may deactivate available NO, converting it to the oxidant, 
peroxynitrite, which induces substrate nitration and, subsequently, further disrupts 
endothelial NO synthase and enzyme activity.7 Acknowledging that other signalling 
pathways of vasomotion may be affected by oxidative stress, reduced NO 
bioavailability is considered a strong predictor of CVD outcomes.7 Cardiometabolic 
diseases are characterized by abnormally frequent hyperglycemic excursions. Such 
exposure to a hyperglycemic environment that is ‘chronic’ in nature may also induce 
VSM cell proliferation by disrupting its natural apoptosis.255 Furthermore, 
hyperglycemia may enhance the production of advanced glycation end products and 
collagen cross-linking.255 Collectively, these mechanisms stiffen the arterial wall, 
possibly explaining why vascular reactivity may be reduced in those with impaired 
glucose tolerance, MetS and T2D. Ultimately, this increase in myogenic tone elevates 
the risk of injury to the endothelial wall; an event that is significant in the pathogenesis 
of CVD.  
 
There are several inherent limitations to this research that must be addressed. Many 
studies included in this network meta-analysis used control groups that had no specific 
health classification. Considering this, mean clinical data from all included studies 
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assessing health groups not defined as T2D, with or without complications, were 
checked against current definitions for the different health groups. Although this 
approach allowed us to obtain more homogeneous health groups while acknowledging 
the definitions and criteria that have evolved over time, it does not take into account 
the heterogeneity between subjects within each study arm. Furthermore, most studies 
did not include parameters that define MetS and are known to have an influence on 
vascular reactivity, such as insulin resistance; and, therefore, the effect of such factors 
could not be accounted for in this analysis. It must also be recognised that while there 
is a large amount of data focusing on endothelium-dependent vascular reactivity, the 
number of studies that assessed endothelium-independent vascular reactivity was 
limited; thus, reducing the power to detect differences between health groups and 
develop conclusions about the changes in endothelium-independent vascular reactivity.  
Similarly, few studies assessed vascular reactivity in those with impaired glucose 
tolerance. Although potential bias was detected in several outcomes in this study, the 
SAQOR revealed a predominantly low risk of bias. Finally, the GRADE indicates that 
the quality of evidence for outcomes assessed in this study is low-to-very low; as is the 
nature of observational data. Although this does not affect the conclusion regarding the 
trends, the confidence in the effects estimates is more limited. Similarly, sensitivity 
analyses including only studies in which the outcome assessors were blinded to the 
health group indicate that the trends remain the same, but with lower effects estimates. 
This highlights evaluation biases, which is a limitation in techniques such as FMD. 
Similarly, funnel plot asymmetry and the Egger’s regression test suggest possible 
publication bias in patients with T2D (endothelium-dependent reactivity data). 
However, there is no major asymmetry for other health groups; and, therefore, the 
impact of publication bias on these findings is difficult to evaluate. 
 
This present study demonstrates that vascular reactivity may be impaired early, even in 
those considered overweight; while previous research from our laboratory has 
demonstrated that acute hyperglycemia, induced by excess sugar consumption, 
transiently blunts endothelium-dependent vascular reactivity, even in those considered 
healthy.256  Considering this, further research is needed to assess if transient 
impairments in vascular reactivity, mediated by several dietary and lifestyle factors, 
develop into chronic vascular impairment before, when someone is still considered 
clinically healthy, or after the clinical onset of an overweight state or insulin resistance. 
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Furthermore, given that there may be differences in vascular function between 
ethnicities and gender,210 future research may also assess vascular reactivity, as well as 
the mechanisms that underlie any impairment (e.g. disruption of the NO pathway), in 
varying health populations from a range of ethnic backgrounds.   
 
In conclusion, this network meta-analysis demonstrates a continuum where vascular 
reactivity is progressively impaired throughout the pathogenesis of obesity and/or 
insulin resistance; where for every 1mmol/l increase in fasting blood glucose 
concentration, FMD decreases by 0.52 %. Ultimately, though, these results support the 
need for early interventions in at-risk populations, to overturn the progressive 
deterioration of vascular health and, subsequently, improve cardiovascular outcomes.  
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5.7 Supplemental material 
 
5.7.1 Supplemental methods 
 
5.7.1.1 Study selection 
Two investigators (J. L. and F.T) independently performed study selection using 
Covidence©, an online, Cochrane approved, software for conducting systematic 
reviews.252 Discrepancies in inclusion/exclusion were solved through consultation with 
a third (G. W.) or fourth reviewer (M.R.). To be included in this review, each study had 
to assess vascular reactivity in the basal state, in two or more of the health groups of 
interest. Only data from vascular assessments completed on those aged ≥18 years were 
included.  
 
To avoid confounding factors that are known to influence vascular reactivity, health 
groups of interest were excluded from the review if it included patients with a history 
of cancer or transplant (e.g. kidney, bone marrow, or blood transfusion), patients with 
the human immunodeficiency virus, blood disorders (e.g. anaemia, sickle-thalassemia, 
or hemophilia), rheumatoid arthritis, lupus, polycystic ovary syndrome, non-diabetic 
chronic kidney disease or end stage renal disease (kidney failure), or sleep apnea. 
Health groups that included patients with type 1 diabetes, gestational diabetes or who 
were pregnant, or postpartum, at the time of assessment were also excluded. In any 
circumstance where a study included a cohort comprised of more than one health group 
of interest (e.g. MetS with and without T2D or T2D with and without complications), 
that group was excluded from all analyses; and, indeed, if that study subsequently 
presented less than two health groups of interest, it was excluded from the review. 
Finally, inclusion was limited to studies originally published in the English language 
or where translated copies had been made available. 
 
5.7.1.2 Data extraction and quality assessment 
Where available, the following variables were summarized from each study into a pre-
formatted spreadsheet by two investigators (J.L. and M.R.): authors, year of 
publication, characteristics of participants (n, health status, % female, menstruation 
status, age, ethnicity, aerobic fitness [VO2 max], weight, height, body mass index, waist 
circumference, waist-to-hip ratio, body fat %, resting blood pressure, resting heart rate, 
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fasting blood glucose, HbA1c %, fasting blood insulin, HOMA-IR, total cholesterol, 
concentration of HDL cholesterol, LDL cholesterol, triglycerides, history of 
hypertension, dyslipidemia, neuropathy, retinopathy, nephropathy, diabetic foot 
ulceration, stroke, adverse cardiovascular events, smoking status and details of 
medication use, as well as blood biomarkers of inflammation, oxidative stress, 
endothelial dysfunction, liver function, and kidney function) and vascular variables 
(vascular region assessed, method used [test of vascular reactivity, occlusion period, 
temperature applied or dose of vasoactive drug, iontophoretic protocol, length of time 
post-vascular reactivity test to vascular assessment] and the vascular response to each 
test of reactivity). If data were unclear or were not available in the published 
manuscripts, the corresponding or first author was contacted by email to request this 
information.  
 
In the event of multiple publications pertaining to the same research, the first published 
or more comprehensive study was included. If two cohorts of the same health group 
were included in a single study along with a third health group of interest (e.g. three 
health groups in a single study: two groups with T2D and one healthy group), the 
sample of the third group (e.g. healthy) was evenly divided into two separate (healthy) 
groups to compare to the two groups with T2D; allowing for each separate health group 
to be included in the network meta-analysis, whilst maintaining the same power. 
Indeed, if the study included three cohorts that had the same health classification, three 
separate studies were subsequently created for the same reason. If a single study 
examined vascular reactivity, using the same methodology in two different vascular 
regions (e.g. calf and forearm), in all health groups of interest included in that research, 
then each set of data (classified by vascular region) were treated as separate studies. 
Where a single study assessed basal vascular reactivity multiple times in the same 
sample, only data for the initial assessment was included in the analysis. If blood 
perfusion was measured following varying concentrations of acetylcholine or sodium 
nitroprusside intravenous infusion, then vascular data measured at the strongest 
concentration was included in the analysis. To minimize heterogeneity, research using 
methods of assessing microvascular reactivity that were not often used in the literature 
(i.e. in <5 studies: oral administration of berapost sodium [number of studies, n = 2]; 
iontophoresis of insulin [n = 2]; intravenous infusion of BQ123 [n = 2], methacholine 
[n = 3], verapamil [n = 2], isoprenaline [n = 2], endothelin-1 [n = 4], norepinephrine [n 
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= 3], insulin [n = 2], bradykinin [n = 2], serotonin [n = 3] or serotonin with insulin [n = 
1]; pressure-induced vasodilation [n = 1]; and near-infrared spectroscopy [n = 1]), were 
excluded from the network meta-analyses. 
 
A SAQOR, previously applied in meta-analyses of observational studies evaluating 
vascular function,54,214 was performed to provide assessment of study quality. The 
SAQOR was scored out of 17, quality deemed better with a greater score. The GRADE 
was performed to provide assessment of the quality of evidence for outcomes 
investigated by this meta-analysis.154 The GRADE for each outcome was classified as 
high quality, moderate quality, low quality, or very low quality. As the design of all 
studies included in this review are observational, the quality of evidence was rated low 
before being downgraded or upgraded. Quality of evidence decreased due to: 1) study 
limitations, 2) inconsistency of results, 3) indirectness of evidence, 4) imprecision, or 
5) reporting bias. Quality of evidence was upgraded if there was: 1) a large magnitude 
of effect, 2) a dose-response gradient, or 3) plausible biases would decrease the 
magnitude of an apparent treatment effect. Assessments of study quality and quality of 
evidence were performed independently by two investigators (J.L. and F.T.). 
Discrepancies were solved by consensus or through consultation with a third reviewer 
(G. W.). 
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5.7.2 Supplemental figures 
 
A 
 
B 
 
 
Figure 5-S1.  Detection of publication bias following evaluation of funnel plot 
asymmetry in data for (A) macrovascular and (B) microvascular endothelium-
dependent reactivity in those with type 2 diabetes.
 
 
149 
 
Figure 5-S2. Forest plots of the mean difference (MD) in macrovascular reactivity and standardized mean difference (SMD) in microvascular 
reactivity between each health group included in the network meta-analyses, using each health group’s vascular data as the reference. CI, 
confidence interval; IGT, impaired glucose tolerance; MetS, metabolic syndrome; T2D, type 2 diabetes; T2DC, type 2 diabetes with complications.
Macrovascular endothelium-dependent 
reactivity
Macrovascular endothelium-independent 
reactivity
Microvascular endothelium-dependent 
reactivity
Microvascular endothelium-independent 
reactivity
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Figure 5-S3. A netheat plot illustrating the consistency of the direct and indirect 
comparisons. Grey squares indicate the contribution of the direct estimate (shown in 
the columns) to the network estimate (shown in the rows). The colours are associated 
with the change in inconsistency between direct and indirect evidence. Blue colours 
indicate an increase and warm colours indicate a decrease; with the stronger the 
intensity of the colour, the stronger the change. IGT, impaired glucose tolerance; MetS, 
metabolic syndrome; T2D, type 2 diabetes; T2DC, type 2 diabetes with complications. 
Macrovascular endothelium-
independent reactivity
Microvascular endothelium-
dependent reactivity
Microvascular endothelium-
independent reactivity
Macrovascular endothelium-
dependent reactivity
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Figure 5-S4. Sensitivity analysis: Forest plots of the mean difference (MD) in macrovascular reactivity and the standardized mean difference 
(SMD) in microvascular reactivity between each health group with a classification of overweight, obesity or cardiometabolic disease as compared 
to the healthy group, including only blinded studies, in the network meta-analysis. CI, confidence interval; IGT, impaired glucose tolerance; MetS, 
metabolic syndrome; T2D, type 2 diabetes; T2DC, type 2 diabetes with complications. 
Macrovascular endothelium-dependent reactivity Microvascular endothelium-dependent reactivity
Macrovascular endothelium-independent reactivity Microvascular endothelium-independent reactivity
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Figure 5-S5. The results from meta-regressions analyses demonstrating the correlation between flow-mediated dilation and fasting blood glucose 
data; with the healthy group plotted against each health group classified as A) overweight (Ov) or B) obese (Ob), or those with C) impaired glucose 
tolerance (IGT), D) metabolic syndrome (MetS), E) type 2 diabetes (T2D) or F) type 2 diabetes and complications (T2DC). MD, mean difference. 
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Figure 5-S6. (A) The ranking plot and (B) Hasse diagram demonstrate the impairment 
of microvascular and macrovascular reactivity throughout the pathogenesis of type 2 
diabetes (T2D). IGT, impaired glucose tolerance; MetS, metabolic syndrome; T2DC, 
type 2 diabetes with complications. 
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5.7.3 Supplemental tables 
 
Table 5-S1. The search criteria used in MEDLINE and EMBASED for this systematic review and network meta-analysis. 
Field 1 (Title, abstract and subject headings) 
obes* OR pre-diabet* OR prediabet* OR metabolic syndrome OR metS OR diabet* OR T2D 
AND 
Field 2 (Title, abstract and subject headings) 
flow-mediated dilation OR FMD OR nitrate-mediated dilation OR NMD OR brachial artery ultrasound OR post-occlusive reactive hyper* OR 
PORH OR iontophoresis OR skin microdialysis OR intradermal injection* OR pressure-induced vasodilation OR PIV OR local thermal hyper* 
OR LTH OR current-induced vasodilation OR CIV OR nerve-axon reflex OR laser Doppler* OR LDF OR LDPI OR LDPM OR LDI OR LDSI 
OR laser speckle* OR LSCI OR LASCA OR Doppler wires OR strain gauge plethysmography OR venous occlusion plethysmography 
Field 1 and Field 2 were combined by the Boolean operator “AND”. Terms within each field were combined with the Boolean operator “OR”. 
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Table 5-S2. The main characteristics of each study included in the systematic review and network meta-analysis 
Study, year of publication 
Quality Score 
(0-17) Risk of Bias Health Groups (n =) 
Tests of vascular reactivity 
Microvascular Macrovascular 
Joris et al,257 2017 15 Low H (25); Ob (23); MetS (26)  FMD 
Blum et al,258 2016 12.5 Moderate Ov (23); T2D (25); T2DC (48)  FMD 
Dimassi et al,259 2016 15 Low H (46); Ob (69) LDF - LTH, ACh  
Dow et al,260 2016 13.5 Low H (11); Ob (10); MetS (11) SGP - ACh  
Fakhrzadeh et al,261 2016 17 Low Ov (103); T2D (105)  FMD 
Fetterman et al,262 2016 16 Low Ov (98); T2D (74); T2DC (48)  FMD; NMD 
Francois et al,263 2016 11.5 Moderate Ov (12); T2D (12)  FMD 
Jahn et al,264 2016 11.5 Moderate H (16); MetS (18)  FMD 
Kovamees et al,265 2016 14 Moderate H (12); T2D (12) LDF - ACh  
Nasr et al,31 2016 15 Low H (211); Ob (183) LDF - ACh  
Park et al,266 2016 8 High H (16); T2DC (20) LDI - PORH, LTH  
Patik et al,267 2016 12.5 Low H (13); Ob (14) LDF - SNP  
Roustit et al,30 2016 16 Low Ov (59); IGT (75)  FMD 
Shimabukuro et al,268 2016 12.5 Low H (18); MetS (19) SGP - ACh, SNP  
Sorensen et al,269 2016 16 Low Ov (863); IGT (254) LDF - LTH  
Zeng et al,270 2016 13.5 Low H (40); T2D (40)  FMD; NMD 
Antonopoulos et al,271 2015 15 Low H (196); T2D (214); T2DC (70)  FMD 
Diaw et al,272 2015 14.5 Low H (14); T2D (14)  FMD 
Greyling et al,273 2015 13 Low Ov (10); T2D (10)  FMD 
Heidari et al,274 2015 17 Low Ov (101); T2D (107)  FMD 
Ito et al,275 2015 16 Low H (95); T2DC (161)  FMD 
Janczura et al,276 2015 16 Low Ov (126); MetS (109)  FMD 
Kramer-Aguiar et al,277 2015 15.5 Low H (9); Ov (11); Ob (60) SGP - ACh, SNP  
Lind,278 2015 15 Low H and MetS (totals unclear) SGP - ACh, SNP FMD 
Lu et al,279 2015 13 Low H (148); T2D (245)  FMD 
Madsen et al,280 2015 17 Low Ob (13); T2D (10)  FMD 
Regensteiner et al,281 2015 13.5 Low Ov (34); T2D (29) SGP - PORH  
Schinzari et al,282 2015 15 Moderate H (56); Ob (34) SGP - ACh  
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Schreuder et al,283 2015 13.5 Moderate Ov (10); T2D (13)  FMD; NMD 
Siasos et al,284 2015 12 Moderate H (100); T2D (108); T2DC (92)   FMD 
Walther et al,285 2015 16 Low H (40); MetS (53); T2D (25) LDF - ACh, SNP FMD; NMD 
Alatab et al,286 2014 15 Low Ov (153); T2D (125)  FMD 
Fernandes et al,287 2014 13.5 Moderate H (10); MetS (21)  FMD 
Franklin et al,288 2014 16 Low H (8); Ob (9)  FMD 
Hallmark et al,289 2014 13.5 Moderate H (14); Ob (14)  FMD 
Kinouchi et al,290 2014 17 Low Ov (153); T2D (167)  FMD 
Liao et al,291 2014 16.5 Low H (13); T2D (22)  FMD; NMD 
Mahfouz et al,292 2014 14 Low Ov (78); IGT (92)  FMD 
Martin-Rodriguez et al,293 2014 16 Low H (30); Ob (25) LDF - PORH  
Nguyen et al,294 2014 16 Low H (25); Ob (30); T2D (118)  FMD 
Pienaar et al,295 2014 15.5 Low H (21); IGT (16) LDI - ACh  
Ramakumari et al,296 2014 16 Low H (42); T2D (42)  FMD; NMD 
Schreuder et al,297 2014 13.5 Low Ov (9); T2D (12)  FMD; NMD 
Shimabukuro et al,298 2014 14 Moderate IGT (5); MS (6)  FMD; NMD 
Xiang et al,299 2014 17 Low H (52); T2D (55)  FMD; NMD 
Zhang et al,300 2014 14 Moderate H (30); T2D (36)  FMD 
Fonseca et al,301 2013 14 Low H (19); Ov (35); Ob (34)  FMD; NMD 
Jan et al,302 2013 10.5 Moderate Ov (8); T2DC (18) LDF - PORH, LTH  
Lupattelli et al,303 2013 14 Low Ov (28); Ob (65)  FMD 
Palazzo et al,304 2013 16 Low Ov (18); T2D (26)  FMD 
Rajapakse et al,305 2013 12.5 Low H (11); T2D (9) SGP - SNP  
Rossi et al,306 2013 15.5 Low H (78); Ob (113) SGP - PORH  
Yiu et al,307 2013 14 Moderate H (150); T2D (100)  FMD 
Aellen et al,308 2012 14.5 Moderate H (21); MetS (25); T2D (21) LDI - LTH  
Biere-Rafi et al,309 2012 14.5 Low H (50); Ob (42)  FMD 
Bruno et al,310 2012 16 Low Ov (257); T2D (84)  FMD; NMD 
Dosi et al,311 2012 13.5 Moderate H (40); T2D (40)  FMD; NMD 
Shemyakin et al,312 2012 13.5 Low Ov (16); T2DC (16) SGP - SNP  
Sogawa et al,313 2012 14 Low H (21); T2D (30); T2DC (41)  FMD 
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Tian et al,314 2012 14.5 Moderate H (59); T2D (116)  FMD; NMD 
Al-Tahami et al,315 2011 12.5 Low H (36); Ob (36) LDF - ACh, SNP  
Anderson et al,316 2011 13.5 Moderate Ov (19); T2DC (26)  FMD; NMD 
Ayer et al,317 2011 17 Low H (19); Ob (19)  FMD; NMD 
Bruno et al,318 2011 14.5 Low Ov (76); T2D (32)  FMD; NMD 
Ceriello et al,163 2011 13 Low Ov (12); T2D (16)  FMD 
Chen et al,319 2011 16 Low H (25); T2D (33)  FMD; NMD 
Doupis et al,320 2011 16 Low H (40); Ob (37) LDI - ACh, SNP FMD; NMD 
Mah et al,321 2011 13 Low H (8); Ob (8)  FMD 
Rossi et al,322 2011 13 Moderate H (28); Ob (19), T2D (18) LDF - PORH  
Taslipinar et al,323 2011 14 Low T2D (30); T2DC (25)  FMD; NMD 
Tian et al,324 2011 11.5 Moderate H (83); T2D (87)  FMD 
Tomiyama et al,325 2011 16 Low H (1879); MetS (257)  FMD 
Vinet et al,223 2011 15.5 Low H (16); Ob (16)  FMD; NMD 
Yim-Yeh et al,326 2011 17 Low H (14); Ob (33); T2D (68) LDF - ACh, SNP FMD; NMD 
Zhang et al,327 2011 13 Moderate H (483); T2D (512)  FMD 
Ayer et al,328 2010 17 Low H (11); Ob (11) SGP - PORH FMD; NMD 
Barutcuoglu et al,329 2010 15.5 Low H (10); Ov (18); T2D (26)  FMD; NMD 
Biasucci et al,330 2010 16 Low H (13), Ob (58)  FMD 
Buscemi et al,331 2010 14.5 Low Ob (30); MetS (23); T2D (22)  FMD; NMD 
Chousos et al,332 2010 15.5 Low Ov (24); T2D (20) LDF - ACh, SNP  
Czernichow et al,333 2010 16.5 Low H (130); Ov (120) LDF - LTH, ACh  
de Matthaeis et al,334 2010 16 Low Ov (137); MetS (43)  FMD; NMD 
Eyileten et al,335 2010 17 Low Ov (33); T2D (32)  FMD 
Feng et al,336 2010 17 Low H (15); T2D (35)  FMD 
Jelic et al,337 2010 16 Low H (5); Ov (11); Ob (17)  FMD 
Kizhakekuttu et al,338 2010 13.5 Moderate Ov (14); T2D (29)  FMD; NMD 
Liao et al,103 2010 17 Low H (51); T2D (46)  FMD; NMD 
Quinn et al,339 2010 17 Low Ov (24); IGT (40)  FMD 
Ran et al,340 2010 13.5 Low T2D (18); T2DC (32)  FMD; NMD 
Schinzari et al,341 2010 13 Low H (13); MetS (14) SGP - ACh, SNP  
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Yilmaz et al,342 2010 17 Low Ov (38); T2DC (78)  FMD 
Aizawa et al,343 2009 16 Low Ov (44); MetS (45)  FMD; NMD 
Fahs et al,344 2009 14 Low H (36); Ov (37); Ob (37) SGP - PORH  
Lind et al,345 2009 8.5 Moderate H (19); Ob (19)  FMD 
McLellan et al,346 2009 9.5 Moderate H (30); T2D (15) LDF - LTH  
Rousseau et al,347 2009 17 Low H (10); T2D (20) LDF - PORH, ACh, SNP  
Yeh et al,348 2009 13 Low Ov (52); T2D (213)  FMD; NMD 
Brooks et al,349 2008 13.5 Moderate Ov (20); T2D (20); T2DC (20) LDF - ACh, SNP  
Donald et al,350 2008 9.5 Moderate H (25); T2D (25)  FMD 
Esposito et al,351 2008 17 Low Ov (44); T2D (30)  FMD 
Ghiadoni et al,352 2008 14 Moderate Ov (78); MetS (29)  FMD; NMD 
Hamburg et al,353 2008 16 Low Ov (1361); MetS (762)  FMD 
Irace [A] et al,354 2008 16 Low Ov (65); T2D (118)  FMD; NMD 
Irace [B] et al,355 2008 14 Moderate Ov (30); T2D (66)  FMD; NMD 
Maenaka et al,356 2008 11 Moderate H (20); T2D (20) SGP - PORH  
Makino et al,357 2008 14 Low T2D (121); T2DC (96)  FMD; NMD 
Malecki et al,358 2008 17 Low T2D (111); T2DC (71)  FMD 
Mizia-Stec et al,359 2008 16 Low H (16); Ov (18); Ob (22)  FMD; NMD 
Natali et al,180 2008 17 Low Ov (20); IGT (16); T2D (117) SGP - ACh, SNP  
Petrofsky et al,360 2008 12.5 Low H (30); T2D (15) LDI - LTH  
Plantinga et al,361 2008 14 Moderate H (166); Ov (260); MetS (131)  FMD; NMD 
Quattrini et al,362 2008 12.5 Moderate H (12); T2D (12); T2DC (41) LDF - ACh, SNP  
Su et al,363 2008 14 Low H (46); IGT (99); T2D (44)  FMD; NMD 
Title et al,364 2008 14 Moderate Ov (1150); MetS (267)  FMD; NMD 
Van Guilder et al,365 2008 13 Low H (42); Ob (44) SGP - ACh  
Voidonikola et al,366 2008 15 Low H (154); Ob (155)  FMD 
Xiang et al,192 2008 17 Low H (26); IGT (21)  FMD; NMD 
Yilmaz et al,367 2008 17 Low Ov (38); T2D (85)  FMD; NMD 
Acree et al,368 2007 15 Low H (30); Ov (28), Ob (29)  SGP - PORH  
Bahia et al,369 2007 12.5 Moderate H (8); MetS (18) SGP - ACh, SNP  
Cangemi et al,370 2007 13.5 Moderate H (30); MetS (18)  FMD 
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Esposito et al,371 2007 17 Low Ov (20); T2D (30)  FMD 
Jin et al,372 2007 15.5 Low H (13); T2DC (19) LDF - LTH  
Karabag [A] et al,373 2007 14 Low Ov (40); T2D (70)  FMD; NMD 
Karabag [B] et al,374 2007 14 Low Ov (16); T2D (59)  FMD; NMD 
Krishnan et al,375 2007 12.5 Moderate H (12); T2DC (12) LDF - LTH  
Schmiedel et al,376 2007 16.5 Low Ov (10); T2D (12); T2DC (17) LDF - LTH, ACh, SNP  
Suetsugu et al,377 2007 13.5 Moderate H (20); T2D (59); T2DC (43)  FMD 
Waring et al,378 2007 14 Moderate Ov (10); T2D (10) SGP - ACh, SNP  
Bahia et al,379 2006 12.5 Moderate H (9); MetS (18) SGP - ACh, SNP  
Baykan et al,380 2006 12.5 Low T2D (39); T2D (29)  FMD 
Chan et al,381 2006 15.5 Low H (52); T2D (32); T2DC (26)  FMD; NMD 
Colberg et al,382 2006 13.5 Low Ob (9); T2D (10) LDF - LTH  
Esposito [A] et al,383 2006 14 Moderate Ov (60), MetS (100)  FMD 
Esposito [B] et al,384 2006 17 Low H (40); MetS (41)  FMD; NMD 
Esposito [C] et al,385 2006 17 Low Ov (50); MetS (100)  FMD 
Hermann et al,386 2006 9.5 Moderate H (15); T2D (15) SGP - SNP  
Madsen et al,387 2006 9.5 Low H (33); T2D (13)  FMD 
Olson et al,388 2006 16 Low H (18); Ov (22); Ob (19)  FMD; NMD 
Pulerwitz et al,389 2006 16 Low H (130); Ov (278); Ob (146)  FMD 
Shemyakin et al,390 2006 12.5 Moderate H (8); IGT (12) SGP - ACh, SNP  
Tretjakovs et al,391 2006 16.5 Low Ov (10); T2DC (20) LDF - PORH  
van Wijk et al,392 2006 13.5 Moderate Ov (14); T2D (13)  FMD; NMD 
Colberg et al,393 2005 12.5 Low Ob (10); T2D (9)   
Gooding et al,394 2005 14 Low Ov (20); T2D (17) LDI - ACh, SNP  
Rodriguez et al,395 2005 16.5 Low Ov (484); IGT (95)  FMD 
Skilton et al,396 2005 15 Low H (15); Ov (15); T2D (15) SGP - PORH FMD 
Strain et al,397 2005 17 Low Ov (100); Ob (88); T2D (117) LDF - PORH, LTH  
Tesauro et al,398 2005 10.5 Moderate H (12); MetS (12) SGP - ACh, SNP  
Williams et al,399 2005 15.5 Low H (24); Ov (15)  FMD; NMD 
de Jongh [A] et al,400 2004 13.5 Low H (16); Ob (12) LDF - ACh, SNP  
de Jongh [B] et al,401 2004 16.5 Low H (16); Ob (12) LDF - ACh, SNP  
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Economides et al,402 2004 15.5 Low H (7); T2D (38) LDI - ACh, SNP FMD; NMD 
Henry et al,403 2004 16 Low Ov (246); IGT (135)  FMD; NMD 
Krishnan et al,404 2004 13.5 Moderate H (20); T2D (20); T2DC (18) LDF - LTH  
Krishnan and Rayman,405 2004 14.5 Low H (12); T2D (12); T2DC (12) LDI - LTH  
Nair et al,406 2004 16 Low T2D (23); T2DC (23)  FMD 
Nystrom [A] et al,407 2004 10.5 Moderate H (10); T2D (12)  FMD; NMD 
Nystrom [B] et al,408 2004 12.5 Moderate H (10); Ov (10); T2D (12)  FMD; NMD 
Park et al,409 2004 7.5 High H (13); T2D (11)  FMD 
Seywert et al,410 2004 14.5 Low H (16); Ob (16) LDI - PORH  
Shimabukuro et al,411 2004 11.5 Low H (12); MetS (22) SGP - PORH NMD 
Strey et al,412 2004 13 Moderate Ov (10); T2D (19) SGP - PORH, ACh  
Bhargava et al,413 2003 13 Low H (67); T2D (38); T2DC (35)  FMD 
Caballero et al,414 2003 16 Low T2D (27); T2DC (31) LDI - ACh, SNP FMD; NMD 
Ching et al,415 2003 15.5 Low H (27); Ov (23); T2D (15) SGP - PORH  
Colberg et al,416 2003 13.5 Low Ob (13); T2D (17) LDF - LTH  
de Kreutzenberg et al,417 2003 13.5 Low Ov (10); Ob (10) SGP - SNP  
Hamdy et al,418 2003 14 Low Ob (8); IGT (8); T2D (8)  FMD 
Regensteiner et al,419 2003 13.5 Low H (10); T2D (10) SGP - PORH FMD 
Rizzoni et al,420 2003 13.5 Low Ov (15); MetS (15); T2D (30)  FMD 
Colberg et al,421 2002 12.5 Low Ob (8); T2D (8) LDF - PORH, LTH  
Ihlemann et al,422 2002 17 Low Ov (23); T2D (23)  FMD; NMD 
van Etten et al,423 2002 14 Low Ov (21); T2D (23) SGP - SNP  
Woodman et al,424 2002 16.5 Low Ov (17); T2D (29)  FMD; NMD 
Hamdy et al,425 2001 12 Moderate Ov (69); T2D (42) LDF - ACh, SNP  
Heitzer et al,426 2001 10.5 Moderate H (11); T2D (39) SGP - ACh, SNP  
Kimura et al,427 2001 15 Low H (12); T2D (15)  FMD; NMD 
Rask-Madsen et al,428 2001 16.5 Low H (31); T2DC (28) SGP - ACh  
Ghiadoni et al,429 2000 16.5 Low H (10); T2D (8)  FMD; NMD 
Heitzer et al,430 2000 10 Moderate H (12); T2D (23) SGP - ACh, SNP  
Preik et al,431 2000 16.5 Low Ov (12); IGT (12); T2D (20) SGP - ACh, SNP  
Watts et al,432 2000 10.5 Moderate Ov (19); Ob (20) SGP - PORH  
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Bornmyr et al,433 1999 8.5 Moderate H (80); T2D (50) LDI - LTH  
Caballero et al,434 1999 15.5 Low Ov (30); IGT (32) LDI - ACh, SNP FMD 
Hogikyan et al,435 1999 13.5 Moderate H (6); T2D (11) SGP - SNP  
Lim et al,436 1999 12.5 Low Ov (20); T2D (45); T2DC (14) LDI - ACh, SNP  
Stansberry et al,437 1999 16.5 Low Ob (10); T2D (10) LDF - PORH, LDF  
Hashimoto et al,438 1998 17 Low H (23); Ob (15)  FMD; NMD 
Hogikyan et al,439 1998 15.5 Low Ov (20); T2D (17) SGP - ACh, SNP  
Jaap et al,440 1997 17 Low H (24); IGT (24) LDF - LTH  
McVeigh et al,441 1992 17 Low H (21); T2D (29) SGP - ACh  
Tenembaum et al,442 1981 9.5 Moderate H (19); T2D (20) SGP - PORH  
Study quality was assessed using a modified systematic appraisal for observational research. Risk of bias was assessed according to the guidelines 
for evaluating observational studies presented by the Grading of Recommendations Assessment, Development and Evaluation. H, Healthy; Ov, 
overweight; Ob, Obese; MetS, metabolic syndrome; IGT, impaired glucose tolerance; T2D, type 2 diabetes; T2DC, type 2 diabetes with 
complications; SGP, strain-gauge plethysmography; LDI, laser Doppler imaging; LDF, laser Doppler flowmetry; ACh, acetylcholine; SNP, sodium 
nitroprusside; PORH, post-occlusive reactive hyperemia; FMD, flow-mediated dilation; NMD, nitrate-mediated dilation. 
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Table 5-S3. Quality of evidence for each outcome in macrovascular endothelium-dependent reactivity when comparing overweight or obese 
populations, or populations with cardiometabolic disease, to a healthy population 
Health Group (Outcome)  
No. of 
Studies  Risk of Bias Inconsistency Indirectness Imprecision Other Considerations* 
Quality of 
Evidence 
(GRADE) 
Overweight (Impaired) 9  Not detected Serious† Not detected Not detected None Very low 
Obese (Impaired) 22 Not detected Serious† Not detected Not detected None Very low 
IGT (Impaired) 2 Not detected Not detected Not detected Not detected Publication bias likely‡ Very low 
MetS (Impaired) 9 Not detected Serious† Not detected Not detected None Very low 
T2D (Impaired) 38 Not detected Not detected Not detected Not detected Publication bias likely‡ Very low 
T2DC (Impaired) 7 Not detected Not detected Not detected Not detected None Low 
Due to the nature of this present study’s research question, all studies included in the network meta-analyses are considered observational and, 
thus, the quality of evidence for all outcomes begin as low before down-grading or up-grading according to the GRADE (Grading of 
Recommendations Assessment, Development and Evaluation). H, Healthy; Ov, overweight; Ob, Obese; MetS, metabolic syndrome; IGT, impaired 
glucose tolerance; T2D, type 2 diabetes; T2DC, type 2 diabetes with complications. 
 
*Large-magnitude of effect, dose-response, plausible biases decreasing the magnitude of effect, or publication bias. 
†Large I2 and/or point estimates vary widely across studies indicating that macrovascular endothelium-dependent reactivity is impaired in those 
considered overweight or obese, or in those with impaired glucose tolerance. 
‡Publication bias is likely as the evidence consists of a small number of studies or funnel plot asymmetry was detected. 
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Table 5-S4. Quality of evidence for each outcome in macrovascular endothelium-independent reactivity when comparing overweight or obese 
populations, or populations with cardiometabolic disease, to a healthy population 
Health Group (Outcome)  
No. of 
Studies Risk of Bias Inconsistency Indirectness Imprecision Other Considerations* 
Quality of 
Evidence 
(GRADE) 
Overweight (No Effect) 6 Not detected Serious† Not detected Serious‡ None Very low 
Obese (No Effect) 10 Not detected Serious† Not detected Serious‡ None Very low 
IGT (Impaired) 2 Not detected Not detected Not detected Not detected Publication bias likely|| Very low 
MetS (Impaired) 3 Not detected Not detected Not detected Not detected Publication bias likely|| Very low 
T2D (Impaired) 19 Not detected Serious† Not detected Not detected None Very low 
T2DC (Impaired) 1 Not detected Not detected Not detected Not detected Publication bias likely|| Very low 
Due to the nature of this present study’s research question, all studies included in the network meta-analyses are considered observational and, 
thus, the quality of evidence for all outcomes begin as low before down-grading or up-grading according to the GRADE (Grading of 
Recommendations Assessment, Development and Evaluation) criteria. H, Healthy; Ov, overweight; Ob, Obese; MetS, metabolic syndrome; IGT, 
impaired glucose tolerance; T2D, type 2 diabetes; T2DC, type 2 diabetes with complications. 
 
*Large-magnitude of effect, dose-response, plausible biases decreasing the magnitude of effect, or publication bias. 
†Large I2 and/or point estimates vary widely across studies indicating that macrovascular endothelium-independent reactivity is impaired and 
unaffected in those considered overweight or obese, or in those with type 2 diabetes. 
‡The 95 % confidence interval includes both negative and positive effects of an overweight or obese state on macro-VSM reactivity.  
||Publication bias is likely as the evidence consists of a small number of studies or funnel plot asymmetry was detected. 
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Table 5-S5. Quality of evidence for each outcome in microvascular endothelium-dependent reactivity when comparing overweight or obese 
populations, or populations with cardiometabolic disease, to a healthy population 
Health Group (Outcome)  
No. of 
Studies Risk of Bias Inconsistency Indirectness Imprecision Other Considerations* 
Quality of 
Evidence 
(GRADE) 
Overweight (No Effect) 6 Not detected Not detected Not detected Not detected None Low 
Obese (Impaired) 20 Not detected Serious† Not detected Not detected None Very low 
IGT (No Effect) 3 Not detected Not detected Not detected Not detected Publication bias likely‡ Very low 
MetS (Impaired) 10 Not detected Not detected Not detected Not detected Publication bias likely‡ Very low 
T2D (Impaired) 25 Not detected Not detected Not detected Not detected Publication bias likely‡ Very low 
T2DC (Impaired) 9 Not detected Not detected Not detected Not detected Publication bias likely‡ Very low 
Due to the nature of this present study’s research question, all studies included in the network meta-analyses are considered observational; and, 
thus, the quality of evidence for all outcomes begin as low before down-grading or up-grading according to the GRADE (Grading of 
Recommendations Assessment, Development and Evaluation) criteria. H, Healthy; Ov, overweight; Ob, Obese; MetS, metabolic syndrome; IGT, 
impaired glucose tolerance; T2D, type 2 diabetes; T2DC, type 2 diabetes with complications. 
 
*Large-magnitude of effect, dose-response, plausible biases decreasing the magnitude of effect, or publication bias. 
†Large I2 and point estimates vary widely across studies indicating that microvascular endothelium-dependent reactivity is impaired and 
unaffected in those considered obese. 
‡Publication bias is likely as the evidence consists of a small number of studies or funnel plot asymmetry was detected. 
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Table 5-S6. Quality of evidence for each outcome in microvascular endothelium-independent reactivity when comparing overweight or obese 
populations, or populations with cardiometabolic disease, to a healthy population 
Health Group (Outcome)  
No. of 
Studies Risk of Bias Inconsistency Indirectness Imprecision Other Considerations* 
Quality of 
Evidence 
(GRADE) 
Overweight (No Effect) 1 Not detected Not detected Not detected Not detected Publication bias likely|| Very low 
Obese (Impaired) 9 Not detected Serious‡ Not detected Not detected None Very low 
IGT (No Effect) 1 Serious† Not detected Not detected Not detected Publication bias likely|| Very low 
MetS (Impaired) 7 Not detected Not detected Not detected Not detected None Low 
T2D (Impaired) 10 Not detected Serious‡ Not detected Not detected None Very low 
T2DC (Impaired) 3 Not detected Not detected Not detected Not detected Publication bias likely|| Very low 
Due to the nature of this present study’s research question, all studies included in the network meta-analyses are considered observational; and, 
thus, the quality of evidence for all outcomes begin as low before down-grading or up-grading according to the GRADE (Grading of 
Recommendations Assessment, Development and Evaluation) criteria. H, Healthy; Ov, overweight; Ob, Obese; MetS, metabolic syndrome; IGT, 
impaired glucose tolerance; T2D, type 2 diabetes; T2DC, type 2 diabetes with complications. 
 
*Large-magnitude of effect, dose-response, plausible biases decreasing the magnitude of effect, or publication bias. 
†Failure to adequately control for confounding factors including differences in clinical characteristics and medication status. 
‡Large I2 and/or point estimates vary widely across studies indicating that microvascular endothelium-independent reactivity is impaired and 
unaffected in those considered obese or in those with type 2 diabetes. 
||Publication bias is likely as the evidence consists of a small number of studies or funnel plot asymmetry was detected. 
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Table 5-S7. Results of the node-splitting method assessing the evidence from direct and indirect comparisons, as well as the discrepancies between 
direct and indirect results, in macrovascular endothelium-dependent reactivity 
Comparison  k prop nma 95%-CI direct 95%-CI indir. 95%-CI Diff 95%-CI z p-value 
Healthy:Overweight 9 0.23 -0.41 (-0.98, 0.15) -1.24 (-2.43, -0.05) -0.17 (-0.82, 0.48) -1.07 (-2.43, 0.28) -1.55 0.121 
Healthy:Obese 22 0.77 -1.33 (-1.98, -0.67) -0.87 (-1.61, -0.12) -2.87 (-4.24, -1.50) 2 (0.45, 3.56) 2.52 0.0116 
Healthy:IGT 2 0.26 -1.75 (-2.80, -0.70) -1.18 (-3.22, 0.86) -1.96 (-3.18, -0.74) 0.78 (-1.60, 3.16) 0.64 0.5212 
Healthy:MetS 9 0.5 -1.99 (-2.73, -1.24) -1.75 (-2.80, -0.69) -2.23 (-3.28, -1.17) 0.48 (-1.01, 1.97) 0.63 0.5289 
Healthy:T2D 38 0.73 -3.22 (-3.69, -2.75) -3.59 (-4.14, -3.03) -2.23 (-3.14, -1.33) -1.35 (-2.41, -0.29) -2.5 0.0123 
Healthy:T2DC 8 0.44 -4.26 (-4.97, -3.54) -3.13 (-4.22, -2.05) -5.12 (-6.08, -4.17) 1.99 (0.54, 3.43) 2.69 0.0071 
Overweight:Obese 7 0.32 0.91 (0.16, 1.67) 1.63 (0.28, 2.98) 0.58 (-0.33, 1.49) 1.05 (-0.58, 2.68) 1.26 0.2064 
Overweight: IGT 6 0.59 1.34 (0.34, 2.33) 2.09 (0.79, 3.38) 0.26 (-1.29, 1.81) 1.82 (-0.19, 3.84) 1.77 0.0762 
Overweight: MetS 9 0.54 1.57 (0.84, 2.31) 1.43 (0.43, 2.42) 1.75 (0.67, 2.83) -0.32 (-1.79, 1.15) -0.43 0.6675 
Overweight:T2D 34 0.66 -2.8 (-3.29, -2.32) -2.83 (-3.42, -2.24) -2.75 (-3.58, -1.93) -0.08 (-1.09, 0.94) -0.14 0.8852 
Overweight:T2DC 8 0.32 -3.84 (-4.57, -3.12) -3.87 (-5.14, -2.60) -3.83 (-4.71, -2.95) -0.04 (-1.59, 1.50) -0.05 0.9564 
Obese:IGT 1 0.12 0.42 (-0.74, 1.59) -0.4 (-3.82, 3.02) 0.53 (-0.70, 1.77) -0.93 (-4.57, 2.71) -0.5 0.6156 
Obese:MetS 2 0.19 0.66 (-0.25, 1.57) -0.75 (-2.85, 1.34) 0.99 (-0.02, 2.00) -1.74 (-4.07, 0.58) -1.47 0.1421 
Obese:T2D 5 0.26 -1.89 (-2.61, -1.17) -1.39 (-2.80, 0.03) -2.07 (-2.90, -1.23) 0.68 (-0.96, 2.32) 0.81 0.4162 
Obese:T2DC 0 0 -2.93 (-3.84, -2.02) . . -2.93 (-3.84, -2.02) . . . . 
IGT:MetS 1 0.09 -0.24 (-1.40, 0.93) -1.75 (-5.65, 2.15) -0.09 (-1.31, 1.13) -1.66 (-5.75, 2.43) -0.8 0.426 
IGT:T2D 2 0.22 -1.47 (-2.50, -0.44) -2.76 (-4.96, -0.57) -1.1 (-2.27, 0.07) -1.66 (-4.15, 0.82) -1.31 0.1897 
IGT:T2DC 0 0 -2.51 (-3.68, -1.33) . . -2.51 (-3.68, -1.33) . . . . 
MetS:T2D 3 0.16 -1.23 (-1.99, -0.47) 0.14 (-1.76, 2.04) -1.5 (-2.33, -0.66) 1.64 (-0.44, 3.71) 1.55 0.1217 
MetS:T2DC 0 0 -2.27 (-3.21, -1.33) . . -2.27 (-3.21, -1.33) . . . . 
T2D:T2DC 18 0.71 -1.04 (-1.69, -0.38) -1.69 (-2.46, -0.91) 0.53 (-0.67, 1.74) -2.22 (-3.66, -0.79) -3.03 0.0024 
k, number of studies providing direct evidence; prop, direct evidence proportion; nma, estimated treatment effect (md) in the network meta-
analysis; direct, estimated treatment effect (md) derived from direct evidence; indir., estimated treatment effect (md) derived from indirect 
evidence; diff, difference between direct and indirect treatment estimates; z, z-value of test for disagreement (direct versus indirect);  p-value, p-
value of test for disagreement (direct versus indirect); MetS, metabolic syndrome; IGT, impaired glucose tolerance; T2D, type 2 diabetes; T2DC, 
type 2 diabetes with complications. 
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Table 5-S8. Results of the node-splitting method assessing the evidence from direct and indirect comparisons, as well as the discrepancies between direct and 
indirect results, in macrovascular endothelium-independent reactivity 
Comparison  k prop nma 95%-CI direct 95%-CI indir. 95%-CI Diff 95%-CI z p-value 
Healthy:Overweight 6 0.26 -0.98 (-1.79, -0.17) -1.19 (-2.77, 0.39) -0.91 (-1.85, 0.03) -0.29 (-2.13, 1.55) -0.3 0.7606 
Healthy:Obese 10 0.71 -0.34 (-1.39, 0.71) -1.4 (-2.65, -0.16) 2.29 (0.33, 4.24) -3.69 (-6.01, -1.37) -3.12 0.0018 
Healthy:IGT 2 0.6 -1.5 (-2.95, -0.06) -0.91 (-2.77, 0.96) -2.4 (-4.68, -0.12) 1.49 (-1.46, 4.43) 0.99 0.3222 
Healthy:MetS 3 0.42 -1.47 (-2.48, -0.46) -1.39 (-2.94, 0.15) -1.53 (-2.86, -0.20) 0.14 (-1.90, 2.18) 0.13 0.8957 
Healthy:T2D 19 0.72 -2.68 (-3.36, -1.99) -2.25 (-3.05, -1.45) -3.79 (-5.09, -2.49) 1.54 (0.01, 3.06) 1.97 0.0484 
Healthy:T2DC 1 0.14 -3.14 (-4.20, -2.08) -4.4 (-7.25, -1.55) -2.94 (-4.08, -1.79) -1.46 (-4.53, 1.61) -0.93 0.3515 
Overweight:Obese 4 0.26 -0.64 (-1.81, 0.52) 0.61 (-1.65, 2.88) -1.09 (-2.45, 0.26) 1.71 (-0.93, 4.34) 1.27 0.2047 
Overweight: IGT 1 0.32 0.52 (-0.96, 2.00) 0.83 (-1.77, 3.43) 0.38 (-1.42, 2.17) 0.45 (-2.71, 3.62) 0.28 0.778 
Overweight: MetS 5 0.63 0.49 (-0.43, 1.42) 0.35 (-0.82, 1.51) 0.74 (-0.79, 2.27) -0.39 (-2.31, 1.53) -0.4 0.6901 
Overweight:T2D 19 0.62 -1.69 (-2.35, -1.04) -2.1 (-2.94, -1.27) -1.03 (-2.10, 0.03) -1.07 (-2.42, 0.29) -1.55 0.122 
Overweight:T2DC 4 0.46 -2.16 (-3.12, -1.20) -1.09 (-2.51, 0.32) -3.08 (-4.39, -1.77) 1.99 (0.06, 3.92) 2.02 0.0438 
Obese:IGT 0 0 1.17 (-0.56, 2.89) . . 1.17 (-0.56, 2.89) . . . . 
Obese:MetS 1 0.29 1.13 (-0.16, 2.43) 3.2 (0.81, 5.59) 0.29 (-1.25, 1.82) 2.91 (0.07, 5.75) 2.01 0.0445 
Obese:T2D 2 0.35 -2.34 (-3.45, -1.23) -5.06 (-6.95, -3.18) -0.89 (-2.27, 0.48) -4.17 (-6.50, -1.84) -3.51 0.0005 
Obese:T2DC 0 0 -2.8 (-4.18, -1.43) . . -2.8 (-4.18, -1.43) . . . . 
IGT:MetS 1 0.04 0.03 (-1.61, 1.67) -1.87 (-9.89, 6.15) 0.11 (-1.56, 1.79) -1.98 (-0.18, 6.21) -0.47 0.6351 
IGT:T2D 1 0.34 -1.17 (-2.63, 0.29) -0.33 (-2.85, 2.19) -1.6 (-3.39, 0.20) 1.27 (-1.83, 4.36) 0.8 0.4217 
IGT:T2DC 0 0 -1.64 (-3.31, 0.03) . . -1.64 (-3.31, 0.03) . . . . 
MetS:T2D 2 0.29 -1.2 (-2.18, -0.23) -1.85 (-3.68, -0.03) -0.94 (-2.10, 0.22) -0.91 (-3.08, 1.25) -0.83 0.4083 
MetS:T2DC 0 0 -1.67 (-2.92, -0.42) . . -1.67 (-2.92, -0.42) . . . . 
T2D:T2DC 8 0.7 -0.47 (-1.36, 0.43) -1.26 (-2.33, -0.18) 1.39 (-0.26, 3.03) -2.64 (-4.61, -0.68) -2.64 0.0083 
k, number of studies providing direct evidence; prop, direct evidence proportion; nma, estimated treatment effect (md) in the network meta-
analysis; direct, estimated treatment effect (md) derived from direct evidence; indir., estimated treatment effect (md) derived from indirect 
evidence; diff, difference between direct and indirect treatment estimates; z, z-value of test for disagreement (direct versus indirect);  p-value, p-
value of test for disagreement (direct versus indirect); MetS, metabolic syndrome; IGT, impaired glucose tolerance; T2D, type 2 diabetes; T2DC, 
type 2 diabetes with complications. 
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Table 5-S9. Results of the node-splitting method assessing the evidence from direct and indirect comparisons, as well as the discrepancies between 
direct and indirect results, in microvascular endothelium-dependent reactivity 
Comparison  k prop nma 95%-CI direct 95%-CI indir. 95%-CI Diff 95%-CI z p-value 
Healthy:Overweight 6 0.33 -0.2 (-0.48, 0.08) 0 (-0.49, 0.49) -0.3 (-0.64, 0.05) 0.3 (-0.30, 0.90) 0.98 0.3295 
Healthy:Obese 20 0.75 -0.66 (-0.90, -0.41) -0.69 (-0.97, -0.41) -0.56 (-1.06, -0.07) -0.13 (-0.69, 0.44) -0.43 0.6642 
Healthy:IGT 3 0.41 -0.63 (-1.10, -0.16) -0.73 (-1.46, -0.01) -0.56 (-1.17, 0.05) -0.18 (-1.13, 0.77) -0.37 0.7115 
Healthy:MetS 10 0.90 -1.01 (-1.39, -0.63) -1.03 (-1.42, -0.63) -0.84 (-2.06, 0.38) -0.19 (-1.47, 1.10) -0.29 0.7752 
Healthy:T2D 25 0.66 -1.1 (-1.31, -0.89) -1.17 (-1.43, -0.90) -0.98 (-1.34, -0.61) -0.19 (-0.64, 0.26) -0.82 0.4118 
Healthy:T2DC 9 0.56 -1.49 (-1.83, -1.14) -1.23 (-1.69, -0.77) -1.81 (-2.34, -1.29) 0.58 (-0.12, 1.28) 1.63 0.1026 
Overweight:Obese 4 0.30 0.46 (0.13, 0.79) 0.64 (0.04, 1.23) 0.39 (0.00, 0.77) 0.25 (-0.46, 0.96) 0.69 0.4876 
Overweight: IGT 3 0.52 0.43 (-0.04, 0.90) 0.3 (-0.35, 0.95) 0.57 (-0.11, 1.25) -0.27 (-1.21, 0.67) -0.56 0.5763 
Overweight: MetS 0 0.00 0.81 (0.35, 1.27) . . 0.81 (0.35, 1.27) . . . . 
Overweight:T2D 15 0.67 -0.9 (-1.16, -0.64) -0.6 (-0.92, -0.28) -1.51 (-1.97, -1.06) 0.91 (0.36, 1.47) 3.23 0.0013 
Overweight:T2DC 5 0.36 -1.29 (-1.67, -0.90) -1.83 (-2.47, -1.19) -0.98 (-1.46, -0.50) -0.85 (-1.65, -0.04) -2.07 0.0387 
Obese:IGT 0 0.00 -0.03 (-0.54, 0.48) . . -0.03 (-0.54, 0.48) . . . . 
Obese:MetS 1 0.11 0.35 (-0.09, 0.79) -0.26 (-1.60, 1.08) 0.42 (-0.04, 0.89) -0.68 (-2.10, 0.73) -0.95 0.3441 
Obese:T2D 8 0.38 -0.44 (-0.72, -0.17) -0.73 (-1.17, -0.28) -0.27 (-0.62, 0.08) -0.45 (-1.02, 0.11) -1.56 0.1179 
Obese:T2DC 0 0.00 -0.83 (-1.23, -0.42) . . -0.83 (-1.23, -0.42) . . . . 
IGT:MetS 0 0.00 -0.38 (-0.98, 0.22) . . -0.38 (-0.98, 0.22) . . . . 
IGT:T2D 2 0.29 -0.47 (-0.94, 0.00) -0.49 (-1.36, 0.38) -0.46 (-1.02, 0.09) -0.03 (-1.06, 1.01) -0.05 0.9620 
IGT:T2DC 0 0.00 -0.86 (-1.41, -0.30) . . -0.86 (-1.41, -0.30) . . . . 
MetS:T2D 2 0.26 -0.09 (-0.51, 0.32) -0.1 (-0.91, 0.72) -0.09 (-0.58, 0.39) 0 (-0.95, 0.95) -0.01 0.9927 
MetS:T2DC 0 0.00 -0.48 (-0.98, 0.03) . . -0.48 (-0.98, 0.03) . . . . 
T2D:T2DC 7 0.56 -0.38 (-0.73, -0.04) -0.22 (-0.68, 0.24) -0.59 (-1.11, -0.07) 0.37 (-0.33,  1.07) 1.05 0.2958 
k, number of studies providing direct evidence; prop, direct evidence proportion; nma, estimated treatment effect (md) in the network meta-
analysis; direct, estimated treatment effect (md) derived from direct evidence; indir., estimated treatment effect (md) derived from indirect 
evidence; diff, difference between direct and indirect treatment estimates; z, z-value of test for disagreement (direct versus indirect);  p-value, p-
value of test for disagreement (direct versus indirect); MetS, metabolic syndrome; IGT, impaired glucose tolerance; T2D, type 2 diabetes; T2DC, 
type 2 diabetes with complications. 
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Table 5-S10. Results of the node-splitting method assessing the evidence from direct and indirect comparisons, as well as the discrepancies 
between direct and indirect results, in microvascular endothelium-independent reactivity 
Comparison  k prop nma 95%-CI direct 95%-CI indir. 95%-CI Diff 95%-CI z p-value 
Healthy:Overweight 10 0.74 -0.50 (-0.80, -0.19) -0.31 (-0.66, 0.05) -1.02 (-1.61, -0.43) 0.72 (0.03, 1.41) 2.04 0.0411 
Healthy:Obese 1 0.06 -0.04 (-0.42, 0.34) -0.14 (-1.66, 1.38) -0.03 (-0.42, 0.36) -0.11 (-1.68, 1.46) -0.14 0.8919 
Healthy:IGT 7 0.95 -0.55 (-0.94, -0.16) -0.58 (-0.97, -0.18) -0.07 (-1.78, 1.63) -0.50 (-2.25, 1.25) -0.56 0.574 
Healthy:MetS 9 0.85 -0.48 (-0.84, -0.13) -0.57 (-0.96, -0.18) 0.00 (-0.91, 0.92) -0.57 (-1.57, 0.42) -1.13 0.2596 
Healthy:T2D 3 0.29 -0.87 (-1.32, -0.42) -1.11 (-1.95, -0.27) -0.78 (-1.31, -0.24) -0.33 (-1.33, 0.66) -0.65 0.5142 
Healthy:T2DC 0 0 -0.01 (-0.70, 0.68) . . -0.01 (-0.70, 0.68) . . . . 
Overweight:Obese 1 0.2 -0.01 (-0.43, 0.41) -1.33 (-2.27, -0.39) 0.31 (-0.15, 0.78) -1.64 (-2.69, -0.59) -3.07 0.0022 
Overweight: IGT 2 0.52 0.04 (-0.50, 0.58) -0.15 (-0.89, 0.60) 0.25 (-0.53, 1.03) -0.40 (-1.48, 0.68) -0.72 0.4717 
Overweight: MetS 1 0.25 0.05 (-0.42, 0.52) -0.00 (-0.95, 0.95) 0.07 (-0.47, 0.61) -0.07 (-1.16, 1.02) -0.13 0.8973 
Overweight:T2D 4 0.57 -0.84 (-1.26, -0.42) -1.02 (-1.57, -0.46) -0.60 (-1.24, 0.03) -0.41 (-1.26, 0.43) -0.96 0.3384 
Overweight:T2DC 5 0.7 -0.38 (-0.77, 0.01) -0.22 (-0.69, 0.24) -0.73 (-1.44, -0.03) 0.51 (-0.33, 1.36) 1.19 0.2351 
Obese:IGT 2 0.58 0.50 (-0.04, 1.05) 0.40 (-0.32, 1.11) 0.66 (-0.19, 1.50) -0.26 (-1.37, 0.85) -0.46 0.6452 
Obese:MetS 0 0 0.51 (-0.01, 1.04) . . . . 0.51 (-0.01, 1.04) . . 
Obese:T2D 0 0 -0.39 (-0.93, 0.15) . . . . -0.39 (-0.93, 0.15) . . 
Obese:T2DC 11 0.81 -0.46 (-0.74, -0.18) -0.45 (-0.76, -0.13) -0.51 (-1.15, 0.14) 0.06 (-0.66, 0.78) 0.16 0.8704 
IGT:MetS 0 0 0.06 (-0.59, 0.71) . . . . 0.06 (-0.59, 0.71) . . 
IGT:T2D 0 0 -0.33 (-0.97, 0.31) . . . . -0.33 (-0.97, 0.31) . . 
IGT:T2DC 0 0 0.07 (-0.45, 0.59) . . . . 0.07 (-0.45, 0.59) . . 
MetS:T2D 0 0 -0.32 (-0.90, 0.26) . . . . -0.32 (-0.90, 0.26) . . 
MetS:T2DC 2 0.32 0.45 (-0.01, 0.90) 0.51 (-0.30, 1.32) 0.42 (-0.13, 0.97) 0.09 (-0.89, 1.07) 0.18 0.8586 
T2D:T2DC 1 0.22 -0.54 (-1.12, 0.04) -0.79 (-2.03, 0.45) -0.47 (-1.13, 0.19) -0.32 (-1.73, 1.09) -0.45 0.6558 
k, number of studies providing direct evidence; prop, direct evidence proportion; nma, estimated treatment effect (md) in the network meta-
analysis; direct, estimated treatment effect (md) derived from direct evidence; indir., estimated treatment effect (md) derived from indirect 
evidence; diff, difference between direct and indirect treatment estimates; z, z-value of test for disagreement (direct versus indirect);  p-value, p-
value of test for disagreement (direct versus indirect); MetS, metabolic syndrome; IGT, impaired glucose tolerance; T2D, type 2 diabetes; T2DC, 
type 2 diabetes with complications. 
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Table 5-S11. Results of the meta-regressions for each potential effect modifier of flow-
mediated dilation 
Covariate Available data (% of the total) Mean 
95% Credibility 
Interval 
Age 122 (92%) -0.47 (-1.54; 0.58) 
Resting brachial artery diameter  64 (48%) -0.48 (-2.42; 1.34) 
Body mass index 117 (89%) 0.80 (-0.47; 2.15) 
Systolic blood pressure  102 (77%) -0.24 (-1.32; 0.87) 
Diastolic blood pressure  100 (76%) 0.74 (-0.40; 1.88) 
Total cholesterol 105 (80%) 0.13 (-1.37; 1.60) 
High-density lipoproteins 101 (77%) -0.02 (-1.16; 1.13) 
Low-density lipoproteins 88 (67%) 0.31 (-0.99; 1.63) 
Triglycerides 99 (75%) -0.25 (-1.49; 0.98) 
Fasting glucose 100 (76%) -1.76 (-3.18; -0.35) 
HbA1c  69 (52%) -0.66 (-2.65; 1.18) 
Significant results are in bold font. 
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Chapter 6 – Study four: Assessing cutaneous microvascular 
function with iontophoresis: Avoiding non-specific 
vasodilation 
 
Publication statement: 
This chapter is comprised of a manuscript that is published in Microvascular Research. 
 
Loader J, Roustit M, Taylor F, MacIsaac RJ, Stewart S, Lorenzen C, Walther G. 
Assessing cutaneous microvascular function with iontophoresis: Avoiding non-specific 
vasodilation. Microvascular Research. 2017:113:29-39. Doi: 
10.1016/j.mvr.2017.04.006. 
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6.1 Linking paragraph 
 
As outlined in the literature review, chapter 2.2.2, of this thesis, there is an array of 
techniques available for researchers to assess microvascular reactivity. One of the most 
commonly used techniques to assess microvascular reactivity in the research included 
in studies one and three was iontophoresis of a vasoactive agent; a methodology that, 
within itself, presents a range of varying protocols for researchers to choose from, with 
no standardization of the methods or data expression. In addition to lack of 
standardization amongst the variety of techniques used to assess microvascular 
reactivity, the considerable heterogeneity observed in the microvascular data from 
studies one and three may have also been influenced by non-specific vasodilatory 
effects that can be induced by the iontophoresis technique. Indeed, there is no consensus 
as to which protocols of iontophoresis are free of non-specific vasodilatory effects. 
Considering this, study four aimed to examine the reliability of several published 
protocols of acetylcholine, sodium nitroprusside and insulin iontophoresis, including 
those developed by our research team and utilized in study two, by evaluating each for 
evidence of non-specific vasodilatory effects. Acetylcholine and sodium nitroprusside 
are the most commonly utilized vasoactive agents in the literature, while interest in 
insulin iontophoresis is growing due to its status in those with impaired glucose 
tolerance and T2D. Overall, this study also aimed to provide updated recommendations 
for the collection and treatment of microvascular data acquired with iontophoresis. 
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6.2 Abstract 
 
Aim  
Iontophoresis of vasoactive agents is commonly used to assess cutaneous 
microvascular reactivity. However, it is known that iontophoresis can be limited by 
confounding non-specific vasodilatory effects. Despite this, there is still no 
standardization of protocols or data expression. Therefore, this study evaluated 
commonly used protocols of iontophoresis by assessing each for evidence of non-
specific vasodilatory effects and examined the reproducibility of those protocols that 
are free of non-specific responses.  
 
Approach and results 
Twelve healthy participants were administered doses of acetylcholine 1-2 % and 
sodium nitroprusside 1 %, diluted in sodium chloride 0.9 % or deionized water, and 
insulin 100 U/mL in a sterile diluent using iontophoresis coupled with LSCI. Increases 
in blood flux at a control electrode, containing the diluent only, indicated a non-specific 
response. Reproducibility of iontophoresis protocols that were free of non-specific 
vasodilatory effects were subsequently compared to that of PORH, used as a standard, 
in 20 healthy participants. Iontophoresis of acetylcholine or sodium nitroprusside in 
sodium chloride (0.02 mA for 200 and 400 s, respectively) and acetylcholine in 
deionized water (0.1 mA for 30 s) mediated the least non-specific vasodilatory effects. 
Microvascular responses to insulin were mediated mainly by non-specific effects. 
Compared to PORH, the intraday and interday reproducibility for iontophoresis of 
acetylcholine and sodium nitroprusside (0.02 mA for 200 and 400 s, respectively) with 
LSCI was weaker, but still deemed good to excellent when data was expressed, in PU 
or CVC, as the absolute peak blood flux response to the vascular reactivity test or as 
the change in blood flux between peak and baseline values. 
 
Conclusion 
This study provides updated recommendations for assessing cutaneous microvascular 
reactivity with iontophoresis.  
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6.3 Introduction 
 
Cardiovascular disease remains the single leading cause of death representing an 
estimated 31 % of the global mortality rate.209 In recent decades it has become widely 
accepted that vascular dysfunction is a primary mechanism in the pathogenesis of CVD, 
occurring long before atherosclerotic remodelling of the vascular network or even the 
onset of obesity, MetS or diabetes.214 Indeed, vascular dysfunction may also contribute 
to the initial development and adverse progression of obesity and such cardiometabolic 
diseases.17 Interestingly, emerging evidence suggests that coronary microvascular 
disease may explain the occurrence of myocardial ischemia, heart failure and CVD 
mortality following myocardial infarction without apparent coronary macrovascular 
disease;233 highlighting the microcirculation, which represents most of the arterial 
vascular network and exerts dominant control over local blood flow to the nutritive 
network, as an important concentration in the study of vascular function. Increased 
focus in the field of microvascular research warrants the need to comprehensively 
evaluate the reliability of existing methods that are used to assess microvascular 
function in order to further determine their potential clinical and prognostic 
applications. 
 
Microvascular function is often assessed at the cutaneous microcirculation due, mostly, 
to its accessibility and its potential role as a surrogate marker of systemic microvascular 
function;443 using common tests of vascular reactivity that include iontophoresis and 
PORH coupled with laser-based technologies, such as LSCI, LDF and LDI.38 
Iontophoresis involves the delivery of a vasoactive agent to the cutaneous 
microcirculation using a low-intensity electrical current and, in microvascular research, 
is typically used to administer acetylcholine or insulin to assess endothelium-dependent 
microvascular reactivity, or sodium nitroprusside that examines endothelium-
independent microvascular reactivity.444 However, it is known that iontophoresis may 
induce non-specific vasodilatory effects that are influenced by variations in the type of 
diluent used for each vasoactive agent, administration of a higher intensity current or a 
higher total iontophoretic current density; or by the method of electrical current delivery 
(e.g. continuous or multiple pulses).220 Ultimately, non-specific vasodilatory effects 
confound the microvascular response to the vasoactive agent being studied, limiting the 
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technique and the overall interpretation of the microcirculatory data, as well as any 
subsequent conclusions. Despite this, there are still no standardized protocols for 
iontophoresis; and, consequently, there is an array of methods for iontophoresis being 
utilized in the literature with no consensus as to which are free of non-specific 
vasodilatory effects. 
 
Therefore, the primary objective of this present study was to examine the reliability of 
several published protocols for iontophoresis of acetylcholine, sodium nitroprusside 
and insulin by evaluating each for evidence of non-specific vasodilatory effects. The 
second objective of this study was to compare the reproducibility of those protocols 
that were found to be free of non-specific vasodilatory effects to the excellent 
reproducibility of PORH,66 as observed when performed in conjunction with LSCI.   
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6.4 Methods 
 
This study was comprised of two separate protocols. As explained in detail below, 
Protocol A evaluated the reliability of several published protocols of iontophoresis by 
testing each method for evidence of non-specific vasodilatory effects. Protocol B was 
then conducted to compare the intraday and interday (morning and afternoon) 
reproducibility of iontophoresis protocols that were found to be free of non-specific 
vasodilatory effects in Protocol A to the excellent reproducibility of PORH,66 when 
performed in conjunction with LSCI.  
 
6.4.1 Participants and screening 
Healthy male and female students were recruited through email and poster 
advertisements to participate in one of, or both Protocol A and Protocol B (Table 6-1). 
Participants were excluded if they had any history of CVD, cigarette smoking, or 
current use of any vasoactive medications. The Human Research Ethics Committee at 
the Australian Catholic University approved this study and written informed consent 
was obtained from all participants prior to commencing each protocol.  
 
Table 6-1. Basal characteristics of each separate study population as measured at trial 
one of each Protocol A and Protocol B 
 Protocol A Protocol B 
n  12  20 
Gender (Male/Female) 6/6 10/10 
Age (years) 25.9 ± 3.4 22.9 ± 3.2 
BMI (kg/m2) 23.4 ± 2.4 23.7 ± 3.0 
Fasting blood glucose 
(mmol/L) 
5.2 ± 0.5 4.9 ± 0.4 
Heart rate (beats.min-1) 59.8 ± 10.4 63.4 ± 11.2 
Blood pressure (mmHg)   
SBP 109.9 ± 8.8 113.9 ± 11.5 
DBP 64.1 ± 6.1 67.7 ± 7.3 
MAP  79.4 ± 5.6 83.1 ± 7.7 
Values are mean ± SD. n, sample size; BMI, body mass index; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure.  
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6.4.2 Study design 
All clinical and vascular measurements were performed in a temperature controlled 
(23.1 ± 1.7°C) room and all five testing sessions included in Protocol A were conducted 
separately to the four testing sessions that comprised Protocol B. From the 12 
participants who completed Protocol A, a total of four participants also participated in 
Protocol B. To standardize the responses to the tests of cutaneous microvascular 
reactivity, participants were instructed to abstain from strenuous exercise for 48 hours, 
alcohol consumption for 24 hours, and caffeine consumption for 12 hours preceding 
each testing session; and to maintain their current level of physical activity throughout 
each protocol. Additionally, participants were instructed to present to each testing 
session in Protocol A following overnight fasting in order to minimize postprandial 
hyperglycemia-mediated variations in vascular reactivity. However, given that testing 
sessions in Protocol B were conducted in the morning and afternoon, participants were 
instructed to present only four hours fasted. Clinical measurements assessing each 
participant’s height and mass were performed at the beginning of the first testing 
session for both Protocol A and B, while fasting blood glucose, blood pressure, resting 
heart rate, and skin temperature measurements were conducted at all testing sessions 
following 20 minutes of acclimatization in a supine position; immediately prior to the 
beginning of cutaneous microvascular measurements.  
 
6.4.2.1 Protocol A – Examining published protocols of iontophoresis for evidence of 
non-specific vasodilatory effects 
Ten experiments, each assessing a unique published protocol of iontophoresis, were 
conducted over five testing sessions that were separated by no less than 48 hours; with 
two separate experiments being performed at each testing session. Cutaneous 
microvascular reactivity was first assessed on the participant’s right arm (experiment 
one) before the LSCI and iontophoresis equipment was immediately moved and aligned 
with the participant’s left arm. Cutaneous microvascular reactivity and another unique 
protocol of iontophoresis was then assessed on the participant’s left arm (experiment 
two). Participants remained rested in a supine position throughout microvascular 
assessment and the repositioning of the equipment from right to left arm alignment. 
This sequence of testing was repeated at the next four testing sessions, in which, the 
remaining eight unique protocols of iontophoresis were assessed. 
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6.4.2.2 Protocol B – The intraday and interday reproducibility of iontophoresis and 
PORH coupled with LSCI 
To assess the variability between LSCI measurements when performed in conjunction 
with iontophoresis and PORH, each participant’s cutaneous microvascular reactivity 
was assessed during testing session one and testing session two in the morning and 
afternoon, respectively, of day zero. This sequence of testing was then repeated seven 
days later with testing sessions three (morning) and four (afternoon) allowing for 
evaluation of intraday reproducibility on day zero and interday reproducibility 
(morning and afternoon) between day zero and seven measurements. Morning and 
afternoon testing sessions were seperated by five hours. The sequence of clinical and 
vascular measurements remained the same for each testing session. 
 
6.4.3 Clinical measurements 
Height and mass were measured using a stadiometer and calibrated scale, respectively. 
Body mass index was calculated as mass (kg) divided by height² (m). Fasting blood 
glucose concentrations were assessed with a handheld blood glucose monitoring system 
(Freestyle Optium, Abbott Diabetes Care Ltd, UK). Systolic and diastolic blood 
pressure, heart rate, and skin temperature were measured using a digital 
sphygmomanometer (Dinamap, GE Medical Systems, Milwaukee, USA). Blood 
pressure variables were expressed as mean arterial pressure (mmHg) calculated by [(2 
X diastolic blood pressure) + systolic blood pressure]/3.  
 
6.4.4 Cutaneous microvascular assessment  
Changes in cutaneous microvascular blood flux, in response to iontophoresis and 
PORH, were quantified by LSCI using a 70mW system (PeriCam PSI System®, 
Perimed, Järfälla, Sweden) with a laser wavelength of 785 nm. The laser head working 
distance, laser measurement area and image acquisition rate were set at 15 cm, 100 cm2 
(10 cm X 10 cm), and 10 images/s, respectively. Briefly, the LSCI head unit emits and 
detects light in the tissue that is partially backscattered by moving blood cells, causing 
a change in frequency from which variations in microvascular blood flux are 
calculated.219 Laser speckle measurements were recorded continuously at a frequency 
of 18 Hz using an interfaced computer with data acquisition software (PimSoft 1.2.2.0®, 
Perimed, Järfälla, Sweden). In preparation for each iontophoresis experiment, two 
adhesive drug delivery electrodes (LI 611, Perimed, Järfälla, Sweden) with 
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administration areas of 1.54 cm2 were installed approximately 5 cm apart on the ventral 
surface of the forearm, avoiding any hair, broken skin, areas of increased skin 
pigmentation and visible veins. Dispersive electrodes (PF 384, Perimed, Järfälla, 
Sweden) were then positioned at the elbow and wrist approximately 10 cm from each 
drug delivery electrode to complete the electrical current circuit. Basal cutaneous 
microvascular blood flow was measured with LSCI for two minutes before 
iontophoresis was performed using PF 751 PeriIont systems (Perimed, Järfälla, 
Sweden). Changes in blood flow were then recorded for 18-22 minutes from the 
beginning of iontophoresis. Electrical cutaneous resistance was also recorded by the 
PeriIont systems simultaneously to delivery of the electrical current.  
 
6.4.4.1 Protocol A – Protocol for detecting non-specific vasodilatory effects in response 
to iontophoresis 
Ten unique published protocols of iontophoresis that administer doses of acetylcholine, 
sodium nitroprusside, or insulin were assessed for evidence of non-specific 
vasodilatory effects across 10 separate experiments (Table 6-2). For each experiment, 
the vasoactive agent dissolved in its specified diluent was pipetted into the proximal 
electrode; while to detect evidence of non-specific vasodilatory effects, the diluent only 
was injected into the distal (control) electrode. The iontophoresis protocol being 
assessed was administered simultaneously to the proximal and distal electrodes. Anodal 
and cathodal currents were used to administer acetylcholine (Sigma-Aldrich, Australia) 
and sodium nitroprusside (Sigma-Aldrich, Australia), respectively.  Additionally, a 
cathodal current was used to administer insulin (Humulin R® - 100 U/mL, Lilly, 
Australia) and its control, a sterile insulin-specific diluent (Sterile Diluent for Humulin 
R®, Lilly, Australia). The sterile diluent had the same composition as insulin Humulin 
R®, but did not contain insulin molecules. Increases in cutaneous microvascular blood 
flux from baseline values in the control electrode during and following iontophoresis 
indicated that the protocol induced non-specific vasodilatory effects.   
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Table 6-2.  The 10 experiments conducted that assessed published protocols of iontophoresis for evidence of non-specific vasodilatory effects 
Vasoactive agent 
(concentration) 
Diluent 
(concentration) 
Iontophoretic electrical 
current strength and duration 
Current density 
(mA/cm2) 
Total iontophoretic 
charge density 
(mC/cm2) 
Vasoactive 
agent 
(concentration) REF 
ACh (2 %*) NaCl (0.9 % **) 0.02 mA for 200 s 0.01 2.60 ACh (2 %*) 256 
ACh (1 %***) Deionized H2O 7 pulses of 0.1 mA for 20 s each; 
60 s intervals 
0.06 9.09 ACh (1 %***) 229 
ACh (2 %) Deionized H2O 0.1 mA for 30 s 0.06 1.95 ACh (2 %) 445 
ACh (2 %) Deionized H2O Pulses of 0.03, 0.06, 0.09, 0.12, 
0.15, and 0.18 mA for 10 s each; 
60 s intervals 
0.02, 0.04, 0.06, 
0.08, 0.10, and 0.12 
4.09 ACh (2 %) 446 
SNP (1 %**) NaCl (0.9 %) 0.02 mA for 400 s 0.01 5.19 SNP (1 %**) 256 
SNP (1 %) Deionized H2O 9 pulses of 0.2 mA for 20 s each; 
90 s intervals 
0.13 23.38 SNP (1 %) 229 
SNP (1 %) Deionized H2O 0.1 mA for 30 s 0.06 1.95 SNP (1 %) 445§ 
SNP (1 %) Deionized H2O Pulses of 0.03, 0.06, 0.09, 0.12, 
0.15, and 0.18 mA for 10 s each; 
60 s intervals 
0.02, 0.04, 0.06, 
0.08, 0.10, and 0.12 
4.09 SNP (1 %) 446§ 
INS (100 U/mL) Sterile diluent† 
 
12 pulses of 0.2 mA for 20 s 
each; 90 s intervals 
0.13 31.17 INS (100 U/mL) 447 
INS (100 U/mL) Sterile diluent 6 pulses of 0.1 mA for 20 s each; 
40 s intervals 
0.06 7.79 INS (100 U/mL) 448 
ACh, acetylcholine; H2O, water; INS, insulin (Humulin R®); NaCl, sodium chloride; REF, reference; SNP, sodium nitroprusside. *2 % = 0.02 
g/mL. **0.9 % = 0.009 g/mL.  ***1 % = 0.01 g/mL. †The sterile diluent had the same composition as insulin Humulin R®, but did not contain 
insulin molecules. §The protocol was originally used in the cited publication for acetylcholine iontophoresis only, but it was also tested for 
iontophoresis of sodium nitroprusside in this present study. 
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6.4.4.2 Protocol B – Iontophoresis and PORH protocols for reproducibility assessment 
The reproducibility of iontophoresis coupled with LSCI was conducted for protocols 
that did not present any non-specific vasodilatory effects in Protocol A. The methods 
for performing iontophoresis remained unchanged between Protocol A and Protocol B. 
Post-occlusive reactive hyperemia was performed immediately following the 
conclusion of iontophoresis. In brief, a sphygmomanometer cuff was positioned around 
the upper arm, ipsilateral to iontophoresis measurements, 2-3 cm proximal to the 
antecubital fossa. Following two minutes of basal measurements, the cuff was inflated 
to 50 mmHg above resting systolic blood pressure, occluding the forearm circulation 
for three minutes. The cuff was then rapidly deflated inducing PORH that was recorded 
for a further five minutes.66 Cutaneous microvascular blood flow was measured with 
LSCI throughout the baseline, occlusion, and PORH periods.  
 
6.4.5 Data analyses 
The PimSoft data acquisition software was used to set regions of interest at 30 mm2 for 
both iontophoresis and PORH. These regions of interest were adjusted retrospectively 
to find the area of maximal blood flux in response to iontophoresis. All data were 
exported to Microsoft Excel and coded by a researcher (CL) not involved in data 
collection or analyses in order to blind the investigator. Cutaneous microvascular blood 
flux values were averaged for the 30 seconds immediately prior to the beginning of 
iontophoresis or occlusion in PORH for baseline and for the five seconds at every two-
minute interval following the beginning of iontophoresis in Protocol A; and for the five 
seconds at the maximal plateau in response to iontophoresis or during peak PORH in 
Protocol B. The vascular response to iontophoresis was expressed as the absolute blood 
flux in PU at each two-minute interval from the beginning of iontophoresis in Protocol 
A. In Protocol B, the vascular response to iontophoresis and PORH was expressed as 
the absolute peak blood flux response, the change in blood flux between peak and 
baseline values, the percentage increase from baseline to peak values and the area under 
the curve. Absolute data were expressed as PU or CVC, which is the blood flux in PU 
divided by the mean arterial pressure (mmHg), to account for variations in blood 
pressure between testing sessions in Protocol B.38  
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6.4.6 Statistical analyses 
Protocols of iontophoresis were analysed for non-specific vasodilatory effects using the 
two-way ANOVA for repeated measures, which assessed the similarity of the 
microvascular response to iontophoresis between each the electrode containing the 
vasoactive agent and the control electrode; and by using the one-way ANOVA for 
repeated measures with Sidak post-hoc analyses, which detected increases in blood flux 
from baseline measurements at each electrode.220 The intraday and interday 
reproducibility of iontophoresis or PORH with LSCI were assessed using the within-
subjects coefficients of variation with <35 % deemed acceptable; and the intra-class 
correlation of coefficients, ranging from 0 to 1 with values of <0.40, 0.40 to 0.75 and 
>0.75 representing poor, fair to good and excellent agreements, respectively.66,68 
Quantitative data were reported as mean ± standard deviation, unless stated otherwise. 
Statistical comparisons were performed using SPSS (version 23; IBM Corp., Armonk, 
NY, USA) and Microsoft Excel. A P-value of <0.05 was considered statistically 
significant. 
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6.5 Results 
 
6.5.1 Non-specific vasodilatory effects in published protocols of iontophoresis 
 
6.5.1.1 Acetylcholine 
In each acetylcholine protocol, there was a rapid significant increase in cutaneous 
microvascular blood flux from baseline values within two minutes from beginning the 
administration of the anodal electrical current (Figure 6-1). When each protocol was 
performed at the control electrode containing the diluent only (i.e. sodium chloride 0.9 
% or deionized water), the change in blood flux was not similar to the response to 
iontophoresis at the electrode containing both the vasoactive agent and diluent. 
However, in a protocol that administered a total iontophoretic charge density of 9.09 
mC/cm2 (Figure 6-1B), the peak blood flux response to iontophoresis at the control 
electrode, containing deionized water, was nearly significantly greater than baseline 
values (44.45 ± 19.38 vs. 17.81 ± 3.21 PU, P=0.057). The peak response to 
iontophoresis of acetylcholine occurred later (between 8-10 minutes) in each protocol 
that administered the electrical current using multiple pulses (Figures 6-1B and 6-1D), 
compared to a faster peak response (between 2-4 minutes) in those that used a 
continuous method. Interestingly, the rate of return for blood flux towards basal 
conditions was also slower in the protocols that used multiple pulses to deliver the 
electrical current. Indeed, protocols using continuous delivery of 0.02 mA for 200 s and 
of 0.1 mA for 30 s, delivering total iontophoretic charge densities of 2.60 mC/cm2 and 
1.95 mC/cm2, respectively, induced minimal non-specific vasodilatory effects as 
demonstrated by only a slight peak increase in blood flux from baseline values (6.82 ± 
3.81 ΔPU and 2.98 ± 2.92 ΔPU, respectively) at the control electrode (Figure 6-1A and 
6-1C).  
 
6.5.1.2 Sodium nitroprusside 
The cutaneous microvascular blood flux responses to iontophoresis of sodium 
nitroprusside and of the diluent alone were different for all protocols (Figure 6-2). 
However, in addition to mediating a significant increase in blood flux following 
iontophoresis of sodium nitroprusside, three protocols that used deionized water as a 
diluent, detailed in Figures 6-2B, 6-2C and 6-2D, also induced a significant increase in 
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blood flux at the control electrode within six to eight minutes from the beginning of 
administering the cathodal electrical currents; when a total iontophoretic charge density 
of 10.39 mC/cm2, 1.95 mC/cm2 and 4.09 mC/cm2, respectively, had been delivered in 
conjunction with current densities >0.013 mA/cm2. Indeed, in each of these protocols 
the peak blood flux response was greater than baseline values at the control electrode 
(79.13 ± 27.70 vs. 23.64 ± 3.75 PU; 62.77 ± 25.66 vs. 23.20 ± 3.84 PU; and 83.34 ± 
22.76 vs. 26.60 ± 4.42 PU, respectively, P<0.01). Iontophoresis of sodium nitroprusside 
in sodium chloride 0.9 %, using a low cathodal electrical current charge (0.02 mA) for 
a period of 400 s, induced a peak blood flux response greater than baseline values (92.28 
± 21.25 vs. 30.65 ± 4.34 PU, P<0.01), but did not mediate any significant non-specific 
vasodilatory effects when delivered to the control electrode. Of note, this maximal 
blood flux plateau occurred ~16 minutes after the beginning of iontophoresis. 
 
6.5.1.3 Insulin 
In contrast to the acetylcholine and sodium nitroprusside protocols, the cutaneous 
microvascular blood flux responses to iontophoresis of insulin in the insulin specific 
diluent and at the control electrode were similar for each protocol (Figure 6-3). Indeed, 
there were simultaneous increases in blood flux at both the electrode containing insulin 
and the control electrode for each protocol. Each significant increase in blood flux 
occurred after delivering a total charge density of 10.39 mC/cm2 in the first protocol 
(Figure 6-3A) and 5.19 mC/cm2 in the second protocol (Figure 6-3B).  
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Figure 6-1. Changes in cutaneous microvascular blood flux in response to 
iontophoresis of the vasoactive substance, acetylcholine (ACh), in its diluent, sodium 
chloride (NaCl) or deionized water; and in response to iontophoresis of the diluent 
alone (control). Significant increases in cutaneous microvascular blood flux from 
baseline measurements (0 minutes) in response to iontophoresis of the diluent alone 
indicates that the protocol induces non-specific vasodilatory effects. Data are expressed 
as mean ± SEM. PU, perfusion units. *P<0.01 ACh vs. control; †P<0.05 first significant 
increase from baseline; **P<0.01 vs. baseline.   
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Figure 1. Changes in cutaneous microvascular blood flux in response to iontophoresis of the vasoactive substance, acetylcholine (ACh), in its diluent, 
sodium chloride (NaCl) or deionized water; and in response to iontophoresis of the diluent alone (control). Significant increases in cutaneous 
microvascular blood flux from baseline measurements (0 minutes) in response to iontophoresis of the diluent alone indicates that the protocol induces 
non-specific vasodilatory effects. Data are expressed as mean ± SEM. PU, perfusion units. *P<0.01 ACh vs. control; †P<0.05 first significant increase 
from baseline; **P<0.01 vs. baseline.   
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Figure 6-2. Changes in cutaneous microvascular blood flux in response to 
iontophoresis of the vasoactive substance, sodium nitroprusside (SNP), in its diluent, 
sodium chloride (NaCl) or deionized water; and in response to iontophoresis of the 
diluent alone (control). Significant increases in cutaneous microvascular blood flux 
from baseline measurements (0 minutes) in response to iontophoresis of the diluent 
alone indicates that the protocol induces non-specific vasodilatory effects. Data are 
expressed as mean ± SEM. PU, perfusion units. *P<0.01 SNP vs. control; †P<0.05 first 
significant increase from baseline; **P<0.01 vs. baseline.   
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Figure 2. Changes in cutaneous microvascular blood flux in response to iontophoresis of the vasoactive substance, sodium nitroprusside (SNP), in its 
diluent, sodium chloride (NaCl) or deionized water; and in response to iontophoresis of the diluent alone (control). Significant increases in cutaneous 
microvascular blood flux from baseline measurements (0 minutes) in response to iontophoresis of the diluent alone indicates that the protocol induces non-
specific vasodilatory effects. Data are expressed as mean ± SEM. PU, perfusion units. *P<0.01 SNP vs. control; †P<0.05 first significant increase from 
baseline; **P<0.01 vs. baseline.   
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Figure 6-3. Changes in cutaneous microvascular blood flux in response to 
iontophoresis of the vasoactive substance, insulin, in insulin diluent; and in response to 
iontophoresis of the insulin diluent alone (control). Significant increases in cutaneous 
microvascular blood flux from baseline measurements (0 minutes) in response to 
iontophoresis of the insulin diluent alone indicates that the protocol induces non-
specific vasodilatory effects. Data are expressed as mean ± SEM. PU, perfusion units. 
*P<0.01 insulin vs. insulin diluent; †P<0.05 first significant increase from baseline; 
**P<0.02 vs. baseline.   
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Figure 3. Changes in cutaneous microvascular blood flux in response to iontophoresis of the vasoactive substance, insulin, in insulin diluent; and in 
response to iontophoresis of the insulin diluent alone (control). Significant increases in cutaneous microvascular blood flux from baseline measurements 
(0 minutes) in re p nse to iontoph resis of the insulin diluent alo e ind cates that the protocol induces non-specific va odilatory effects. Data are 
expressed as mean ± SEM. PU, perfusion units. *P<0.01 insulin vs. insulin diluent; †P<0.05 first significant increase from baseline; **P<0.02 vs. baseline.   
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6.5.2 The intraday and interday reproducibility of iontophoresis and PORH with 
LSCI 
Considering that previous research has investigated some aspects of LSCI 
reproducibility when measuring the cutaneous microvascular response to a single pulse 
of acetylcholine 2 % iontophoresis that delivers an electrical current of 0.1 mA for 30 
s,68,445,449 this present study evaluated the reproducibility of continuous delivery of 0.02 
mA for 200 s coupled with LSCI that, when assessed in Protocol A of this present study, 
induced similar blood flux responses with no significant non-specific vasodilatory 
effects. Indeed, protocols that used multiple pulses to deliver the electrical current in 
acetylcholine iontophoresis induced a vascular response that may be more influenced 
by non-specific vasodilatory effects than that in protocols that used a continuous 
method as indicated by a delayed peak and a slower rate of return for blood flux towards 
basal conditions. Additionally, given that it was the only sodium nitroprusside protocol 
that was free of significant non-specific vasodilatory effects in Protocol A, Protocol B 
used continuous delivery of 0.02 mA for 400s when assessing the reproducibility of 
sodium nitroprusside iontophoresis with LSCI. Given that each insulin protocol was 
found to induce significant non-specific vasodilatory effects in Protocol A, the 
reproducibility of insulin iontophoresis with LSCI was not evaluated in this present 
study.  
 
The intraday and interday (morning and afternoon) reproducibility of LSCI with PORH 
was excellent when data was expressed, in PU or CVC, as the absolute peak blood flux 
response during reactive hyperemia and as the change in blood flux between peak and 
baseline values (Tables 6-3 and 6-4). The intraday and interday (morning measurements 
only) reproducibility of acetylcholine and sodium nitroprusside iontophoresis were also 
good to excellent when evaluating the same outcome measures. However, there was 
greater variation between trials of iontophoresis than that between assessments of 
PORH. In contrast, the interday reproducibility of iontophoresis was only poor to fair 
when performed in the afternoon; acknowledging that there was no difference in 
electrical cutaneous resistance, measured during iontophoresis of acetylcholine and 
sodium nitroprusside, between any of the trials. Finally, LSCI data was most 
reproducible when expressed as the absolute peak blood flux response, in either PU or 
CVC, for all reactivity tests. Indeed, the reproducibility of LSCI data was poor or 
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deemed not acceptable when data was expressed as the percentage increase from 
baseline measurements or area under the curve. 
 
 
Table 6-3. The intraday reproducibility of acetylcholine and sodium nitroprusside 
iontophoresis and PORH when assessed with LSCI on the forearm 
 AM PM CV (%) ICC 
ACh Peak (PU) 67.59 ± 15.44 66.99 ± 15.25 17.37 0.73 [0.30 - 0.89] 
ACh Peak (CVC) 0.82 ± 0.18 0.84 ± 0.20 18.51 0.65 [0.10 - 0.86] 
ACh Δ (PU) 47.12 ± 15.23 45.12 ± 14.27 23.73 0.80 [0.48 - 0.92] 
ACh Δ (CVC)  0.57 ± 0.18 0.56 ± 0.19 25.05 0.75 [0.34 - 0.90] 
ACh %Δ 241.46 ± 90.00 229.15 ± 132.00 34.37 0.60 [-0.04 - 0.84] 
ACh AUC 467.89 ± 240.57 404.62 ± 205.07 63.32 0.57 [-0.48 - 0.88] 
SNP Peak (PU) 86.40 ± 16.73 93.71 ± 21.16 14.65 0.73 [0.34 - 0.89] 
SNP Peak (CVC) 1.05 ± 0.23 1.18 ± 0.30 15.14 0.74 [0.32 - 0.90] 
SNP Δ (PU) 63.24 ± 15.48 69.00 ± 21.94 19.23 0.76 [0.42 - 0.91] 
SNP Δ (CVC) 0.77 ± 0.22 0.87 ± 0.29 20.61 0.74 [0.37 - 0.90] 
SNP %Δ 292.84 ± 124.09 295.82 ± 134.61 35.81 0.41 [-0.56 - 0.77] 
SNP AUC 809.23 ± 226.34 801.18 ± 327.91 28.31 0.83 [0.55 - 0.94] 
PORH Peak (PU) 87.71 ± 12.77 86.79 ± 11.13 8.24 0.77 [0.42 - 0.91] 
PORH Peak (CVC)  1.06 ± 0.14 1.08 ± 0.14 8.95 0.76 [0.39 - 0.90] 
PORH Δ (PU) 55.08 ± 9.84 55.00 ± 8.72 13.02 0.67 [0.16 - 0.87] 
PORH Δ (CVC) 0.66 ± 0.11 0.69 ± 0.12 12.78 0.71 [0.28 - 0.88] 
PORH %Δ 171.14 ± 31.92 175.74 ± 32.85 30.02 0.25 [-0.97 – 0.71] 
PORH AUC 134.37 ± 30.13 139.99 ± 35.99 17.26 0.66 [0.15 - 0.87] 
Data are presented as the mean ± standard deviation and reported as the peak blood flux 
and the change (Δ) in blood flux between peak and baseline values, expressed in 
perfusion units (PU) and cutaneous vascular conductance (CVC); as well as the 
percentage change (%Δ) from baseline measurements and the area under the curve 
(AUC). Coefficients of variation (CV) of <35 % were deemed acceptable and intra-
class correlation coefficient (ICC) values of <0.40, 0.40 to 0.75 and >0.75 represented 
poor, fair to good and excellent agreements, respectively. ACh, acetylcholine; PORH, 
post-occlusive reactive hyperemia; SNP, sodium nitroprusside. 
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Table 6-4. The interday reproducibility of acetylcholine and sodium nitroprusside iontophoresis and PORH when assessed with LSCI on the 
forearm in the morning and afternoon of day zero and day seven 
 Day 0 - AM Day 7 - AM CV (%) ICC Day 0 - PM Day 7 - PM CV (%) ICC 
ACh Peak (PU) 67.59 ± 15.44 70.04 ± 18.31 21.21 0.55 [-0.16 - 0.82] 66.99 ± 15.25 61.76 ± 16.51 25.72 0.27 [-0.81 - 0.71] 
ACh Peak (CVC) 0.82 ± 0.18 0.86 ± 0.25 21.75 0.59 [-0.03 - 0.84] 0.84 ± 0.20 0.78 ± 0.20 25.43 0.31 [-0.72 - 0.72] 
ACh Δ (PU) 47.12 ± 15.23 47.77 ± 17.09 28.24 0.63 [0.03 - 0.86] 45.12 ± 14.27 41.73 ± 14.71 36.14 0.31 [-0.77 - 0.73] 
ACh Δ (CVC)  0.57 ± 0.18 0.59 ± 0.23 28.30 0.66 [0.13 - 0.87] 0.56 ± 0.19 0.52 ± 0.18 36.26 0.35 [-0.66 - 0.74] 
ACh %Δ 241.46 ± 90.00 219.05 ± 78.82 31.61 0.58 [-0.05 - 0.83] 229.15 ± 132.00 215.78 ± 83.53 37.14 0.64 [0.07 - 0.86] 
ACh AUC 467.89 ± 240.57 462.80 ± 182.11 40.79 0.66 [-0.27 - 0.91] 404.62 ± 205.07 371.08 ± 182.18 66.66 0.07 [-2.87 - 0.75] 
SNP Peak (PU) 86.40 ± 16.73 91.90 ± 22.88 13.75 0.79 [0.49 - 0.92] 93.71 ± 21.16 91.12 ± 16.99 18.25 0.54 [-0.18 - 0.82] 
SNP Peak (CVC) 1.05 ± 0.23 1.13 ± 0.28 14.39 0.80 [0.49 - 0.92] 1.18 ± 0.30 1.15 ± 0.22 21.14 0.39 [-0.60 - 0.76] 
SNP Δ (PU) 63.24 ± 15.48 67.15 ± 22.12 19.55 0.77 [0.42 - 0.91] 69.00 ± 21.94 67.02 ± 15.69 25.23 0.55 [-0.16 - 0.83] 
SNP Δ (CVC) 0.77 ± 0.22 0.83 ± 0.27 20.96 0.76 [0.41 - 0.90] 0.87 ± 0.29 0.84 ± 0.19 28.26 0.40 [0.57 - 0.77] 
SNP %Δ 292.84 ± 124.09 277.82 ± 97.10 36.97 0.19 [-1.14 - 0.69] 295.82 ± 134.61 288.99 ± 85.98 32.22 0.55 [-0.17 - 0.83] 
SNP AUC 809.23 ± 226.34 870.30 ± 272.04 22.40 0.80 [0.48 - 0.92] 801.18 ± 327.91 814.64 ± 203.80 40.39 0.53 [-0.30 - 0.83] 
PORH Peak (PU) 87.71 ± 12.77 90.05 ± 9.59 10.19 0.49 [-0.30 - 0.80] 86.79 ± 11.13 83.91 ± 16.27 10.45 0.81 [0.53 - 0.92] 
PORH Peak (CVC)  1.06 ± 0.14 1.10 ± 0.13 9.92 0.59 [0.01 - 0.84] 1.08 ± 0.14 1.06 ± 0.22 12.57 0.78 [0.44 - 0.91] 
PORH Δ (PU) 55.08 ± 9.84 56.96 ± 8.81 11.69 0.66 [0.16 - 0.87] 55.00 ± 8.72 51.67 ± 15.51 21.81 0.66 [0.16 - 0.86] 
PORH Δ (CVC) 0.66 ± 0.11 0.70 ± 0.12 11.67 0.69 [0.24 - 0.87] 0.69 ± 0.12 0.65 ± 0.20 23.59 0.67 [0.17 - 0.87] 
PORH %Δ 171.14 ± 31.92 178.08 ± 43.46 20.49 0.45 [-0.42 - 0.78] 175.74 ± 32.85 163.99 ± 52.16 31.39 0.31 [-0.74 - 0.73] 
PORH AUC 134.37 ± 30.13 138.52 ± 40.17 29.80 0.05 [-1.56 - 0.63] 139.99 ± 35.99 129.87 ± 34.14 24.45 0.56 [-0.07 - 0.83] 
Data are presented as the mean ± standard deviation and reported as the peak blood flux and the change (Δ) in blood flux between peak and baseline 
values, expressed in perfusion units (PU) and cutaneous vascular conductance (CVC); as well as the percentage change (%Δ) from baseline 
measurements and the area under the curve (AUC). Coefficients of variation (CV) of <35 % were deemed acceptable and intra-class correlation 
coefficient (ICC) values of <0.40, 0.40 to 0.75 and >0.75 represented poor, fair to good and excellent agreements, respectively. ACh, acetylcholine; 
PORH, post-occlusive reactive hyperemia; SNP, sodium nitroprusside. 
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6.6 Discussion 
 
Currently, there are no standardized methods for iontophoresis in the literature and, 
consequently, researchers are using an array of protocols that may be at risk of inducing 
non-specific vasodilatory effects; confounding the overall interpretation of the 
microvascular data and any subsequent conclusions. Considering this, this study aimed 
to provide updated recommendations for using iontophoresis to assess cutaneous 
microvascular reactivity; assessing the reliability of several published protocols by 
evaluating each for evidence of non-specific vasodilatory effects. Following this, the 
reproducibility of those protocols that were free of non-specific vasodilatory effects 
was compared to the excellent reproducibility of PORH.66 The findings of this study 
reveal that of the ten protocols of iontophoresis that were assessed, only three protocols, 
which delivered continuous electrical currents with low total iontophoretic charge 
densities to administer doses of acetylcholine 2 % (0.02 mA for 200 s, diluted in sodium 
chloride 0.9 %; and 0.1 mA for 30 s, diluted in deionized water) and sodium 
nitroprusside 1 % (0.02 mA for 400 s, diluted in sodium chloride 0.9 %), were found to 
have no evidence of non-specific vasodilatory effects. Indeed, although no protocol of 
acetylcholine iontophoresis induced a significant non-specific increase in blood flux at 
the control electrode, protocols that used multiple pulses to deliver the electrical current 
may have mediated a vascular response that is more influence by non-specific 
vasodilatory effects than that which delivers continuous stimulation; indicated by a 
delayed peak blood flux response that coincides with increased non-specific 
vasodilatory responses at the control electrode and a slower rate of return to basal blood 
flux conditions.  Interestingly, all protocols for iontophoresis of insulin in its insulin-
specific diluent and sodium nitroprusside in deionized water induced non-specific 
vasodilatory effects. Considering these results, reproducibility assessments for 
iontophoresis of acetylcholine and sodium nitroprusside coupled with LSCI were then 
performed using the protocols that delivered the lowest continuous electrical current 
charge of 0.02 mA for 200 and 400 s, respectively. Compared to PORH, the intraday 
and interday (morning measurements only) reproducibility for iontophoresis of 
acetylcholine and sodium nitroprusside with LSCI was weaker, but still deemed good 
to excellent when data was expressed, in PU or CVC, as the absolute peak blood flux 
 
 
192 
response to the vascular reactivity test or as the change in blood flux between peak and 
baseline values.  
  
In recent decades, several studies have brought further understanding to the 
mechanisms and variables that mediate non-specific vasodilatory effects in 
iontophoresis.220,446,450–456 In one such study, it was found that non-specific vasodilatory 
effects can be prevented by limiting the current density and the total iontophoretic 
charge density to <0.013 mA/cm2 and <7.80 mC/cm2, respectively, for both anodal and 
cathodal iontophoresis.220 Despite these recommendations, it is still not entirely clear 
as to which protocols of iontophoresis from the literature should be utilized to 
accurately assess cutaneous microvascular function without confounding non-specific 
vasodilatory effects. The results of this present study were consistent with those from 
Droog et al.,220 demonstrating that non-specific vasodilatory effects were induced in 
several protocols for cathodal iontophoresis of insulin and sodium nitroprusside after 
total iontophoretic charge densities of 7.79 mC/cm2 and 10.39 mC/cm2 were 
administered. The importance of limiting the total iontophoretic charge density was 
further highlighted by the results of anodal iontophoresis of acetylcholine, which, 
although being generally less susceptible, still induced considerable non-specific 
vasodilatory effects when a total charge density of 9.09 mC/cm2 was delivered. Non-
specific vasodilatory responses were also induced in protocols of sodium nitroprusside 
iontophoresis that administered total iontophoretic charge densities of just 1.95 mC/cm2 
and 4.09 mC/cm2, but delivered current densities that were >0.013 mA/cm2; supporting 
recommendations to administer electrical currents with a low current density. The 
results from this study also demonstrate that the cutaneous microvascular response to 
iontophoresis of insulin can be attributed primarily to non-specific vasodilatory effects. 
These findings contrast those of a previous study, in which, the increase in 
microvascular blood flux at the control electrode was not similar to that observed in 
response to iontophoresis of insulin; when assessing the efficacy of the same protocol 
(12 pulses of 0.2 mA for 20 s each with 90 s interval between each pulse) as that 
examined in this present study and when using a similar insulin-specific diluent as the 
control solution.447 These varied results may be explained by differences in the laser-
based technologies used to estimate skin blood flux between the two studies. Whereas 
this study used LSCI at depths of ~300 µm, de Jongh et al used single point LDF,447 
which penetrates to ~1-1.5 mm.38 Indeed, the non-specific increases in blood flux 
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observed using LSCI might be less apparent in the deeper cutaneous microvasculature 
that is assessed by LDF.   
  
In addition to higher current densities and total iontophoretic charges applied during 
iontophoresis, the use of protocols that deliver multiple pulses of an electrical current 
may also contribute to inducing non-specific vasodilating effects. This study assessed 
protocols for iontophoresis of acetylcholine 2 % diluted in deionized water using either 
a continuous dose (0.1 mA for 30 seconds) or multiple pulses (single pulses of 0.03, 
0.06, 0.09, 0.12, 0.15 and 0.18 mA for 10 s each with 60 s interval between each pulse) 
of an electrical current, each delivering a total iontophoretic charge density within the 
recommended limits and a current density outside the recommended limits. Despite 
these similarities between each protocol, the rate of return from peak blood flux towards 
basal flux appeared to be decreased following delivery multiple pulses of the electric 
current, relative to rate of return in the continuous protocols. Indeed, such prolonged 
elevation in blood perfusion may be explained by the influence of non-specific 
vasodilatory effects. It must be acknowledged that previous research has revealed that 
this exact protocol for iontophoresis of acetylcholine, which uses multiple pulses of an 
electrical current, can induce non-specific increases in blood flux.446 This study also 
reaffirms the importance of diluent selection in minimizing non-specific vasodilatory 
effects with the results demonstrating that, aside from one acetylcholine protocol (0.1 
mA for 30 s, diluted in deionized water), non-specific increases in blood flux were 
observed in each protocol that used deionized water as a diluent; contrasting those 
protocols using sodium chloride as a diluent. Indeed, sodium chloride may suppress 
non-specific vasodilatory effects by enhancing the permeability of the skin (i.e. 
minimizing the resistance of the circuit) and, thus, allowing for application of a lower 
potential to drive the electrical current.454,455 Although the type of diluent is an 
important variable to consider when minimizing interference to the physiological effect 
of the vasoactive agent, it has been suggested that non-specific vasodilatory effects can 
be attributed entirely to application of the iontophoretic electrical current.457 The 
mechanisms underlying the non-specific vasodilatory response vary between anodal 
and cathodal electrical currents. Application of an anodal electrical current may 
hyperpolarize the cell membrane, resulting in a local increase in positive charges or a 
decrease in negative charges in the extracellular fluid that decreases the flow of Ca2+ 
into the VSM cell; whereas, when a cathodal electrical current is applied, the cell 
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membrane may depolarize as a result of a decrease in positive charges and an increase 
in negative charges in the extracellular fluid.455 Indeed, application of higher 
iontophoretic electric currents may depolarize nociceptive C-afferent nerve fibres and 
induce vasodilation via a local nerve-axon reflex;457 providing important information 
about the health of vascular sensory nerves and their capacity to modulate cutaneous 
microvascular function.    
  
Previously, the microvascular responses to tests of vascular reactivity have been 
quantified mostly using laser-based technologies including LDF or LDI. More recently, 
non-invasive LSCI has emerged as a more reliable tool for quantifying cutaneous 
microvascular function due, in part, to improvements in design that decrease the spatial 
and temporal variability typically associated with the LDF and LDI technologies, 
respectively.65,218 Therefore, after determining which protocols of iontophoresis were 
free of non-specific vasodilatory effects, this study compared the reproducibility of two 
protocols for iontophoresis of acetylcholine 2 % (0.02 mA for 200 s, diluted in sodium 
chloride 0.9 %) and sodium nitroprusside 1 % (0.02 mA for 400 s, diluted in sodium 
chloride 0.9 %) to the reproducibility of PORH, when performed in conjunction with 
LSCI. Notably, this present study was the first to assess the reproducibility of a protocol 
for iontophoresis of sodium nitroprusside coupled with LSCI; as well as the first to 
evaluate the intraday reproducibility of LSCI and the interday reproducibility with 
respect to the timing of assessment (e.g. morning or afternoon). Importantly, the results 
of this study support those in previous research, finding that the reproducibility of 
PORH coupled with LSCI is excellent for assessing cutaneous microvascular 
function.66,67,449 Compared to the excellent reproducibility of PORH with LSCI, the 
reproducibility of acetylcholine and sodium nitroprusside iontophoresis was decreased, 
but still good to excellent for intraday and interday (morning) measurements only. 
Indeed, this level of reliability was consistent with previous research, which assessed 
the interday reproducibility for iontophoresis of acetylcholine 1 % in deionized water 
using an anodal current of 0.1 mA for 30 s.68 Interestingly, the interday reproducibility 
of performing iontophoresis with LSCI in the afternoon was only poor to fair, while the 
reproducibility of PORH with LSCI was slightly decreased. Noting that although 
participants were instructed to present to morning measurements of microvascular 
function at least four hours fasted, most presented to morning assessments following 
complete overnight fasting and to afternoon assessments exactly four hours fasted, out 
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of convenience to their daily schedule. Considering these differences in durations of 
fasting between morning and afternoon measurements, as well as the increased 
variation in afternoon measurements of cutaneous microvascular function, collectively, 
reaffirms the importance of applying a standardized duration of overnight fasting to the 
design of any study that is assessing vascular function. Finally, consistent with previous 
research,66–68 LSCI data was most reproducible when expressed as the absolute peak 
blood flux response and as the change in blood flux between peak and baseline values, 
in either PU or CVC, for all reactivity tests. In addition to emphasizing the poor or 
unacceptable reproducibility of LSCI data expressed as the percentage increase from 
baseline measurements, this study, for the first time, demonstrates that LSCI data is 
unacceptable when expressed as area under the curve. Considering all results from this 
present study, a brief set of recommendations for performing iontophoresis, without 
confounding non-specific vasodilatory effects, is presented in Table 6-5. 
 
There are several inherent limitations to this present study that must be addressed. As 
stated previously, the imaging depth of LSCI is less to that of LDF;38 and, thus, it cannot 
be confirmed if the non-specific vasodilatory effects, occurring in response to the 
numerous published protocols of iontophoresis assessed by this study, also occur in 
deeper regions of the cutaneous microcirculation. It must also be acknowledged that 
although this study indicates which protocols of iontophoresis induce non-specific 
vasodilatory effects, it does not reveal exactly what percentage of the increase in 
cutaneous microvascular blood flux induced by iontophoresis is attributed to the 
vasoactive agent, itself, or to the mediators of non-specific vasodilatory responses such 
as the iontophoretic electrical current. Indeed, when the vasoactive agent is not present 
in the diluent, the ionic composition of the solution is changed, altering how the 
electrical current is carried towards the skin and, possibly, how the cutaneous 
microcirculation responds.444 Given that this and previous research has examined the 
reliability of LSCI in predominantly Caucasian populations or has not defined the 
population of interest, findings may not be automatically be extrapolated to all 
ethnicities as differences in skin pigmentation may effect blood flux measurements. 
Considering this, future research should further explore the efficacy of using LSCI with 
common tests of vascular reactivity to measure cutaneous microvascular blood flux, 
validating its use across a range of ethnicities. Furthermore, those studies using 
iontophoresis with other laser-based technologies such as LDF or LDI to measure 
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cutaneous microvascular function should demonstrate that all protocols utilized are free 
of non-specific vasodilatory effects. Moreover, noting that peak blood flux responses 
to iontophoresis of sodium nitroprusside occurred ~16 minutes after beginning the 
application of the iontophoretic electrical current, all future studies should report the 
duration of microvascular assessment; ensuring that recording periods are long enough 
in duration to detect the maximal microvascular response to the vasoactive agent. 
 
In conclusion, this research demonstrates a lack of a consensus in the literature; 
highlighting that many studies of microvascular function may be utilizing protocols of 
iontophoresis that induce non-specific vasodilatory effects. Furthermore, this study 
provides additional data that demonstrates the excellent reproducibility of LSCI. 
Altogether, this study provides new recommendations that minimize the influence of 
non-specific vasodilatory effects during iontophoresis, ensuring that vascular data more 
reflects the microvascular response to the vasoactive agent being studied; ultimately, 
improving the understanding of how underlying mechanisms of microvascular function 
change throughout the pathogenesis of cardiometabolic and CVD.  
 
 
 
 
  
 
 
197 
Table 6-5. Recommendations for using iontophoresis with LSCI to assess cutaneous 
microvascular function based on findings from this present study 
Assessment of endothelium-dependent vascular reactivity 
Vasoactive 
agent 
(concentration) 
Diluent 
(concentration) 
Iontophoretic 
electrical 
current 
intensity  
Duration of 
iontophoretic 
electrical 
current 
Recommended 
duration of 
vascular 
assessment*  
ACh (2 %) NaCl (0.9 %) 0.02 mA 200 s 10 mins 
ACh (2 %) Deionized H2O 0.1 mA 30 s 10 mins 
INS (100 
U/mL) 
Results indicate that current protocols for iontophoresis of INS, 
coupled with LSCI, are not suitable for assessing cutaneous 
microvascular insulin-mediated endothelial function. Measurements 
more specific to the vascular response may be acquired using LDF; 
noting that its reproducibility is poor when compared to LSCI. 
Assessment of endothelium-independent vascular reactivity  
Vasoactive 
agent 
(concentration) 
Diluent 
(concentration) 
Iontophoretic 
electrical 
current 
strength 
(mA) 
Duration of 
iontophoretic 
electrical 
current 
Recommended 
duration of 
vascular 
assessment*  
SNP (1 %) NaCl (0.9 %) 0.02 mA 400 s 20 mins 
Expression of LSCI data when using iontophoresis 
Expression Reproducibility**  
Absolute peak blood flux response (PU) Good to excellent – 
recommended  
Absolute peak response (CVC) Good to excellent – 
recommended 
Change between baseline and peak blood flux (PU) Good to excellent – 
recommended 
Change between baseline and peak blood flux 
(CVC) 
Good to excellent – 
recommended 
Percentage increase from baseline Poor – not recommended 
Area under the curve Poor – not recommended 
ACh, acetylcholine; CVC, cutaneous vascular conductance; H2O, water; INS, insulin 
(Humulin R®); LSCI, laser speckle contrast imaging; NaCl, sodium chloride; PU, 
perfusion units; SNP, sodium nitroprusside. *Duration of vascular assessment from the 
beginning of iontophoresis. **Based on recommendations that microvascular 
assessments are most reproducible when performed in the morning, following 
overnight fasting. Note: recommendations are based on results acquired using an 
iontophoretic electrode with a drug delivery surface area of 1.54 cm2. 
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Chapter 7 – General discussion, limitations and conclusion 
 
The primary objective of this program of research was to evaluate the extent and nature 
of vascular dysfunction across the spectrum of cardiometabolic health, from healthy 
populations, to those with obesity, MetS, impaired glucose tolerance, T2D and T2D 
with complications. To our best knowledge, this research is the first to provide evidence 
that there is a progressive impairment in endothelium-dependent and endothelium-
independent reactivity throughout the pathogenesis of T2D and its complications; and 
that this continuum of impairment may be adversely influenced by excess sugar 
consumption, such as that in the form of SSB; which induces transient endothelial 
dysfunction in those considered healthy or obese and in those with cardiometabolic 
disease. Furthermore, this research highlights major flaws in many studies of 
microvascular function, demonstrating that they may be utilizing protocols of 
iontophoresis that induce non-specific vasodilatory effects and that, subsequently, 
confound the interpretation of their vascular data. Importantly, this research responds 
by providing new recommendations that minimize the influence of these non-specific 
effects and, ultimately, improve the capacity to understand how microvascular function 
changes throughout the pathogenesis of obesity, cardiometabolic disease and CVD. 
 
This data demonstrates that chronic vascular dysfunction begins early in the decline of 
cardiometabolic health, presenting in those considered overweight, long before the 
clinical onset of obesity, MetS or T2D. The impact of chronic vascular dysfunction on 
the pathogenesis of CVD, even at this early stage, may be significant with data showing 
that the risk of coronary heart disease is increased in those who are metabolically 
healthy, but are considered obese.254 A slight increase in endothelium-independent 
vascular reactivity can be observed in obese patients after an initial impairment in those 
considered overweight. This increase in endothelium-independent vascular reactivity 
following an initial impairment may be chance, or a local protective mechanism, 
exerted by the perivascular adipose tissue.458 Indeed, the perivascular adipose tissue is 
not only a structural support surrounding the arteries, but also a source of vasoactive 
molecules that affect the underlying vascular cells.459 Such protective mechanisms in 
the decline of cardiometabolic health may explain the obesity paradox, which suggests 
that mildly obese patients with CVD have better outcomes than in their leaner 
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counterparts.460 Interestingly, data from this research program contradicts popular 
hypotheses that microvascular dysfunction precedes macrovascular dysfunction;233 
demonstrating that, when compared to water consumption, a single 600 mL SSB 
impaired both microvascular and macrovascular endothelial function even in a healthy 
population. Importantly, in contrast to many previous studies of vascular function, this 
research accounted for differences in vascular shear rate between assessments of 
macrovascular function, confirming that in addition to microvascular dysfunction, 
acute hyperglycemia induces a macrovascular dysfunction that is explained by the 
disruption of vasoactive mechanisms intrinsic to the macrocirculation.34,58 Considering 
this finding, it may be more suitable at this time to use FMD or NMD of the brachial 
artery to assess vascular reactivity, procedures that are more standardized and easy to 
perform in a routine clinical setting; rather than using methods of evaluating 
microvascular reactivity that lack the same consensus as that in macrovascular 
techniques.  
 
Notably, meta-regression analyses of FMD data and potential effect modifiers found 
one significant, negative correlation, that between FMD and fasting blood glucose 
concentration; indicating that as fasting blood glucose concentration increases by 1 
mmol/l, FMD decreases by 0.52%. Indeed, hyperglycemia is one of several other 
factors, including insulin resistance, obesity and low-grade inflammation, which may 
influence vascular function throughout the decline of cardiometabolic health. Current 
evidence suggests that acute hyperglycemia induces transient endothelial dysfunction, 
even in those considered healthy, by mediating an abnormal elevation in oxidative 
stress that disturbs normal underlying mechanisms of NO synthesis.235,236 While it is 
important to acknowledge that other signalling pathways of vasomotion may be also be 
affected by oxidative stress, reduced NO bioavailability is considered a strong predictor 
of CVD outcomes.7 In the postprandial state, oxidative metabolism initiates oxidative 
phosphorylation of adenosine triphosphate at the electron transport chain of the 
mitochondria, which via the phenomenon of electron leakage causes superoxide 
generation of ROS.85 Moreover, it has been clearly reported that increased glycemia is 
responsible for the activation of NADPH oxidase, which also contributes to production 
of the superoxide anion.24 Although these ROS are normally readily detoxified, 
elevated activity within this mechanism such as that following excess sugar 
consumption increases production to a rate beyond the suppressive capabilities of the 
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antioxidant systems.86 Importantly, the applicability of this oxidative stress-dependent 
mechanism to acute hyperglycemia-mediated endothelial dysfunction in living 
organisms was also demonstrated in this research, which revealed for the first time in 
an in vivo experimental rat model that antioxidant treatment also fully restores 
cutaneous microvascular endothelial function during acute hyperglycemia. This 
research also found that eNOSser1177 and the eNOS dimer/monomer ratios remained 
preserved during acute hyperglycemia, while the concentration of nitrites was 
decreased. Such experimental findings provide evidence that acute hyperglycemia-
mediated endothelial dysfunction is due, at least in part, to decreased bioavailability of 
NO that is not caused by a disruption to the synthesis of NO via the eNOS pathway. 
Indeed, the reaction between NO and free radical superoxide results in the formation of 
peroxynitrite, a potent cytotoxic molecule.237 This nitro-oxidative stress could be a 
primary mechanism responsible for the decrease in NO bioavailability that was 
observed in our model of acute hyperglycemic stress. Although the effects of acute 
hyperglycemia are initially transient, habitual excess sugar consumption promotes the 
development of obesity, dysglycemia, insulin resistance and low-grade inflammation. 
Indeed, elevated generation of ROS appears to be the unifying pathway between these 
factors and chronic vascular dysfunction, driving the progressive impairment of 
vascular reactivity across the spectrum of cardiometabolic health.7 Obesity and 
cardiometabolic diseases are characterized by abnormally frequent hyperglycemic 
excursions, which may also induce VSM cell proliferation by disrupting VSM cell 
apoptosis.255 Furthermore, hyperglycemia may enhance the production of AGE and 
collagen cross-linking.255 Collectively, these mechanisms stiffen the arterial wall; 
possibly explaining why endothelium-independent vascular reactivity may be reduced 
in those with obesity, impaired glucose tolerance, MetS and T2D. Ultimately, this 
increase in myogenic tone elevates the risk of injury to the endothelial wall; an event 
that is significant in the pathogenesis of CVD. 
 
There are several inherent limitations to this research that must be addressed. Given 
that previous studies have demonstrated differences in vascular function between 
ethnicities,210 it must acknowledged that this research focussed on Caucasian 
populations or assessed data from studies in which ethnicity was poorly reported. 
Furthermore, some of this research focussed on healthy male populations. Therefore, 
the findings of this data cannot be automatically extrapolated across all ethnicities, 
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genders and health populations. Although this research confirmed that excess sugar 
consumption transiently impairs endothelial function, it must also be considered that 
ingredients other than sugar that comprise commercial SSB were not evaluated 
individually in this research and, therefore, it is not known how they may contribute to 
the observed acute hyperglycemia-mediated endothelial dysfunction. Additionally, it 
was not possible to blind participants to the intervention by using a sugar-free placebo 
such as a commercial diet soda due to previous research suggesting that even artificial 
sweeteners may interact with taste receptors stimulating insulin secretion, which may 
induce a vascular response.241 Many studies included in the network meta-analysis used 
control groups that had no specific health classification. Considering this, mean clinical 
data from all included studies assessing health groups not defined as T2D, with or 
without complications, was checked and, if need be, redefined according to the World 
Health Organization guidelines for classification of overweight and obesity;249 the joint 
interim statement of the International Diabetes Federation Task Force on Epidemiology 
and Prevention, harmonizing the criteria for defining MetS;250 and the American 
Diabetes Association criteria for impaired glucose tolerance and diabetes.251 It also 
must be acknowledged that most studies did not include parameters that define MetS 
and are known to have an influence on vascular function, such as insulin resistance; 
and, therefore, the effect of such factors on the development of vascular function could 
not be accounted for in this analysis. Additionally, while there is a large amount of data 
focussing on macrovascular endothelium-dependent vascular reactivity in studies of 
vascular function, the amount of research that has assessed endothelium-independent 
vascular reactivity and microvascular endothelium-dependent reactivity is limited. 
Finally, study four demonstrated that a majority of the studies included in the reviews 
of this research have utilized methodology that induces non-specific effects and 
confounds vascular data. Therefore, while the direction of the effect may be accurate, 
the magnitude of the microvascular impairment during acute hyperglycemia or across 
the spectrum of cardiometabolic health may not yet be fully revealed.  
 
Acknowledging the findings and limitations of this study, it is still not clear where in 
the pathophysiological continuum that transient endothelial dysfunction becomes 
chronic vascular dysfunction. Indeed, this present study demonstrates that vascular 
reactivity may be impaired early, even in those considered overweight; while previous 
research from our laboratory has demonstrated that acute hyperglycemia, induced by 
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excess sugar consumption, transiently decreases endothelial function, even in those 
considered healthy.256  Considering this, further research is needed to assess if transient 
impairments in endothelial function, mediated by several dietary and lifestyle factors, 
develop into chronic vascular dysfunction before, when someone is still considered 
clinically healthy, or after the clinical onset of an overweight state or insulin resistance. 
Furthermore, given that there may be differences in vascular reactivity between 
ethnicities,210 future research may also assess this continuum of vascular impairment, 
as well as the mechanisms that underlie any dysfunction (e.g. disruption of the NO, 
PGI2 or EDHF pathways) in varying health populations from a range of ethnic 
backgrounds. Before further vascular research is performed, several methodological 
issues should be addressed. Future studies should ensure that assessments of 
macrovascular reactivity with FMD and ultrasound of the brachial artery account for 
changes in shear stress between assessments, ensuring that intrinsic function of the 
macrocirculation is being examined. Furthermore, future vascular studies would also 
benefit highly from research that standardizes protocols for assessing microvascular 
function, ensuring that the impact of obesity and cardiometabolic disease, as well as 
dietary and lifestyle habits, on vascular function is interpreted with greater accuracy. 
While it is important to understand the physiological effects of poor lifestyle, a 
multidisciplinary approach should be used to also understand the psychology that drives 
sedentary behaviours and poor diet, such as excess sugar consumption, in both adults 
and children. Indeed, comprehensive understanding of these multifactorial systems will 
provide the foundation for developing mechanisms, which may enhance cardiovascular 
function, and interventions that promote healthy lifestyles and reduce the incidence of 
obesity and cardiometabolic disease.  
 
In conclusion, this research program demonstrates that there is a progressive 
impairment in vascular reactivity across the spectrum of cardiometabolic health, from 
healthy populations, to those with obesity, MetS, impaired glucose tolerance, T2D and 
T2D with complications. This research program also confirmed that excess sugar 
consumption, including that in the form of SSB, induces transient impairments in 
endothelial function, which may contribute to the initial and ongoing development of 
chronic vascular dysfunction, obesity, MetS, T2D and CVD. It is still unclear where in 
the continuum that transient endothelial dysfunction develops into chronic vascular 
impairment. Therefore, further research is needed to assess if transient impairments in 
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vascular reactivity, mediated by several dietary and lifestyles factors, develop into 
chronic vascular dysfunction before, when the individual is still considered clinically 
healthy, or after the clinical onset of an overweight state. However, several issues 
within the current methodology for assessing vascular function should be addressed 
before further research is completed. Regardless, the findings of this research program 
demonstrate and further inform public health policy that transient and chronic 
impairments of vascular reactivity, which are representative of critical events in the 
pathogenesis of CVD and that are associated with CVD mortality,461 occur long before 
the clinical onset of obesity, MetS and T2D. Furthermore, they provide data that may 
enhance the timing and, subsequent, effectiveness of treatment or preventative 
strategies that aim to improve vascular health and outcomes in CVD. 
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Chapter 9 – Appendices 
 
Appendix I: Research Portfolio 
 
Study one 
 
Loader J, Montero D, Lorenzen C, Watts R, Meziat C, Reboul C, Stewart S, Walther 
G. Acute hyperglycemia impairs vascular function in healthy and cardiometabolic 
diseased subjects: systematic review and meta-analysis. Arter Thromb Vasc Biol. 
2015:35(9):2060-72. Doi: 10.1161/ATVBAHA.115.305530. 
 
Contribution statement: GW was responsible for the concept and design of the study. 
Acquisition of data was performed by JL, DM, CL and GW. JL, DM and GW analysed 
and interpreted the data. Drafting of the manuscript was completed by JL, DM and GW. 
JL, DM, CL, RW, CM, CR, SS and GW critically revised the manuscript for important 
intellectual content. DM provided statistical expertise and JL, CL, RW, SS and GW 
provided administrative, technical or material support. All authors approved the final 
version of the manuscript. 
 
Approximate percentage contributions:  
Loader J, 60 %; Montero D, 10 %; Lorenzen C, 10 %; Watts R, 2.5 %; Meziat C, 2.5 
%; Reboul C, 2.5 %; Stewart S, 2.5 %; Walther G, 10 %. 
 
 
I acknowledge that my contribution to the above publication is 60 % (6/10). 
     
Jordan Luke Loader       Date: 29/09/2017 
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I acknowledge that my contribution to the above publication is 10 %. 
    
David Montero       Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 10 %. 
     
Christian Lorenzen       Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 2.5 %. 
      
Rani Watts        Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 2.5 %. 
     
Cindy Meziat        Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 2.5 %. 
     
 
 
Cyril Reboul        Date: 29/09/2017 
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I acknowledge that my contribution to the above publication is 2.5 %. 
     
Simon Stewart       Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 10 %. 
    
Guillaume Walther       Date: 29/09/2017 
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Study two 
 
Loader J*, Meziat C*, Watts R, Lorenzen C, Sigaudo-Roussel D, Stewart S, Reboul 
C, Meyer G, Walther G. Effects of sugar-sweetened beverage consumption on 
microvascular and macrovascular function in a healthy population. Arter Thromb Vasc 
Biol. 2017:37(6):1250-60. Doi: 10.1161/ATVBAHA.116.308010. 
 
Contribution statement: GW was responsible for the concept and design of the study. 
CM, GM and GW performed data acquisition. JL exported and blinded the data. CM 
and GW analysed the data. GW provided statistical expertise. JL, CM, CR and GW 
interpreted the data. JL, CM and GW performed drafting of the manuscript. JL, CM, 
RW, CL, DSR, SS, CR, GM and GW provided administrative, technical or material 
support; and critically revised the manuscript for important intellectual content. All 
authors approved the final version of the manuscript. 
 
 
Approximate percentage contributions: Loader J, 50 %; Meziat C, 40 %; Watts R, 0.5 
%; Lorenzen C, 0.5 %; Sigaudo-Roussel D, 0.5 %; Stewart S, 0.5 %; Reboul C, 1.5 %; 
Meyer G, 1.5 %; Walther G, 5 %. 
 
 
I acknowledge that my contribution to the above publication is 50 % (5/10). 
     
Jordan Luke Loader       Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 40 %. 
    
Cindy Meziat        Date: 29/09/2017 
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I acknowledge that my contribution to the above publication is 0.5 %. 
     
Rani Watts        Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 0.5 %. 
     
Christian Lorenzen       Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 0.5 %. 
      
Dominique Sigaudo-Roussel      Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 0.5 %. 
     
Simon Stewart       Date: 29/09/2017 
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I acknowledge that my contribution to the above publication is 1.5 %. 
     
 
 
Cyril Reboul        Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 1.5 %. 
    
Gregory Meyer       Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 5 %. 
    
Guillaume Walther       Date: 29/09/2017 
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Study three 
 
Loader J, Khouri C, Taylor F, Stewart S, Lorenzen C, Walther G, Roustit M. 
Manuscript to be submitted. 
 
Contribution statement: JL was responsible for the concept and design of the study. JL, 
FT, GW and MR acquired the data.  JL, CK, GW and MR analysed and interpreted the 
data; and drafted the manuscript. JL, CK, FT, SS, CL, GW and MR provided 
administrative, technical or material support; and critically revised the manuscript for 
important intellectual content. All authors approved the final version of the manuscript. 
 
 
Approximate percentage contributions: Loader J, 50 %; Khouri C, 20 %; Taylor F, 2.5 
%; Stewart S, 2.5 %; Lorenzen C, 2.5 %; Walther G, 2.5 %; Roustit M, 20 %. 
 
 
I acknowledge that my contribution to the above publication is 50 %. 
     
Jordan Luke Loader       Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 20 %. 
    
Charles Khouri       Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 2.5 %. 
     
Frances Taylor       Date: 29/09/2017 
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I acknowledge that my contribution to the above publication is 2.5 %. 
     
Simon Stewart       Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 2.5 %. 
     
Christian Lorenzen       Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 2.5 %. 
     
Guillaume Walther       Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 20 %. 
     
 
 
Matthieu Roustit       Date: 29/09/2017 
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Study four 
 
Loader J, Roustit M, Taylor F, MacIsaac RJ, Stewart S, Lorenzen C, Walther G. 
Assessing cutaneous microvascular function with iontophoresis: Avoiding non-specific 
vasodilation. Microvascular Research. 2017:113:29-39. Doi: 
10.1016/j.mvr.2017.04.006. 
 
Contribution statement: JL, CL and GW were responsible for the concept and design 
of the study. JL performed data acquisition, analysed the data and interpreted the data. 
JL performed drafting of the manuscript. JL, MR, FT, RJM, SS, CL and GW provided 
administrative, technical or material support. All authors critically revised the 
manuscript for important intellectual content and approved the final version of the 
manuscript. 
 
 
Approximate percentage contributions: Loader J, 75 %; Roustit M, 5 %; Taylor F, 2.5 
%; MacIsaac RJ, 2.5 %; Stewart S, 2.5 %; Lorenzen C, 2.5 %; Walther G, 10 %. 
 
 
I acknowledge that my contribution to the above publication is 75 % (7.5/10). 
     
Jordan Luke Loader       Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 5 %. 
    
 
 
Matthieu Roustit       Date: 29/09/2017 
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I acknowledge that my contribution to the above publication is 2.5 %. 
     
Frances Taylor       Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 2.5 %.  
     
Richard J. MacIsaac       Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 2.5 %. 
     
Simon Stewart       Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 2.5 %. 
     
Christian Lorenzen       Date: 29/09/2017 
 
 
I acknowledge that my contribution to the above publication is 10 %. 
    
Guillaume Walther       Date: 29/09/2017  
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Appendix II: Published papers that form Chapter 3 
 
 
 
 
 
 
 
 
 
 
 
Loader J, Montero D, Lorenzen C, Watts R, Meziat C, Reboul C, Stewart S, Walther 
G. Acute hyperglycemia impairs vascular function in healthy and cardiometabolic 
diseased subjects: systematic review and meta-analysis. Arter Thromb Vasc Biol. 
2015:35(9):2060-72. Doi: 10.1161/ATVBAHA.115.305530 
 
Due to copyright restrictions, the published version of this journal article is not 
available here. The published version can be viewed online at: 
http://atvb.ahajournals.org/content/35/9/2060 
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Appendix III: Published papers that form Chapter 4 
 
 
 
 
 
 
 
 
 
 
 
 
Loader, J*, Meziat, C*, Watts, R, Lorenzen, C, Sigaudo-Roussel, D, Stewart, S, 
Reboul, C, Meyer, G, Walther, G. Effects of sugar-sweetened beverage consumption 
on microvascular and macrovascular function in a healthy population. Arter Thromb 
Vasc Biol. 2017:37(6):1250-60. Doi: 10.1161/ATVBAHA.116.308010. 
 
Due to copyright restrictions, the published version of this journal article is not 
available here. The published version can be viewed online at: 
http://atvb.ahajournals.org/content/37/6/1250 
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Appendix IV: Published papers that form Chapter 6 
 
 
 
 
 
 
 
 
 
 
 
 
Loader J, Roustit M, Taylor F, MacIsaac RJ, Stewart S, Lorenzen C, Walther G. 
Assessing cutaneous microvascular function with iontophoresis: Avoiding non-specific 
vasodilation. Microvascular Research. 2017:113:29-39. Doi: 
10.1016/j.mvr.2017.04.006. 
 
Due to copyright restrictions, the published version of this journal article is not 
available here. The published version can be viewed online at: 
http://www.sciencedirect.com/science/article/pii/S0026286217300717?via%3Dihub 
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PARTICIPANT INFORMATION LETTER 
 
PROJECT TITLE: Sugar-sweetened beverage consumption in healthy, type 1 
and type 2 diabetic adults  
 
PRINCIPAL INVESTIGATORS:  
Dr. Rani Watts (rani.watts@acu.edu.au)       
Dr. Guillaume Walther (guillaume.walther@univ-avignon.fr)  
 
STUDENT RESEARCHER:  Mr. Jordan Loader (jordan.loader@acu.edu.au) 
 
Dear Participant, 
 
You are invited to participate in the research project described below. 
 
What is the project about? 
A non-healthy diet is commonly accompanied by consumption of sugar-sweetened 
beverages (SSBs), reported to provide little (if any) nutritional benefit. The 2010 
National Nutrition Survey in Australia found that 58% of young adults drink an average 
of 2.1 cans (800 mL) of a SSB per day, which provide the main daily source of sugar. 
Several studies in children and adults have reported strong associations between SSB 
consumption and the risk of developing type 2 diabetes, due to its potential adverse 
effects on weight gain and glucose metabolism. 
 
SSB contain between 70-120 g of sugar per litre and lead to a peak in blood glucose. 
Long-term SSB consumption is reported to be a precursor of insulin resistance but may 
also negatively impact the vascular system (blood vessels). The endothelium is a thin 
layer of cells lining the blood vessels and the heart and helps to control blood pressure 
through vasodilation (widening) and vasoconstriction (narrowing). Very few studies 
have investigated the underlying mechanisms involved in the dysfunction of the 
endothelium in response to blood glucose peaks following SSB consumption.  
 
Endothelial dysfunction, in this context, has been shown to impair the capacity of blood 
vessels to vasodilate (widen). This is likely associated with a reduction in nitric oxide 
(NO) synthesis and its bioavailability.  Nitric oxide (NO) induces a healthy widening 
of the blood vessels. We have previously reported data in healthy rats that implicates 
endothelial dysfunction immediately following a peak in blood glucose. Dysfunction 
was characterized by oxidative stress and lowered activity of nitric oxide synthase 
(eNOS; important for the synthesis of NO) within the microcirculation of blood vessels. 
The aim of this research study is to explore the effect of SSB consumption on 
endothelial function in blood vessels of healthy and type 2 diabetic individuals, with 
a particular focus on the underlying mechanisms of the NO pathway.  
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Who is undertaking the project? 
This project is being conducted by Dr. Rani Watts and Jordan Loader (PhD candidate) 
from the School of Exercise Science at Australian Catholic University in collaboration 
with Dr. Guillaume Walther from the University of Avignon, France. 
 
What will I be asked to do? 
To be eligible to take part in the study you will need to be (i) male or female; (ii) aged 
between 18 and 60 years old; (iii) diabetic (type 1 or type 2) or non-diabetic (healthy); 
and (iv) to agree to refrain from exercise the day prior to the testing being undertaken. 
You will be required to visit the Exercise Science Research Laboratory, in the Daniel 
Mannix Building on ACU’s Fitzroy campus, for three sessions of approximately 1 to 
1.5 hours in duration. During each session, you will be required to remain in a supine 
position (lying down) and we will test your blood glucose and microvascular responses 
with non-invasive, painless devices that use ultrasound and laser light technology. Your 
microvascular responses will be checked before and following the consumption of a 
SSB (600 mL of the Solo brand lemon drink). At two of the three sessions, you will be 
asked to swallow a capsule containing either 10 mg/kg-10 saproterin dihydrochloride 
(BH4) or 500 mg N-acetylcysteine (NAC). At each of these sessions, dilute 
concentrations of insulin (100 U/ml), acetylcholine (a 2% solution) and sodium 
nitroprusside (a 2% solution) will be applied to the skin of the forearm during the 
assessment of your microvascular response to the SSB. Very small droplets of blood 
will be collected from the end of your finger using a simple finger-prick technique (5 
times per session). These small droplets of blood (less than 1/20th of 1ml) will be used 
to measure blood glucose. You are asked to abstain from strenuous exercise in the 24 
hours leading up to the study day and arrive at the laboratory first thing in the morning 
without eating or drinking i.e. in the fasted state. Following testing you will be provided 
with breakfast.  
 
Are there any risks associated with participating in this project? 
This project primarily uses non-invasive techniques (ultrasound and laser light 
technology). While all techniques will be performed by well-trained and experienced 
operators, some risk, although minimal, is associated with participation in this study. 
The researchers take any risk in participating in the study seriously and will do 
everything within their capacity to minimise risk and maximise comfort. Details of (i) 
these risks, (ii) how they can to be minimised and (iii) how they will be managed in the 
unlikely event that they occur are described as follows: 
 
1) Minor infection at the site of blood sampling. Finger-prick sampling will be performed 
to assess your blood glucose response to SSB consumption. The small risk of infection 
from finger-prick sampling will be significantly reduced by swabbing the area with 
alcohol and using a sterile single-use lancet. In the unlikely event of infection, you will 
be advised to consult your medical practitioner. 
2) Temporary hypoglycaemia (low blood sugar). You may experience symptoms of 
temporary hypoglycaemia (e.g. weakness, sweating, intense hunger) following the 
overnight fast. All testing will start early (approximately 8 am) to prevent the risk of 
hypoglycaemia. Analysis of blood glucose undertaken as part of the study will permit 
researchers to monitor and stop the testing if blood glucose levels fall below 3.0 
mmol/L. In the unlikely event that clinical hypoglycaemia occurs, you will be supplied 
with water, coffee or tea and breakfast. Researchers will continue to monitor your blood 
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glucose levels until they return to acceptable levels before allowing you to leave the 
research venue. For safety, it is recommended that you organise for a friend or family 
member to accompany you or drive you home. Alternative arrangements will be made 
by researchers to get you home if this is not possible.   
3) Temporary hyperglycaemia (high blood sugar). A temporary elevation in blood glucose 
levels is expected following the consumption of SSB. However, it is unlikely to be of 
a duration that places participants at risk of producing any symptoms. Should blood 
glucose levels remain elevated beyond 11.1 mmol/L at the end of testing we will advise 
you to seek advice from your medical practitioner. 
4) Headache in response to nitronal-glyceryl trinitrate (NMD) administration. 
Infrequently, headache occurs following sublingual (below the tongue) administration 
of nitronal-glyceryl trinitrate. In the unlikely event of a headache, researchers will 
recommend that you respond to this in your usual way e.g. self-medicate. If headache 
persists, the researchers will recommend you seek advice from your medical 
practitioner. 
5) Temporary reddening, allergic reaction or sensation of ‘pins and needles’ of the skin 
at the site of iontophoresis. For the iontophoresis (microcirculation) procedure, three 
vasoactive substances will be transdermally administered (by placing the substance into 
the small chambers situated on the electrodes) on to the skin of the forearm: insulin 
(100 U/ml), acetylcholine (2% solution) and sodium nitroprusside (2% solution). 
Microvascular endothelium-dependent and independent vasodilation will then be 
assessed using laser light technology. The predictable risk for iontophoresis is the 
possibility of temporary red patches at the placement of the electrodes, regardless of 
which compound is placed into the chamber of the electrode. A prolonged allergic 
reaction is very unlikely and has never been observed in any of our previous studies. 
The researcher will verbally confirm that you have not experienced an allergy to 
transdermal administration of insulin, acetylcholine or sodium nitroprusside in the past. 
If your skin shows excessive reaction to these substances testing will immediately 
cease. You may also feel ‘pins and needles’ at or around the iontophoresis application 
zone (at the electrodes). This sensation will only occur during iontophoresis period (up 
to 2.5 minutes per visit) and is not painful. In the past, the sensation of ‘pins and 
needles’ has occurred in only approximately 10% of participants and no one has yet 
asked to stop the iontophoresis procedure. Nevertheless, the testing will be stopped in 
the case of your expressed discomfort.  
6) Side effects from oral medication administration. Two substances (plus one placebo) 
are to be orally administered: saproterin dihydrochloride (BH4; 10 mg/kg-10) and N-
acetylcysteine (NAC; 500 mg).  
The 10 mg/kg-10 dose of BH4 to be given in this study represents a common starting 
concentration given for treatment in diseases such as phenylketonuria. Patients 
frequently tolerate higher daily doses of 20 mg/kg-10   without side effects. However, 
side effects of this medication may include headache, diarrhoea, abdominal pain and 
nausea, but again these have only been reported for chronic use. Previous studies in 
humans reported excellent acute tolerance with higher plasma BH4 levels.  
The 500 mg dose of NAC given in the present study is the dose reported in clinical 
literature to generate an acute effect in humans. Several previous studies have used this 
antioxidant treatment to study the impact of oxidative stress. NAC is safe for adults, 
when used as a prescription medication. However, side effects of this medication may 
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include nausea, vomiting, diarrhoea or constipation. Rarely, it can cause rashes, fever, 
headache, drowsiness, low blood pressure, and liver problems, although reports of this 
nature are usually associated with oral solutions and less in studies using capsules (as 
proposed in our study). Moreover, previous works reported on doses of 2400 mg per 
day or more. In the unlikely event of experiencing side effects in response to either 
substance, you will be advised to consult your medical practitioner. 
7) Temporary soreness of finger at the site of blood sampling. Finger-prick sampling will 
be undertaken five times during each visit. This method is associated with temporary 
discomfort with the possibility of a short period (~1-2 days) of soreness at the site where 
the finger is pricked, however is a far more well-tolerated and less invasive procedure 
for measuring your blood glucose responses than standard catheterisation or 
venepuncture.  
 
What are the benefits of the research project? 
While there are no immediate benefits to you for participating in this study, we will 
provide you with information about your blood sugar response following SSB 
consumption. This study will allow us to investigate the microvascular response to the 
intake of a single SSB and provide a better understanding of the mechanisms involved 
in endothelial dysfunction of the microcirculation. 
 
Can I withdraw from the study? 
Participation in this study is completely voluntary. You are not under any obligation to 
participate. If you agree to participate, you can withdraw from the study at any time 
without adverse consequences. 
 
Will anyone else know the results of the project? 
We intend to present aggregated data from this study at scientific conferences and 
publish it in a scientific journal. It will also be used in a PhD thesis. Your data will 
remain confidential and known only to the researchers and yourself. 
 
What if I have a complaint or any concerns? 
The study has been reviewed by the Human Research Ethics Committee at Australian 
Catholic University (approval number 2014 02V). If you have any complaints or 
concerns about the conduct of the project, you may write to the Chair of the Human 
Research Ethics Committee care of the Office of the Deputy Vice Chancellor 
(Research): 
Manager, Ethics. C/o Office of the Deputy Vice Chancellor (Research) 
Australian Catholic University; North Sydney Campus; PO Box 968 
NORTH SYDNEY, NSW 2059 
Email: res.ethics@acu.edu.au 
 
Any complaint or concern will be treated in confidence and fully investigated. You will 
be informed of the outcome. 
 
Yours sincerely, 
 
Dr. Rani Watts 
Principal investigator   
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CONSENT FORM 
Copy for Researcher/Copy for Participant to Keep  
 
TITLE OF PROJECT: Sugar-sweetened beverage consumption in adults with and 
without type 2 diabetes 
 
 
 
 (NAME OF) PRINCIPAL INVESTIGATOR: Dr. Rani Watts 
 
 
I ................................................... (the participant) have read (or, where appropriate, 
have had read to me) and understood the information provided in the Letter to 
Participants. Any questions I have asked, have been answered to my satisfaction. I agree 
to participate in this project involving overnight fasting, three x one-hour visits to test 
the blood and blood pressure responses (using ultrasound and light technology) to 
drinking a sugar-sweetened drink (600 mL of Solo Lemon drink). I understand that a 
small, albeit safe, amount of drugs (oral or transdermal application) will be used during 
each visit. I realise that I can withdraw my consent at any time without adverse 
consequences. I agree that research data collected for the study will be password 
protected and may be published or may be provided to other researchers in a form that 
does not identify me in any way.   
   
   
 
 
NAME OF PARTICIPANT: ...........................................................................................   
 
SIGNATURE ..........................................................       DATE ...................................... 
 
SIGNATURE OF PRINCIPAL INVESTIGATOR: ....................................................... 
DATE:……………………….. 
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Study 4: Letters to participants and consent forms 
Study 4 is comprised of 2 separate protocols, which were approved by the local ethics 
committee following receipt of 2 separate applications; and, thus, 2 separate letters to 
participants and 2 separate consent forms are presented below.  
ACU Human Ethics Committee Approval IDs: 2013 238V & 2015-18H 
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PARTICIPANT INFORMATION LETTER 
 
PROJECT TITLE: Intraday and interday reproducibility of skin blood flow 
measurement using laser speckle imaging. 
 
PRINCIPAL INVESTIGATOR: Dr. Christian Lorenzen 
STUDENT RESEARCHER: Jordan Loader  
 
Dear Participant, 
 
You are invited to participate in the research project described below. 
 
What is the project about?  
The research project investigates the repeatability of a piece of equipment that measures 
blood flow and small blood vessel function. The blood flow and function of small blood 
vessels are thought to be early indicators of cardiovascular health.  The PeriMed Laser 
Speckle Contrast Imager is a new laser imaging device that can measure blood flow 
and small blood vessel function quickly with little discomfort for patients.  Presently, 
repeatability of measurement of this device is still not completely understood (i.e. 
whether the device can deliver the same information regarding blood flow when the 
conditions of testing remain similar).  The aim of this study is therefore to assess 
repeatability of blood flow measurement with the PeriMed.  This research is important 
as it will provide important information for clinicians and researchers who wish to 
assess blood flow with the PeriMed.  If the measurements are repeatable, clinicians and 
researchers may use the Perimed to assess the effectiveness of interventions (e.g. 
pharmaceuticals, physical activity) in vascular health. 
 
Who is undertaking the project? 
Dr. Christian Lorenzen and Jordan Loader (PhD candidate) from the Australian 
Catholic University are conducting this project. 
 
Who is eligible to participate? 
We are seeking healthy male and female participants who are over the age of 18 years. 
Those with any significant medical history for chronic cardiovascular disease and the 
use of any medications affecting microcirculation are not eligible to participate. 
 
Are there any risks associated with participating in this project? 
The only foreseeable risk will be discomfort when a blood pressure cuff is pumped 50 
mmHg above your normal resting systolic blood pressure.  The pressure from the cuff 
will be similar to what you experience when you visit the Doctor, although for this 
study, pressure will be maintained for three minutes, in which you may feel a numb 
tingly feeling in your forearm and hand.  If the pressure is too uncomfortable you will 
be free to ask the researcher to deflate the cuff immediately. Medications are 
   275 
administered safe dose levels and will remain in the local application area, not 
spreading around the body. A finger prick for blood glucose testing may cause 
momentary discomfort, and possibly slight bruising at the puncture site.   
 
What will I be asked to do? 
You will be requested to attend the Cardiovascular Research Laboratory in the School 
of Exercise Science, Fitzroy, on four occasions, over a seven day period.  You will be 
required to abstain from caffeine, nicotine and alcohol for at least 4 hours before testing 
to avoid their effects on microcirculation. Test one will be conducted on the morning 
of day one, and test two in the afternoon of day one.  Tests three and four will be 
conducted approximately 7 days later, in the morning and afternoon respectively.  Each 
test will last about 60 minutes, and all testing procedures will be the same from test to 
test.  The step by step procedure for each test will be: 
 
1. You will lay on a bench for 20 minutes in a temperature controlled room for 
acclimatization. 
2. A blood pressure cuff placed will be placed on your upper arm, on the same side 
of the blood flow recordings.   
3. Resting blood pressure assessed. 
4. Baseline blood glucose levels assessed using a finger prick lancet and blood 
glucose monitor. 
5. Two medication-delivery electrodes (acetylcholine and sodium nitroprusside) 
will be placed on your inner forearm.  
6. Two weak electrical currents will be administered simultaneously to move the 
medication to your skin blood vessels. Laser imaging will occur throughout. 
7. You will rotate your arm so that the palm of your hand is flat on the table. 
8. Two minute baseline measurement of blood flow. 
9. Blood pressure cuff inflated for 3 minutes.  
10. Immediately after blood pressure cuff is deflated blood flow will be recorded 
for a 5-minute period. Laser imaging will occur throughout.   
 
How much time will the project take? 
You will be requested to attend four 60 minute sessions over a one week period. 
 
What are the benefits of the research project? 
There will be little direct benefit to you for this study; however, your contribution may 
contribute to community health in the future.  The information in this study may help 
clinicians and researchers interpret data from the Perimed, enabling them to determine 
the success of an intervention (e.g. pharmaceutical or physical activity) more 
confidently and identify at-risk patients. 
 
Can I withdraw from the study? 
Participation in this study is completely voluntary. You are not under any obligation to 
participate. If you agree to participate, you can withdraw from the study at any time 
without adverse consequences. 
 
Will anyone else know the results of the project? 
It is the researcher’s intention to publish the results of this study in an international 
research journal.  You will not be identifiable in this publication as only aggregated 
data will be presented.  During the study, your data will be de-identified and coded so 
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only the Principal Investigator can determine that it is you, and will be stored on a 
password protected computer in the Cardiovascular Research Laboratory in the School 
of Exercise Science, ACU.  At the completion of the study, data will be kept on a 
password protected computer in the Principal Investigators officer.  
 
Will I be able to find out the results of the project? 
On completion of the study, the Principal Investigator will send you via mail a summary 
of the findings, and your individual results. 
 
Who do I contact if I have questions about the project? 
Should you have any questions regarding this project, please contact the Principal 
Investigator: 
 
Dr Christian Lorenzen 
(03) 9953 3849 
School of Exercise Science 
ACU, St Patrick’s Campus, 115 Victoria Parade, Fitzroy, VIC 3065 
 
What if I have a complaint or any concerns? 
The study has been approved by the Human Research Ethics Committee at Australian 
Catholic University (approval number 2013 238V). If you have any complaints or 
concerns about the conduct of the project, you may write to the Chair of the Human 
Research Ethics Committee care of the Office of the Deputy Vice Chancellor 
(Research). 
 
Research Ethics Manager (ResEthics.Manager@acu.edu.au) 
Office of the Deputy Vice-Chancellor (Research) 
Australian Catholic University 
North Sydney Campus 
PO Box 968  
North Sydney, NSW 2059.  
 
Any complaint or concern will be treated in confidence and fully investigated. You will 
be informed of the outcome. 
 
I want to participate! How do I sign up? 
If you wish to participate in this study, contact the Principal Investigator Dr. Christian 
Lorenzen at christian.lorenzen@acu.edu.au. You should sign both copies of the 
provided Consent Form. Please retain one copy for your records and return the other 
copy to the Principal Investigator. 
 
Yours sincerely, 
 
Dr. Christian Lorenzen        
Principal Investigator 
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CONSENT FORM 
Copy for Researcher / Copy for Participant to Keep 
 
TITLE OF PROJECT: Intraday and interday reproducibility of skin blood flow 
measurement using laser speckle imagery 
 
PRINCIPAL INVESTIGATOR: Dr. Christian Lorenzen 
STUDENT RESEARCHER: Jordan Loader  
 
 
I ................................................... have read and understood the information provided 
in the Letter to Participants. Any questions I have asked, have been answered to my 
satisfaction. I agree to participate in this study assessing skin blood flow and blood 
vessel function, and understand that I will be requested to attend the Cardiovascular 
Research Laboratory in the School of Exercise Science, Fitzroy, on four occasions, over 
a seven day period, realising that I can withdraw my consent at any time (without 
adverse consequences).  I agree that research data collected for the study may be 
published or may be provided to other researchers in a form that does not identify me 
in any way.   
 
 
NAME OF PARTICIPANT: ........................................................................................... 
 
SIGNATURE .............................................................. DATE ....................... 
 
SIGNATURE OF PRINCIPAL INVESTIGATOR: ....................................................... 
DATE:……………………….. 
 
If you become distressed, alarmed or disadvantaged while participating in the 
study, it is recommended that you call Lifeline Melbourne on 13 11 14, which is a 
24 hour telephone counselling service for people over 18 years.  If you believe you 
have experienced any negative physical, you are advised to contact your general 
practitioner. 
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PARTICIPANT INFORMATION LETTER 
 
PROJECT TITLE: Improving techniques that assess cardiovascular health 
 
PRINCIPAL INVESTIGATOR: Dr. Christian Lorenzen 
STUDENT RESEARCHER: Jordan Loader (PhD student) 
 
Dear Participant, 
 
You are invited to participate in the research project described below. 
 
What is the project about?  
The blood flow and function of small blood vessels are thought to be early indicators 
of cardiovascular health.  Transdermal iontophoresis, which uses a weak electrical 
current that moves a medication across the skin, is a non-invasive technique that can 
measure blood vessel function quickly with little discomfort for patients.  Presently, it 
isn’t completely understood if widening of the blood vessels (vasodilation) and 
increased blood flow is only responding to the medication or partly due the electrical 
current stimulation (i.e. non-specific vasodilation).  The aim of this study is therefore 
to determine what non-specific vasodilation, if any, is induced using several commonly 
published iontophoresis protocols.  This research is important, as it will provide a 
reliable testing protocol for clinicians and researchers who wish to assess blood vessel 
function with transdermal iontophoresis.  Furthermore, the development of a reliable 
testing protocol free of non-specific vasodilation will allow clinicians and researchers 
to more confidently and non-invasively assess the effectiveness of interventions (e.g. 
pharmaceuticals, physical activity) in vascular health. 
 
Who is undertaking the project? 
Dr. Christian Lorenzen and Jordan Loader (PhD candidate) from the Australian 
Catholic University are conducting this project. 
 
Who is eligible to participate? 
We are seeking healthy male and female participants who are aged 18 years and over. 
Potential participants with any significant medical history of chronic cardiovascular 
disease and regularly using any medications affecting microcirculation are not eligible 
to participate. 
 
Are there any risks associated with participating in this project? 
Medications are administered safe dose levels and will remain in the local application 
area, not spreading around the body. A small brief tingling sensation (i.e. pins and 
needles feeling) and/or skin rash may be experienced locally to the medication 
application area, but any sensation leaves within minutes and any rash leaves within 24 
hours. The effects will be minimized by having a trained and experienced researcher 
administering the tests. A finger prick for blood glucose testing may cause momentary 
discomfort, and possibly slight bruising at the puncture site. You may also feel some 
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discomfort from lying down for an extended period of time or need to leave the testing 
session (e.g. you may need to use the bathroom).  If for any reason you feel 
uncomfortable and wish to cease the test, you will be welcome to do so.  In the unlikely 
event that you experience any physical discomfort beyond what is described above, you 
will be advised to contact your General Practitioner. The cost of your visit to your 
General Practitioner will be covered by the School of Exercise Science, Australian 
Catholic University.  
 
What will I be asked to do? 
You will be requested to attend the Cardiovascular Research Laboratory in the School 
of Exercise Science, Fitzroy, on five occasions, over a two week period.  Each trial will 
be separated by at least 48 hours. You will be required to abstain from caffeine, nicotine 
and alcohol for at least 4 hours before testing to avoid their effects on microcirculation. 
Each testing session will be separated by at least 2 days.  Each test will last about 70 
minutes, and all testing procedures will be the same from test to test. However, the 
medication and current strength will vary.  The step-by-step procedure for each test will 
be: 
 
1. You will lie on a bench for 20 minutes in a temperature controlled room for 
acclimatization. 
2. A blood pressure cuff placed will be placed on your upper left arm. 
3. Resting blood pressure will be taken. 
4. Resting blood glucose levels assessed using a finger prick device and blood 
glucose monitor. 
5. Two medication-delivery electrodes (containing acetylcholine, sodium 
nitroprusside, insulin, insulin diluent, deionized water or saline) will be placed 
on each of your inner left and right forearms.  
6. Two weak electrical currents will be administered simultaneously to move the 
medications to your skin blood vessels on your right forearm. Laser imaging 
will occur throughout. 
7. Following 20 minutes of laser imaging, the process at step 6 will be repeated on 
your left arm for 20 minutes in order to assess another iontophoresis protocol. 
 
How much time will the project take? 
As stated above you will be requested to attend five 70-minute sessions over a two 
week period. 
 
What are the benefits of the research project? 
You will receive a fruit and drink refreshment after each testing session. Your 
participation may also contribute to community health in the future.  The information 
in this study may develop protocols enabling clinicians and researchers to more 
confidently assess before and after an intervention (e.g. pharmaceutical or lifestyle) and 
identify at-risk patients for developing cardiovascular disease. 
 
Can I withdraw from the study? 
Participation in this study is completely voluntary. You are not under any obligation to 
participate. If you agree to participate, you can withdraw from the study at any time 
without adverse consequences. 
 
Will anyone else know the results of the project? 
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It is the researchers’ intention to publish the results of this study in a scientific journal 
and PhD thesis.  You will not be identifiable in this publication, as only averaged data 
will be presented.  During the study, your data will be deidentified and coded so only 
the Principal Investigator can determine that it is you, and will be stored on a password 
protected computer in the Cardiovascular Research Laboratory in the School of 
Exercise Science, at ACU.  At the completion of the study, data will be kept on a 
password-protected computer in the office of the Head of School.  
 
Will I be able to find out the results of the project? 
On completion of the study, the Principal Investigator will send you an email with a 
summary of the findings, and your individual results. 
 
Who do I contact if I have questions about the project? 
Should you have any questions regarding this project, please contact the Principal 
Investigator: 
Dr Christian Lorenzen 
(03) 9953 3849 
School of Exercise Science 
ACU, St Patrick’s Campus, 115 Victoria Parade, Fitzroy, VIC 3065 
 
What if I have a complaint or any concerns? 
This study has been approved by the Human Research Ethics Committee at Australian 
Catholic University (approval number 0000019039). If you have any complaints or 
concerns about the conduct of the project, you may write to the Chair of the Human 
Research Ethics Committee care of the Office of the Deputy Vice Chancellor 
(Research). 
 
Research Ethics Manager (ResEthics.Manager@acu.edu.au)  
Office of the Deputy Vice-Chancellor (Research) 
Australian Catholic University 
North Sydney Campus 
PO Box 968  
North Sydney, NSW 2059.  
 
Any complaint or concern will be treated in confidence and fully investigated. You will 
be informed of the outcome. 
 
I want to participate! How do I sign up? 
 
If you wish to participate in this study, contact the Principal Investigator Dr. Christian 
Lorenzen at christian.lorenzen@acu.edu.au. You should sign both copies of the 
provided Consent Form. Please retain one copy for your records and return the other 
copy to the Principal Investigator. 
 
Yours sincerely, 
 
Dr. Christian Lorenzen        
Principal Investigator  
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CONSENT FORM 
Copy for Researcher / Copy for Participant to Keep 
 
TITLE OF PROJECT: Improving techniques that assess cardiovascular health 
 
 
PRINCIPAL INVESTIGATOR: Dr. Christian Lorenzen 
STUDENT RESEARCHER: Jordan Loader  
 
  
 
I ................................................... have read and understood the information provided 
in the Letter to Participants. Any questions I have asked, have been answered to my 
satisfaction. I agree to participate in this study assessing skin blood flow and blood 
vessel function, and understand that I will be requested to attend the Cardiovascular 
Research Laboratory in the School of Exercise Science, Fitzroy, on five occasions, over 
2 week period. I understand the associated risks with participating in this study, as 
outlined in the Letter to Participants, realising that I can withdraw my consent at any 
time (without adverse consequences).  I agree that research data collected for the study 
may be published or may be provided to other researchers in a form that does not 
identify me in any way.   
 
 
NAME OF PARTICIPANT: ...........................................................................................  
 
SIGNATURE ..................................................................... DATE ....................... 
 
SIGNATURE OF PRINCIPAL INVESTIGATOR: 
DATE:……………………….. 
 
If you believe you have experienced any negative physical reactions as a result of 
participating in this study, you are advised to contact your general practitioner 
and the cost of your visit will be covered by the Australian Catholic University.
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